


The Journal of the American Diabetes Association

diabetes

Volume 14 • 1965

INDEX

By Subject and Author



140349

Copyright 1966, by American Diabetes Association, Inc.

SUBJECT INDEX 1965

This index covers all reading matter in Volume 14 of DIABETES. Entries marked with an asterisk (*) indicate material that appeared in the Abstracts only. The Author Index appears on page 35.

A

- ABDOMEN**
 - and pancreas autograft in dogs, 689-695
- ABORTIONS**, 573, 575
 - and chromosome abnormalities, 340, 367
 - and diabetic pregnancy, 175, 371
 - and hyperthyroidism and diabetes study, 741
 - and triamcinolone-glucose tolerance test, 482
- ACETALDEHYDE**, 18
- ACETATE**
 - oxidation rate, *50
 - thiokinase and carbohydrate metabolism, *683-684
 - and urate excretion, 787, 804
- ACETATE I-C-14**
 - incorporation into fatty acids, 709-715, *747
 - incorporation into lipids, 584
- ACETOACETATES**, 498
 - and diabetic acidosis, 370
 - and myocardial metabolism, *531
- ACETOHEXAMIDE**, *114, *382
 - metabolism, *456
 - in serum and urine, 362-367
- ACETONE**
 - in arterial blood, 663-665
 - and fasting, *381
 - and plasma corticoid elevation, 745
 - tests for juvenile diabetic campers, 678
- ACETONURIA**, *464
 - and juvenile diabetes, *531
- p-ACETYLBENZENESULFONYLUREAS**, *382
- ACETYLCARBOXYLASE**, 662
- N-ACETYL-DL-HOMOCYSTEINE THIOLACTONE**, *236
- ACHILLES REFLEX**, *380, 427
- ACHRESTIC DIABETES**, 718
- ACIDOSIS**
 - and fatty acid metabolism, 713

- and infants, 160
- and juvenile diabetes, *317-318
- and sulfated insulin, *440
- ACIDOSIS, DIABETIC**, *609
 - and acute renal insufficiency, 36-37
 - and bicarbonate therapy, *113
 - biochemical factors, 370
 - and diabetes control study, *469
 - in induced pancreatitis in rats, 637
 - in juvenile diabetes study, 242, 247-249
 - and lactate metabolism, *440
 - and pancreatic diabetes, 95
 - and reduced hyperglycemic response, 104
 - and steroid therapy, *114
- ACIDOSIS, LACTIC**
 - and fasting, *532
 - and nonketacidotic coma, 162
 - and phenformin, *464-465
- ACIDOSIS, METABOLIC**
 - and hyperosmolality, 164
 - in hypophysectomized diabetics, 43
- ACIDS**
 - arachidonic, 105
 - and glucagon and epinephrine, *681
 - ascorbic
 - and alloxan diabetes, 312
 - and diazoxide, 592
 - and glucose oxidase, 224, 225
 - benzoic
 - insulin-like activity, *681
 - dehydroascorbic
 - and alloxan, 289-290
 - glucuronic, 311-312
 - and glucose metabolism, 311-312
 - glutamic
 - and respiration, *685
 - 5-hydroxyindolacetic, *53
 - hydroxy-, and muscle metabolism, 82
 - lactic
 - and 3,5-dimethylpyrazole, 508, 514
 - and free fatty acids, *534
 - in leucocytes of diabetics, 584, 587
 - and nonketacidotic coma, 162, 164
 - 3-methoxy-4-hydroxymandelic, 78, *233
 - nalidixic
 - and convulsions, hyperglycemia, and glycosuria, *683
 - nicotinic
 - and free fatty acid, *532
 - and protein synthesis, *534
- ACROMEGALY**
 - and diabetes, 43
 - and glucose loading, 27, 28
 - and growth hormone, 374
 - and insulin, *167
 - and insulin dosage, *117
 - and insulin resistance, 556
 - and retinopathy, 558
 - and serum insulin response, *532-533
- ACTINOMYCIN D**
 - and glycogen synthesis, *236
- ACTH. See Adrenocorticotrophic hormone**
- ACTINOMYCIN D**
 - and insulin, 633, 662
- ADDISON'S DISEASE**, 562
 - and diabetes, 300-301
 - and myxedema, *317
 - and thyroid insufficiency, *48
- ADENOHYPOPHYSIS**
 - and alloxan diabetic rats, *50
- 3,5-ADENOSINE MONOPHOSPHATE**
 - and phosphorylase activity, *534
- ADENOSINE TRIPHOSPHATASE**
 - and glucocorticoids, 484
- ADENOSINE-PHOSPHATE**, *235
- ADRENAL GLANDS**
 - Addison's disease
 - and diabetes, *48
 - of alloxan-diabetic rats, 502
 - androgens and obesity, 791
 - catecholamines, *532
 - cortex hypertrophy, 95

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

corticosterone
and gravity changes, *535
and cortisol, 195
and diabetes, *169, 300-303
and diazoxide hyperglycemia, 591,
593-594
hemorrhage and infant hypoglycemia,
*815
hyperplasia
and alloxan diabetic pregnancy, 727
in diabetic-lathyrus rats, *613
and hypoglycemia, 249
hypophysal function and diabetic angiopathy, *53
insufficiency and diabetes, *317
and insulin-induced hypoglycemia,
*169
and leukemic mice, 325, 328
and thyroid deficiency, 300-303

ADRENALECTOMY, *684
and adrenocorticotrophic hormone effect, *748
and amino acid incorporation, *115
and diazoxide hyperglycemia study, 591, 592
and 3,5-dimethylpyrazole, 508

ADRENALIN
and glycogenolysis, 345
and hypoglycemic convulsions, *49
and insulin release, *232

ADRENOCORTICOSTEROIDS
and insulin activity, 135

ADRENOCORTICOTROPHIC HORMONE, *534, 562, 563
and adrenalectomized rats, *748
and corticosteroid production, 334
and Cushing's syndrome, *684
and diabetes, 550, 552
and free fatty acids, 87
and hypoglycemic infants, 333
and infant hypoglycemia, *815
and insulin and glucose, *748
and insulin resistance, *818
and lipolysis and lipogenesis, 369

AGE
and asteroid hyalitis, *171
and blood glucose levels, 415-422
and blood saccharin content, 721, 722
and diabetes incidence, 213, 216-218,
222
and diabetic acidosis, 248, 249
and diabetic neuropathy, 4, 428, 520
and diabetic retinopathy, 264
and exercise, *533
and facial redness, 207-208
and fasting serum L-xylulose, 311
and galactose and fructose removal,
156
and glomerulosclerosis, 265

and glucose tolerance, 474, 475, 477,
579-583
and hypertension and diabetes, *749
of Indians at diabetes onset, 405-406,
409
and insulin
dosage, 246
resistance, 433
of juvenile diabetics
in camping program, 677
in survey, 106
and ketosis-resistant diabetes, *814
and leukemic mice, 326-327
and lipid concentration, 250
and liver function, 253
in mass screening for diabetes, 298,
299
of menarchial onset and diabetes, 788-
791
and nonketacidotic coma, 162
old
and cerebrovascular and pancreatic
insular amyloid, *612
and diabetes survey, *47
and diabetic pruritis, *168
and pancreatic exocrine function, *53
of patients
in bone study of diabetics, 142
with ischemic leg ulcers, *318
in juvenile diabetes study, 241-242
in myocardial infarction study, 84,
85
and phenformin hydrochloride study,
*465
and pyruvate excretion study, *231
of subjects
in chronic hypoxia study, 100
in new glucose tolerance test, 97
in RH negative pregnancy study,
*460
in skinfold thickness study, *314
and sulfonylureas, 63, 64, 655
and triglyceride level, 251
and weight and calorie intake, 245

ALANINE
and insulin activity, 698

ALANINE-C-14, 355, 359

L-ALANINE
and liver carbohydrate synthesis, *378

ALBUMIN
and diabetes, *234
-globulin ratio and exercise, *317
and glomerulosclerosis study, 755-770
and insulin, *456-457
antagonism, 82, 86, 566-567
inhibition, *608
and insulin I-131, 27, 31
in juvenile diabetes study, 251
radioimmunoassay, *234
urine test for, 59

ALBUMINURIA
and prednisolone-fed rabbits, 595-596

ALCOHOL
hypoglycemia, 350-360
ingestion
and hemochromatosis and siderosis,
699, 708
and sulfonylureas, *114

ALCOHOLISM
and diabetes, 259
and hypoglycemia, *234
and neuropathy, 2, 4, 8
and nonketacidotic coma, 162
and tolbutamide, *233

ALKALINE PHOSPHATASE, 126, 654

ALLERGIES
and glomerulosclerosis, 755
and induced pancreatitis, 640-642
and insulin resistance, *818
and insulin tests, *457
and neuropathy, 516
in sulfonylurea therapy, 59, 60

ALLOSE G-PHOSPHATE, *52

ALLOXAN, 373
and beta-cell changes, 289
and diabetes production, 306
distribution, *383
and glucose oxidation, *48
injections in male rats, 179-184
and insulin level immunoassay, 669-
671
and obesity, *169
and pancreas islet tissue, *383

ALLOXAN-C-14, *532

ALLOXAN DIABETES, 137
and adenosine phosphate synthesis,
*684
and adipose tissue metabolism changes,
179-185
and ascorbic acid synthesis, 312
and diazoxide, *469
and ethanol disappearance, 14, 16, 17,
18
and fat metabolism, *232, *235, 633,
662, 713
and growth hormone, *50
and hormones, 368
and hyperlipemia, 666-668
and insulin requirements, 373
and ketoacidosis, 289-294
and leukemic mice, 325-332
and lipids
in incubated sciatic nerve, *447
in newborn rats, 724-728
and nerve conduction, *232
in pregnant ewes, *235
and rabbits, 792
and retinopathy, 705
and sex hormones, 501-505

ALPHA-GLOBULINS
and insulin-like activity, 71-76

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

ALPHAMETHYLBENZALHYDRAZINE
and diazoxide-induced hyperglycemia,
*469

ALVEOLAR GAS
and acetone determinations, 663-665

AMERICAN DIABETES ASSOCIATION
Affiliate Associations, 57-58, 120, 174,
324, 386, 548, 616-617, 688,
753, 822-823
and American College of Physicians,
618
annual meetings
Twenty-fifth, 54, 118, 237, 471, 319-
323, 537-545
business, 541
Twenty-sixth, 384, 471, 547, 616,
752, 819
awards
Banting Medals, 538
Banting Memorial, 538-539
Lilly, 472, 541, 547, 616, 687, 753
Outstanding Layman, 541
Board of Directors, 54, 820
Committee of State Coordinators, 56-
57, 821-822
Committee on Affiliate Associations,
56, 821
Committee on Bequests, 56, 821, 822
Committee on Emergency Medical
Care, 56, 821
Committee on Employment, 56, 821
Committee on Food and Nutrition, 55,
820
Committee on Information for Diabet-
ics, 56, 821
Committee on Policies, 56, 821
Committee on Professional Education,
55, 820
Committee on Public Education and
Detection, 56, 821
Committee on Research, 56, 821
Committee on Scientific Awards, 55,
821
Committee on Scientific Programs, 56,
820
Committee on Scientific Publications,
56, 820
Committee on Statistics, 56, 820
Committee to Study the Functions and
Structure of the American
Diabetes Association, 56, 821
Constitutional Committees, 820
Diabetes Week, 238, 324, 386, 472,
547, 616
diagnostic criteria, 478-479
dues increase for overseas members,
820
Executive Committee, 55
FORECAST
"Diabetes: Past, Present, and Fu-
ture," 238
"Job Guidelines for People with
Diabetes," 174
fourth research symposium, 324, 384,
472, 545-546

index, diabetes-related literature, 19-
62, 237
International Congress of Gerontology,
386

Journal
index, 55
volume changes, 55
necrology, 58, 174, 386, 618, 754, 824
new members, 57, 119, 323, 384, 547-
548, 616, 687-688, 753
New Patient Study, 617
News notes, 58, 120, 174, 238, 324,
386, 472, 548, 617, 688, 753-
754, 823
Nominating Committee, 55
officers, 54
personals, 58, 120, 238, 324, 386, 472,
548, 618, 688, 754, 824
postgraduate courses, 385, 471, 547-
548, 614, 617, 686, 750, 819
Research and Development Award
Program, 546-547, 615, 687
Research and Essay Contests, 54-55,
119, 173-174, 615, 686-687,
822
research fellowships, 324
research support program, 472
research symposium
future meetings, 2, 820
sabbatical leave, 55
Silver Anniversary Meeting, 173
submission of abstracts, 54
symposium on automation, 472

AMINO ACIDS
and cortisol and insulin, *115
and glucose production, *235
and growth hormone, 374
incorporation into protein, 305, 306
and insulin, 529, *815
and milk diet, 335
nitrogen
and carbohydrate utilization, *448
and sulfonylureas, 209-211

AMINOACIDURIA, 335

AMMONIUM SULPHATE, 71, 72

AMPUTATIONS
for gangrene, 7

AMYLASE, 132, 135
and diagnosing fibrocystic disease,
*117

AMYLO-1,6-GLUCOSIDASE, 337

AMYLOGLUCOSIDASE
and glycogen content, *232

AMYLOIDOSIS
and old age, *612

AMYOTROPHY, DIABETIC, 1, 427,
428, 520

ANAEROBIOSIS
and adipose water and glucose up-
take, *379

and glucose uptake, 128-131
and glycogen, 749

ANAPHYLAXIS, *116

ANDROGENS
and diabetes, 368

ANDROSTERONE
and chlorophenoxyisobutyrate, *814

ANEMIA, 201
and blood sugar determinations, 673-
674.
and plasma sugar, 165

ANGINA PECTORIS
in diabetic neuropathy, 2, 7

ANGIOPATHY
and antigen-antibody reaction, 110
and diabetes duration, 370
and diabetic neuropathy and nephro-
pathy, 517
and heredity, 518
and hypophyseoadrenal function, *53
and muscular atrophy, 426
ocular, 43
symposium, 309-310

ANOREXIA
and alloxanization, 291
and diabetic neuropathy, 427
induced, *52

ANTABUSE, *114

ANTAGONISTS. See also Antibodies
to insulin
albumin, 356-357

ANTIBIOTICS
aureomycin, 194
and diarrhea, 371
and hypophysectomized dogs, 659
and infants of diabetic mothers, 160
and pancreatectomized dogs, 731
penicillin, 93, 696
streptomycin, 93

ANTIBODIES
to adrenals, *317
antithyroid, 743
binding capacity
and insulin, *815-816
and disc electrophoresis separation,
*50-51
to glucagon, *450
to growth hormone, 44
to insulin, *51, *170, *449, 551, 552,
564
and alloxan-diabetic rats, 183
and diabetic glomerulosclerosis, 755
and diabetic kidney tissue, 277-278
in diabetics and nondiabetics, *531
and heterologous and homologous
insulin, *747-748
and induced diabetes, 369
and insulin, 771-772

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

and insulin-binding, 27-31, 235, 396-402
 and insulin and I-125 insulin, *449
 and insulin-like activity, 805
 and insulin resistance, 309, 432-434, 716
 and pancreas islet studies, *449-450
 and pancreatic changes, 493-500
 and pregnancy, 577
 and Regular Insulin, *316
 pancreatic, 226-227
 in Schmidt's Syndrome, *48

ANTIGEN, 226-227

ANTIHISTAMINES, 60

ANTISERUM
 electrophoresis, *50-51
 and induced diabetes, *52
 insulin, 756
 and radioimmunoassay, 772
 and tissue electrical potential, 529
 and study of renal lesions, 755-756

AORTIC SCLEROSIS
 and diabetic neuropathy, 1-3

L-ARABINOSE, *48

ARGYLL-ROBERTSON PUPIL, 5, 428

ARTERIOLAR NEPHROSCLEROSIS
 and diabetics and nondiabetics, 110

ARTERIOSCLEROSIS, 761
 and diabetes, 84-86, 110, 550
 and diabetic neuropathy, 428, 516-517
 peripheral ischemic, 1

ARTERIOSCLEROSIS OBLITERANS
 and diabetic neuropathy, 7

ARTHROSIS, GOUTY
 and diabetes, *116

ARTHROSIS, RHEUMATOID
 and ischemic leg ulcers, *318
 and phenformin, *532

ASHKENAZI
 and study of diabetes and face color, 201-208

ASPARAGINE
 and insulin activity, 698

ASTEROID HYALITIS
 and diabetes, *171-172

ATHEROGENESIS
 and hyperglyceridemia, *458

ATHEROMATOSIS
 and diabetic neuropathy, 517

ATHEROSCLEROSIS
 and cholesterol, 369
 and diabetes potential, 489-491
 and diabetic lesions, 110
 and dietary control, 307

and glucosamine, *380
 and hypertension and diabetes, *749
 and hypertriglyceridemia, 251
 premature
 and diabetes, 41
 and race, *470
 and serum beta-glucuronidase and glucose tolerance, *682
 and sulfonylureas, *377

ATHEROSCLEROSIS OBLITERANS
 and glycoproteins, *168

ATROPHY
 and diabetic neuropathy, *454
 muscular
 and glucocorticoids, 484

ATROPINE TEST, *747

AUTOANALYZER TEST, 78, 93, 97, 165, 166, *170, 186, 187-188, 192, 193, *232, 296, *452, *453, *458, 494, 507, 580, 591, 672

AZAMETHONIUM
 and free fatty acids, *532

AZOTEMIA
 and diabetic nephropathy, 2
 and insulin response to glucose, *459
 in juvenile diabetes study, 265

B

BALANITIS, 60

BALLISTOCARDIOGRAMS
 in juvenile diabetes study, 267

BANTING, FREDERICK, 37-42

BANTING MEMORIAL LECTURE, 549-568

BANTUS
 and idiopathic hemochromatosis and siderosis, 699, 708

BARBITURATES
 and nonketacidotic coma, 162

BASEMENT MEMBRANE
 changes
 and diabetes, 517
 in prednisolone-induced nephropathy in rabbits, 600-601
 thickening
 and diabetes, *47, 110, 550, 702-706
 and diabetic glomerulosclerosis, *377
 and fatty acids, 370
 and glomerulosclerosis, 759

BENEDICT'S TEST
 and false negative reactions, 224-225

BENSON'S DISEASE. See Asteroid hyalitis

BEST, CHARLES, 37-42

BIBLIOGRAPHY OF MEDICAL TRANSLATIONS, 657

BICARBONATE
 duodenal, *53
 and nonketacidotic coma, 162-164

BIGUANIDES
 and juvenile diabetes, 531
 statistics on, 61

BILIRUBIN
 in juvenile diabetes study, 253

BLADDER
 atonic
 and diabetic neuropathy, 427, 428
 and diabetic neuropathy, 370, *455
 dystonia, *47
 infections
 in juvenile diabetics, 256
 paralysis, 5, 7

BLOOD
 acetate, *235
 acetone determination, 663-665
 antibody content, 28
 cholesterol, 1
 and diabetic neuropathy, 4
 clotting and lesions, 604
 corticosterone and gravity changes, *535
 count in sulfonylurea therapy, 59, 60
 drug levels and sulfonylurea therapy, 653-654, 655-656
 dyscrasias in sulfonylurea therapy, 67
 ethanol in experimental dogs, 15-18
 fatty acids, 395
 flow
 and diabetic neuropathy, 517
 and Krebs's intermediate metabolites, *532
 splanchnic and glucose production, 355
 and free and bound insulin, *608
 and free fatty acids, 87
 fructose
 and hypoglycemic convulsions, *49
 and galactosemia, 335
 glutathione, 132, 135, 136
 and growth hormone determination, 43
 hematocrit
 and blood sugar determination, 672-674
 and hemoglobin in leukemia, 326-327
 hematological indices and growth hormone, *50
 hemoglobin
 in juvenile diabetes study, 253
 and insulin-inhibitors and binders, *234
 in insulin resistance study, 432-434

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

in juvenile diabetic, 121
 ketones
 and ketosis, 744-745
 and labile diabetes study, 286, 287
 lactate
 and free fatty acids, *611
 in newborn calves, *49
 and urate excretion, 739
 levels
 and acetohexamide, *456
 of lipid-infused pancreatectomized dogs, 33-35
 lipids
 and diet, *611, *816
 and phenformin and tolbutamide, *456
 and radioactivity, 709-715
 pancreaticoduodenal venous insulin tests, 393-394
 peripheral venous insulin, 387
 portal
 and plasma insulin, *439
 pressure
 and glomerulosclerosis, 457, 459, 461
 pyruvate, *231
 pyruvic acid
 and diabetic neuropathy, 4
 and radioactivity incorporation into lipid, *747
 red cells
 and alloxan distribution, *383
 and I-C-14 glucose and 6-C-14 glucose metabolism, *747
 saccharoid
 and mental illness, 719-722
 samples
 and acetone determinations, 664-665
 in adrenal steroid study, 730
 and alloxanized rats, 669
 in free fatty acid study, 78
 in glucose disposal-rate study of elderly, 580
 in glucose tolerance test study, 474
 from growth-hormone-injected dogs, *444
 of guinea pigs in cortisol study, 195
 from hypophysectomized dogs, 659
 in insulin-like activity study, 71
 in juvenile diabetes study, 241
 and lactic acidosis, *465
 in new glucose tolerance test, 97
 new technic, 186-193
 of pancreatectomized dogs, 690
 and pentosuria study, 311
 and plasma samples compared, 165-166
 from premature infants, 127
 from siblings of juvenile diabetics, *438
 of umbilical arterial blood, 160
 tests
 in lactose- or galactose-induced hypoglycemia, *682
 and multiple sclerosis, *464

triglyceride removal, *536
 urea nitrogen content, 36
 volume
 respiratory distress syndrome, 436

BLOOD GLUCOSE. See also Blood sugar
 and actinomycin D, 633
 and adrenalectomized rat, *748
 and adrenalin, *49
 and age, sex, and diet, 413-422
 and alloxan, 291, 669-671
 anomers
 measurement method, *747
 and anti-insulin serum, 15
 and autoclaved carbohydrate solutions, *168
 and azotemia, *459
 and carbohydrate tolerance tests, *315-316
 and chlorothiazide, *609
 and chronic hypoxia, 100-104
 and coronary heart disease, *116
 and cortisol, *113, 194
 and diabetes diagnosis, 176
 disappearance rate
 and obesity, *467
 fasting
 and diabetes detection, *685
 and insulin-like activity, 10, 11
 fetal, 577
 finger
 and diabetes detection, 295-299
 and glucose loading, 84-86
 and hypothetically induced emotional stress, *467-468
 of immunized guinea pigs, *52
 and insulin, *169, *684-785
 hypoglycemia, *536
 intestinal, 697-698
 intraperitoneal, 23
 -like activity in juvenile diabetics, *49
 and tolbutamide, *114
 and islet cell tumors, *49
 and labile diabetes study, 283-285, 287
 and lactose-induced hypoglycemia, *682
 and liver perfusion system, *235
 in newborn infants, 127, 156
 after pancreatectomy, 14
 and placenta, *172
 and pregnant women, 578
 regulation
 and insulin, 308
 and secretin, *167
 and serum insulin, *458
 and siblings of diabetics, *438
 and single injection of anti-insulin serum, *49
 and stress, *382
 and sulfated insulin, *440
 and sulfonylurea therapy, *463
 tests, 2, 59, *232, *315
 in alloxan diabetic rats, 180, 181, 182, 184

AutoAnalyzer, 78, 93, 97, 165, 166, *170, 186-188, 192, 193, *232, 296, *452, *453, *458, 494, 507, 580, 591, 672
 Clinistix, 224-225, 247, *746, *816
 Combitrix, 224-225
 compared, *452
 Dextrostix, *170, *232, *381, *383, *611, *817
 Folin-Wu, 247, 651, 690, 720-722
 Hagedorn-Jensen, 59
 Nelson-Somogyi, 591
 new technic, 186-193
 and postgastrectomy hypoglycemia, 526-528
 Schaffer-Hartmann, 2
 Somogyi-Nelson, 33, 78, *116, 165, 202, 363, 388, 420, 526, 586, 651, 720, 722
 in tolbutamide study, 392-394
 and triglyceride-induced hyperketonemia, *448
 and thiazide injections, *115
 and thyroid administration tests, *49
 and tolbutamide
 in ulcer patients, *814

BLOOD PRESSURE
 and glucose tolerance tests, *116
 of juvenile diabetics, 121, 126
 and phenformin overdose, 811
 and tubular necrosis, 36

BLOOD SUGAR. See also Blood glucose
 and alcohol ingestion, 350-360
 and alloxan diabetic rats, 137-138
 and amino acid nitrogen, *448
 and antihypertensive drugs, *377
 assays, 87, 88
 and blood saccharoid content, 719-722
 and caffeine and coffee, *169
 and chlorpropamide and tolbutamide, 650-656
 control
 and M-value, *612
 and cortisol study, 195, 198
 of cortisone-alloxanized rabbits, 793
 and diabetes
 classification, *234
 control study, *469
 detection, *461
 neonatal, *233
 severity, 60
 of diabetic children, *460
 and diabetic neuropathy, *114
 and 3,5-dimethylpyrazole, 507-514
 enzyme-strip determination, *170
 and ethanol ingestion, *52, *171
 fasting, *53
 and diabetes diagnosis in dogs, 700
 and diabetic neuropathy, 428
 and glucose-6-phosphatase, 146
 and leukemic mice, 325-331
 and L-xylulose levels, 311
 and oral hypoglycemics, 405
 and phenformin hydrochloride, *465-466

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

and phenformin and tolbutamide, *456
 and prediabetes, 175
 and fetuses, *235, 371
 and free fatty acids, 369
 and gastric secretory response, *532
 and growth hormone, 43
 and hematocrit, 672-674
 and hormones, *231, 333-338
 and hyperglycemia, 792
 and hypernatremia, 164
 and hypoglycemia, 606-608
 and insulin
 antibodies, 396
 distribution, 345
 Rapitard, *685
 response, *462
 in juvenile diabetes study, 247, 250
 lability, *168
 and L-leucine, *47
 and newborn infants, *815
 and oral insulin, *117
 and oscillatory motion, *317
 in pancreatectomized and normal dogs, 34
 of patients in bone study of diabetics, 142
 and phenformin, *52, 811
 and plasma sugar determinations compared, 165-166
 postprandial
 among Pima Indians, *439
 and prediabetes, 371-372
 and pruritis, *168
 and pyruvate levels, *231
 and skinfold thickness and serum lipids, *314
 and stress, 518
 and sulfation factor, *172
 and sulfonylureas, 362-367
 tests
 and diazoxide hyperglycemia study, 591-594
 glucose oxidase method, *458
 Hagedorn and Jensen method, 195
 and insulin study, *457
 and juvenile diabetes, 121, *317
 in thiazide therapy, 136
 and tolbutamide, *470
 in tubular necrosis case, 36

BLOOD VESSELS
 calcification
 in juvenile diabetes study, 266
 capillaries
 in South African diabetics, *469-470
 and diabetes, 310
 retinal
 reversal of diabetic changes, 121-127
 spinal cord
 in diabetic myopathy, 426

BODY
 face
 color in diabetes, 201-208

finger
 glucose test, 295-299
 growth
 and alloxan-diabetic rats, 502
 of juvenile diabetics, 253-254
 hands and feet
 color in diabetes, 201
 limbs
 and glucose uptake, *383
 lower extremities
 diabetic foot, *172
 and diabetic neuropathy, 2, 8, 427, 520
 ischemic leg ulcers, *318
 skin lesion, *817
 ulcers, *115-116
 rib
 cortical area, *316
 toes
 diabetic microangiopathy, *47
 upper extremities
 and diabetic neuropathy, *454
 metabolism studies, *117
 "thick hand syndrome," *454
 upper and lower extremities
 and ulcers, *684

BONES
 from diabetics, 142-145, 375
 fractured and immobilized
 glucose uptake, *383
 growth
 and Vitamin B₆ deficiency, 515
 metabolism
 and diabetes mellitus, *455
 spontaneous fracture, *683

BOOK REVIEWS
 Annual Review of Biochemistry, edited by E. E. Snell, J. M. Luck, P. D. Boyer, and G. MacKinney, 46
 On Diabetes Mellitus, Selected Topics for Students and Clinicians, by Charles C Thomas, 376
 Diseases of Metabolism, edited by Garfield G. Duncan, 46
 Etiology of Diabetes Mellitus and Its Complications, edited by Cameron and O'Connor, 674-675
 Fat as a Tissue, edited by Kaare Rødahl and Bela Issekutz, Jr., 313
 A Handbook for the Young Diabetic, by Alfred E. Fischer and Dorothy L. Horstmann, 813
 How Diabetics Can Eat Wisely, by Dorothy Tomkins Revell, 313
 Juvenile Diabetes: Adjustment and Emotional Problems, by U.S. Public Health Service, Diabetes and Arthritis Program; National Institute of Arthritis and Metabolic Diseases; Child Guidance Center of Mercer County; and New Jersey State Dept. of Health, 111-112
 Manejo del Paciente Diabetico, by Rafael Rodriguez, 112-113
 Manual del Enfermo Diabetico, by staff of Diabetes and Obesity Clinic of Hospital of Diseases of Nutrition, 112-113
 Modern Nutrition in Health and Disease, by Wohl and Goodhart, 375
 Reports of the Steno Memorial Hospital and the Nordisk Insulin-laboratorium, Volume II, 1963, Gentofte, Denmark, 229-230
 A Textbook of Medicine, by Russell L. Cecil and Robert F. Loeb, 166

BOWMAN'S CAPSULE
 and diabetic dogs, 704, 706
 in prednisolone-treated rabbits, 596-598, 602
 thickening
 and glomerulosclerosis, 759, 761, 768

BRAIN
 and diabetes mellitus
 pathologic changes, 424, 425
 and hypoglycemia, 127
 of infants of diabetic mothers, 436
 and sulfonylurea therapy, *377
 tissue
 glucose utilization, *172
 and vascular disease, 2

BROCA'S FORMULA, 60

BROMSULPHALEIN, 253

BRONCHOPNEUMONIA, 158

BUTYLBIGUANIDE, 60

C

CAFFEINE
 and obese hyperglycemic mice, *169

CALCIUM
 and insulin activity, 430-431
 and ouabain, *534

CALCIUM GLUCONATE
 and hypoglycemia in rabbits, *462

CALORIES
 expenditure
 new device for measuring, *814-815
 increase
 and hyperglyceridemia, *458
 intake in juvenile diabetes study, 244, 245
 and uremia, *169

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

CAMP WIDJIWAGAN, 676-677

CANADA
and diabetes, 214

CARBOHYDRATES
conversion and adipose tissue, 82
cytotoxicity, *47-48
in diet of juvenile diabetics, 240, 245
dietary, *179, 474
and clofibrate therapy, *453
in diabetes, 60
in free fatty acid study, 77
and electrocardiograms, *168
and enzyme activity, *236
and growth hormone, 44
and growth hormone secretion, 557
ingestion
and diabetes detection test, *454
loading
and diabetes detection method, 295-299

metabolism. See *Metabolism, carbohydrate*

and postgastrectomy hypoglycemia, 526

and premature infants, 127, 156

solution for glucose tolerance testing, 96-99

synthesis
and corticosteroids, *378

tolerance
and age, sex, and diet, 413-422
and amyloid deposits, *612
and blood glucose level, *315-316
in children of diabetic families, *438-439
and diazoxide and chlorothiazide, *439
and hyperthyroidism, 740-743
and hypoglycemia, *459-460
and oral hypoglycemic agents, *318

tolerance tests
and amino acid nitrogen alterations, *448

CARBON DIOXIDE
and glucose, 311
production
in leucocytes, 586-587
by perfused rat heart, *685

CARBUTAMIDE, 59-70
in diabetes study in India, 405
and hypoglycemia, 606-607

CARCINOID SYNDROME
and hypoglycemia and pancreas tumor, *53

CARCINOMA
bronchogenic, and insulin and glucagon, *53
of colon, 759
and cyclophosphamide treatment, *612
and diabetic glomerulosclerosis, 763

mortality, 221
and diabetics and nondiabetics, *608-609
hepatic, *234
islet cell
and Cushing's syndrome, *684
and diazoxide, *469, *610
pancreatic, *48, 226-227, *815
and diazoxide, *450

CARDIOMEGLY
and infants of diabetic mothers, 436

CARDIOVASCULAR DISEASE. See also *Heart disease*
and glomerulosclerosis, 759, 761, 763
and small-bowel ulcers, 228

CARTILAGE
powder and diabetic wounds, *170-171

CASE REPORTS
acute tubular necrosis and dialysis treatment, 36-37
attempted suicide with phenformin, 811
blood insulin levels in islet-cell tumor patients, *49
diabetes and gouty arthritis, *116
diabetes and hypophysectomy, 43
diabetes and pituitary insufficiency, *50
diabetic acidosis secondary to steroid therapy, *114
diabetic coma, *609
diabetic glomerulosclerosis and plasma proteins, 757-763
diabetic neuropathy, 3-8, *47
diabetic retinopathy and hemochromatosis, *682
diet and urate excretion, 739
ethanol metabolism in diabetic dogs, 15-17
exocrine pancreas and diabetes, *53
growth hormone survival, *50
hyperinsulinism and Cushing's syndrome, *684
hypoglycemia and dwarfism with growth hormone deficiency, *613
insulin antibodies without insulin treatment, 551
insulin and glucagon in hepatic metastasis, *53
insulin resistance, *612
insulin secreting pancreatic tumors, *115
islet-cell tumors, *49
lactose- or galactose-induced hypoglycemia, *681-682
misleading tolbutamide test, *816
naldixic acid overdose, *683
nondiabetic ketosis in diabetic pregnancy, *464
obesity and fasting, *532

pancreas tumor hypoglycemia and carcinoid syndrome, *53
pancreatectomy, *683
pancreatic secretion in diabetes, *48
peptic ulcer with islet cell tumor, *116
post-pancreatectomy functioning, *613
reactive hypoglycemia and mild diabetes, *612
reversal of retinal vascular changes in diabetes, 121-122
studies of energy metabolism, *50
sulfonylureas during pregnancy, *51
sulfonylurea therapy study, 68
tolbutamide-induced hypoglycemia, *114

CASE STUDY
severe hypoglycemia after tolbutamide and carbutamide treatment, 606-607

CATARACTS
and diabetes, *231-232
in diabetic dogs, 705
and experimental sugar, radiation and metabolism, *611
in juvenile diabetes study, 265

CATECHOLAMINES
and alcohol, *233
and glucose, 78
hyperglycemia, *235
and hypoglycemia, 333
and lipolysis of triglyceride, 184

CELL POISONS
and glucose uptake, 128-131

CELLS
dehydration
and nonketacidotic coma, 162
necrobiosis
in prednisolone-induced nephropathy in rabbits, 599

CEREBRAL ACCIDENTS
and diabetic mortality, 221

CEREBRAL INFARCTS, 759, 761

CEREBRAL THROMBOSIS
and diabetics and nondiabetics, 110

CEREBROSPINAL FLUID
in diabetic neuropathy, 5, 7, 429
in tubular necrosis case, 36

CEREBROVASCULAR SYSTEM
accidents
and diabetic neuropathy, 425
and mortality, 68
and nonketacidotic coma, 162
amyloidosis, *612
disease
and diabetes, 425, 428
and tolbutamide, 654

CESAREAN SECTION, 256
and alloxan diabetic rats, 137-140
and diabetic pregnancy, 157, *379-380

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

CHARCOT'S JOINTS, 427

CHILDREN

- and abnormal insulin, 780-786
- blood sugar data, *460
- camping trips, 676-681
- and Dextrostix tests, *611
- diabetic
 - attitude toward diabetes, 106-109
 - of diabetic families
 - carbohydrate tolerance and tolbutamide response, *438-439
 - and diabetic neuropathy, 428
 - glucose and free fatty acid metabolism in obese adolescents, *746-747
 - and glycogenosis, 337-338
 - and growth hormone levels, 43
 - and hypoglycemia, 348
 - with salicylate poisoning, *315
 - and tolbutamide tolerance, *315
 - and iron in bones, 142
 - and ketotic hypoglycemia, *315
 - and microangiopathy mortalities, 308
 - and neuropathy, 518-519
 - and new glucose tolerance test, 96
 - obese
 - and glucose and free fatty acid metabolism, *610
 - reversal of retinal vascular changes, 121-127
 - siblings of diabetics, *438

CHLOROPHENOXYSOBUTYRATE

- and lipids, fat tolerance and uric acid, *814

CHLOROTHIAZIDE

- and carbohydrate intolerance, *439
- peripheral action, *609

CHLORPHENTERMINE

- and obese diabetics, *451-452

CHLORPROPAMIDE, *51, *114

- and blood glucose and plasma insulin, *463
- and blood sugar, 650-656
- in diabetes study in India, 405, 408
- long-term therapy, *814
- in serum and urine, 362-367
- and severe hypoglycemia, 606
- and urea synthesis and glycogenesis, 209-211

CHOLANGITIS

- and pancreatectomy, *683

CHOLELIITHIASIS, *465

- and aged diabetics, *47

CHOLESTEROL

- and arteries and insulin, *746
- and atherosclerosis, 369
- and diabetic neuropathy, 1
- dietary, 332
- and ethanol, *52, *171
- and high fat diet, *464

- and ischemic heart disease, *234
- in juvenile diabetes study, 250
- lowering response
 - and clofibrate, *453
 - and mebanazine, *236
- and newborn of alloxan-diabetic rats, 724-728
- and pancreatectomy, *681
- and phenformin hydrochloride, *465
- and polyunsaturated fatty acids, 105
- and pregnancy, *609
- and sugar and starch ingestion, *378
- and weight gain, *314

CHOLINE

- and hyperlipemia, 666-668

CHROMATOELECTROPHORESIS, *235

- of insulin-I-131, 342

CHROMATOGRAPHY

- and blood acetone determination, 663-665
- and blood glucose separation, 730
- and distribution of C-14 into fatty acids, *457
- fluorescent insulin, *51
- gas-liquid, 105
- and glycogen metabolism, *749
- and insulin
 - antibodies, 397
 - degradation, 90-91
 - like activity, 809
 - of labeled insulin, *449
 - paper, 690
 - of radioactivity incorporation, 28
 - and separation of bound and free insulin, 392
 - urine, *456
 - and lactose-induced hypoglycemia, *682

CHROMALUM HEMATOXYLIN PHLOXINE, 328

CHROM-HEMATOXYLIN METHOD, 195

CHYLOMICRON

- metabolism in adipose tissue, *535-536

CITRATE

- and lipogenesis, *447

CLOFIBRATE

- and diabetic hyperlipidemia, *452-453

COBALT CHLORIDE

- and glucagon, *51, 368

COMA

- and alcohol ingestion, 350
- hypoglycemic, 606
- and face color, 201

COMA, DIABETIC

- and blood acetone chromatography, 663-665

- and diabetic neuropathy, 425, 428
- and face color, 201, 207
- hyperosmolar nonacidotic, *609
- India and West compared, 409
- without ketoacidosis, 162-165, 371
- and menarchial age, 788, 790
- and mortality, 221
- pre-, 121
- and sodium lactate treatment, *440

CONFERENCE ON DIABETIC VASCULAR PATHOLOGY, 110

CONVULSIONS

- and hypoglycemia, *49
- and nalidixic acid, *683

CORONARY DISEASE. See Heart disease

CORTICOSTEROIDS

- and ACTH, 334
- and diarrhea, 371
- and human growth hormone, *315
- and hydroxycorticoids during fasting, *381
- and liver carbohydrate synthesis, *378
- and partial pancreatectomy, 593

CORTICOTROPHIN, *169

- CORTISOL, *169**
 - and alloxan, *235
 - and amino acid incorporation, *115
 - and carbohydrate metabolism, *113
 - and hyperlipemia and ketonemia, 33-35
 - and insulin, *169
 - like activity, *52
 - and lipolysis and lipogenesis, 369
 - and pancreas, 194-200

CORTISONE

- and alloxan diabetes, 792
- and alloxan-diabetic rat fetuses, 727
- and glomeruli in rabbits, 595
- glucose tolerance tests, *48, *170, *315, 371, *467
- and hypophysectomy, 43, 659
- and insulin
 - requirement, *52
 - resistance, *52
- and islet cell tumors, *115
- and lipemia, 604
- and 5-nucleotidase and adenosine triphosphatase activities, *380
- and tumor growth and glycosuria, 93

CORTISONE ACETATE, 93

- CREATININE, 93**
 - clearance and hyperuricemia, 739
 - and glucose oxidase, 224
 - and severe hypoglycemia, 606

CUSHING'S SYNDROME, *169, 736

- and diabetes, 28
- and hyperinsulinism, *684
- and insulin resistance, 556

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

CYANOSIS, *611
and infants of diabetic mothers, 160

1-CYCLOHEXYL-3-UREA, *684

CYCLOPAL, 513

CYCLOPHOSPHAMIDE
and diabetes, *612

CYSTEINE
and insulin, *53, *114

D

DENMARK
and diabetes, 215

2-DEOXYGLUCOSE, 184
and serum insulin levels, *444

DESOXYCORTICOSTERONE
and hypophysectomized dogs, 659

DEXAMETHASONE, *169

DEXTROSE
and electrocardiographic changes, *168
toxicity, *48

DEXTROSTIX, *170, *232, *611, *817

DIABETES INSIPIDUS

and diabetes mellitus
heredity factors, *116
and hypoglycemia, *169

DIABETES MELLITUS

and acetate I-C-14 incorporation into
fatty acids, 709-715

and Achilles reflex, *380

and Addison's disease and myxedema,
*317

and adrenal function, *169

and adrenal steroids, 729-736

alloxan induced

and anaphylaxis and granuloma for-
mation, *116

and cartilage powder, *170-171

among American Indians, *439-450

and antibodies to insulin, 396-402

and aortic metabolism, 310

and asteroid hyalitis, *171-172

and atherosclerosis, 41

and beta-aminopropionitrile treatment
of lathyrism rats, *613

and beta cell structure in rabbits, 792-
803

and blepharoptosis, *455-456

blood sugar control and M-value, *612

and blood sugar and exercise, *317

and blood vessel changes, 310

and bone metabolism, *455

and capillary changes, *469-470

and carbohydrate tolerance
in Tecumseh, Michigan, 413-422

and cataracts, *231-232, *611
in Chinese hamsters, *448-449
and chlorpropamide, 650-656
and citric acid cycle, 590
classifications, 60
control
and degenerative complications, 3,
4, 7
and environment, *469
and neuropathies, 518
and weight reduction, 2
convocation in Toronto, 37-43
and coronary heart disease, *117
and cyclophosphamide, *612
and degenerative lesions, 1, 2
detection, *461

and enzyme strip test, *452
and fasting plasma assays, *533
and fatty acid metabolism, 715
and glucose tolerance tests, *685
new mass screening method, 295-299
in pregnancy, *170
and reproducibility of glucose toler-
ance tests, 473-479
simplified Glucola screening test,
*453-454
and "stress" blood glucose level,
*462

in Sweden, *531, *534-535

and diabetes insipidus
heredity factors, *116

and diabetic foot, *172

diagnosis, 478-479, 519, 700

and blood saccharoids, 719
and glucose tolerance tests, *535,
583

incorrect, 606-607

and necrobiosis lipoidica, *314-315

oral sodium tolbutamide test, *451
and diet, *318, *463-464, *748, *816,
*817

adherence and artificial sweeteners,
*682
-induced in sand rat, *610

and lipids, *611

and digestive alterations, *465

and diguanides, *53

duration

and atrophic skin lesion, *817
and basement membrane thickness,
*47

and longevity, 40

and microangiopathy, *682

and motor-nerve function, *115

and neuropathy, 3, 6, 428

and oral therapy, 61-62, 64

and retinopathy, *379

early diagnosis, 1, *53, 481-487

and emotional stress, *467-468

and estrogen, *458

and ethanol or wine, 14-18, *52, *171

and ethyl-a-p-chlorophenoxy-isobuty-
rate, *467

etiology, *234, 550, 552

and environmental factors, 518

and exocrine pancreas, *53

and face color, 201-208
and family history study, *609
and fasting

serum insulin-like activity, *442
and fat and protein metabolism, 633,
662

and free fatty acids and glucose tol-
erance, 77-82

and free fatty acid metabolism, *232

and gastrointestinal tract, 371

and glomerulosclerosis, 755-770

and glucose

metabolism in leucocytes, 584-590
-6-phosphatase, 337

tolerance in old age, 581, 582

uptake of muscle, 716-718

and glycoproteins, *168

and gouty arthritis, *116

and growth hormone, 43-45, 308, 369,
556-558

and heredity, *170, *318, 371, *610

and hormones, 368

and hyperlipidemia, *452-453

and hypertension, *377, *748

and hyperthyroidism

and glucose tolerance, 740-743

and hypoglycemia, *314, *459-460

and hypothalamic lesions, *233

and impotence, 370

in India, 404-411

induced in rats, *52

and infection resistance, *114

and insulin, 12, *457, *460-461

antagonism, 369

antibody-induced, 369

-binding, 27-32, *235

degradation, 343

dependence, 552, *747

inhibition, *608

and insulin-like activity, 71-76,
*684-685

resistance, *440, *818

response to protein, *442

uptake by kidney tissue, 274-278

and iron in osteoid seams of bones,
142-145

and ischemic heart disease, *169

and ischemic leg ulcers, *318

juvenile

adjustment problems, 40-41, 260

and antibody titers, 28

attitudes, 106-109

blood sugar levels, *460

course with unmeasured diet, 240-
270

and diet-induced diabetic syndrome,
*441

educational attainments, 259-260

and ethanol, 353-354

glucose loading and insulin activity,
*49

and insulin abnormalities, 780-786

management, *317-318, *531

pancreas study, 619-632

and plasma insulin, 552-553

and sulfonylurea therapy, 64, 68

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58

May, 239-324

September, 549-618

February, 59-120

June, 325-386

October, 619-688

March, 121-174

July, 387-472

November, 689-754

April, 175-238

August, 473-543

December, 755-824

SUBJECT INDEX 1965

and synalbumin antagonist in siblings, *438
 and urinary tract infections, *315
 and wilderness camping, 676-681
 ketosis-resistant, *814
 labile, 41, 279-288
 and lipid metabolism, *447
 and L-xylulose in serum, 311-312
 maternal
 and congenital malformations, 160, 161, 260, 371, 429, 436, 482
 and fetal beta cell granulation, 137-141
 and management of infants, 435-437
 and neonatal problems of infants, 157-161
 and pancreas insulin content in infants and fetuses, 573-578
 and serum proteins of infants, *438
 and tolbutamide tolerance tests of newborn infants, *468
 maturity-onset
 and angiopathy, 309-310
 and bromsulphthalein, serum alkaline phosphatase, and thymol flocculation increases, 253
 death rate, 68
 determination in childhood, *438-439
 and glucose tolerance and serum insulin, *457-458
 and glucose tolerance tests, 77
 and high carbohydrate diet, *458
 and insulin-like activity study, 71
 and insulin response, 387, *442
 and neuropathy, *234
 and serum insulin, 26, 28, 309, *683
 and sulfonylurea therapy, 59, 64
 and monamine-oxidase inhibitors, *236
 and multiple sclerosis, *464
 and myocardial infarction, 84-86
 and necrobiosis lipoidica, *234-235
 neonatal, *233
 and nephropathy, 310
 neurologic disorders, 370, 424-429, 516-520
 new programs for, *51
 nonketotic, 4, 7, 162-165
 and obesity, *748
 onset
 and diabetic neuropathy, 518
 and osteoporosis, *316
 and pancreas beta-cell granulation, *444-445
 and pancreatic isoantibodies, 226-227
 and pancreatic secretion studies, *48
 panel discussion in Great Britain, *48
 and papillary necrosis, *167
 pathophysiology, *815
 and phagocytic activity of leukocytes, *114
 and pituitary insufficiency, *50
 and post-hypophysectomy care, *316-317
 potential, *466, 489-491

and pregnancy, *51
 and premature coronary artery disease, *611
 prevention, 41, *815
 and programmed instruction, *316
 and pruritis, *168
 and pseudotabes syndrome, *47
 psychological factors, 106-109
 and pyruvate excretion, *231
 and race, *236
 and reactive hypoglycemia, *612
 research controversies, 549-568
 and retina
 detachment, *446
 vascular changes, 121-127
 and retinopathy and nephropathy in dogs, 700-707
 Sandmeyer
 and glucose production, *746
 and Schmidt's Syndrome, *48
 and serum globulin system, *382
 serum insulin activity, *453
 and serum insulin-like activity, *382
 sex differences, *454
 and sex hormones, *452
 and socio-economic problems, 40
 spontaneous in mice, *747
 stages, *815
 "starvation," 555-556
 and steroids, *381-382
 and sulfonylureas, 59-70, 392-394, *463
 survey
 of aged, *47
 Oxford, Massachusetts, *461
 of Pima Indians of Arizona, *439-450
 of population groups, 40
 1964 world, 212-223
 susceptibility
 and obesity, *612
 symptoms
 and blood sugar levels, 3
 and taste threshold, *536
 thiazide-induced, 132-136
 and thymic hormone, 325-331
 and tolbutamide, *470, 650-656
 treatment
 with chlorphentermine, *451-452
 with sulfonylureas, 362-367, *377
 and triglycerides, 668
 and tuberculosis, 301
 and tumors, *608-609
 and ulcers, *684
 untreated
 and insulin-like activity, 10, 805-810
 and sulfation factor, *172
 and urinary tract infection, *818
 and urine
 albumin, *234
 bacteria, *533
 and vascular disease, 110-111, 307-308, *440
 and vascular lesions, *817
 and weight reduction, *52

DIABETES, PANCREATIC
 and ketonemia, 33-35
 and steroid diabetes, 93-95

DIABETES, STEROID
 and pancreatic diabetes, 93-95

DIABETOLOGIA, 812-813

DIALYSIS
 and acute tubular necrosis, 36-37
 and conversion of complexed to free insulin, 388
 and insulin binding, 568
 of insulin and fluorescein isothiocyanate, 276
 and serum protein fractionation, 71, 72

DIARRHEA
 and chlorphentermine, *451
 and diabetes, 371, *465
 and diabetic neuropathy, 5, 7, 267, 426, 428, 429, 516, 520
 and hypoglycemia, *53
 in juvenile diabetic, 121

DIAZOXIDE, *115
 -diabetes
 and insulin inhibition, *439
 and hyperglycemia, *469, 591-594
 and hypoglycemia, *610

DICHLOROISOPROTERENOL
 and lipid mobilization, *447

DIET
 and aged diabetics, *47
 in alloxan diabetes and ketoacidosis study, 289, 290
 of animals in insulin-inactivation studies, 88
 atherogenic, 369
 and blood glucose levels, 416-422
 and blood lipids, *611
 and blood sugar response to glucagon, *817
 and carbohydrate contents of foods, *379
 carbohydrate-free, *318
 and chlorpropamide and tolbutamide study, 651

CHO, 121
 choline-deficient, 666-668
 of chronic hypoxia subjects, 100
 in cortisol study, 194
 and diabetes, *318, *817
 study in India, 405, 411
 and diabetic retinopathy, 121-122
 during diazoxide hyperglycemia study, *450
 of dogs in tolbutamide study, 392
 and ethanol and wine, *171
 and exercise, *317
 fatty acids, 395
 in fibrocystic disease of pancreas, *117
 and fructose intolerance, 336
 fructose rich
 and citrate-cleavage activity, *683

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-613
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

in galactosemia, 335
and glucose production, *746
in glucose tolerance test reproducibility study, 474
gluten-free
 and diarrhea, 371
high-carbohydrate, 186
 and ketosis, *464
 and lipogenesis, *236
high fat
 and diabetes, *463-464
 and insulin requirements, 369
 and vascular disease, 307
high protein
 and insulin response, *442
and hormones
 in gluconeogenesis, *445
 and human depot fat, 105
 and hyperglycemia and glycosuria, 43
 and hyperglyceridemia, *458
 and hyperuricemia, 739
 and hypoglycemia, *610
-induced diabetes, *441, *610
-induced diabetic syndrome, *441
in induced pancreatitis in rats, 634
and insulin activity, 71, *114, *816
and intravenous glucagon response, 104
iron-enriched
 and siderosis and hemochromatosis, 699, 708
and juvenile diabetes, 41, 107, 240-270, *317-318, *531, 679-680
ketogenic
 and glucagon, 338
low carbohydrate
 and artificial sweeteners, *682
 -high fat, *52
 and serum insulin, *748
low fat
 and diabetic retinopathy, 44
 high carbohydrates and retinopathy, *816
 high protein, *168
low sodium
 and hypophysectomy, *317
in myocardial infarction and carbohydrate metabolism study, 84
in new glucose tolerance test, 97
and obesity, *451
phenylalanine-deficient, 335
of pancreatectomized dogs, 33, 690, 730
of pancreatectomized rats, 93
and plasma insulin response, *453
of premature infants, 160
and Project Head Start, 723
pyridoxine deficient, *380
Rockland rat, 179
and serum cholesterol and liver lipids, *533
in study of free fatty acids during glucose tolerance tests, 77
in study of labile diabetes, 279-280
in study of thiazide and carbohydrate metabolism, 132
sugar and starch, *378
in sulfonylurea therapy study, 60, 68
and suspected maternal diabetes, *170
and tissue response to insulin, 21
Torula yeast, *114
vitamin B₆ deficient, 515

DIETHYLAMINOETHYL CELLULOSE, 71, 72

DIGUANIDES, *53

DIHYDROXYACETONE, *382

3,5-DIMETHYLPYRAZONE
 and carbohydrate and fatty acid metabolism, 507-514

DIPHOSPHOPYRIDINE NUCLEOTIDE, 18

DIPHTHERIA, 8, 723

DISULFRAM, *114

DPN. See Diphosphopyridine nucleotide

DRUGS
 addiction and glucose tolerance, 477
 adverse reactions reporting programs, 480
 antihypertensive
 and glucose tolerance, *377
 benzothiadiazine
 and carbohydrate metabolism, *612
 and glucose oxidase test, 225
 and nonketacidotic coma, 162
 and prediabetes, 593
 prescription
 and advertising, 506, 525

DUPUYTREN'S CONTRACTURE
 and diabetes, 261

DWARFISM
 and growth hormones, 562, *613
 with hypoglycemia, *613

E

ELECTRICAL POTENTIAL
 and sugar transfer, *47

ELECTROCARDIOGRAPHY, *168
 and exercise, *317
 in juvenile diabetes study, 241, 267

ELECTROPHORESIS
 of fluorescent insulin, *51
 of free and bound insulin, *608
 of growth hormone, *610
 and insulin binding, 564
 of insulin-I-131 antibody complexes, *50-51
 and insulin-like activity assay, 809
 in juvenile diabetes study, 251
 paper
 and exercise, *317

of plasma proteins, 788
polyacrylamide gel, *50-51
serum fraction, 27-32, 72-73, 76
serum glycoproteins, *168
and serum insulin-like activity, 649
serum protein, *116
tumor glucagon, *53

ELECTROENCEPHALOGRAPHY
 in juvenile diabetes study, 241, 259

ENCEPHALOPATHY, 424, 428

ENDOCRINE GLANDS
 and carbohydrate metabolism, *452
disorders, *317, *818
 and diabetes, 300-303
 and insulin resistance, 432
 and thymic hormone, 331
and infants of diabetic mothers, 371
and insulin-induced hypoglycemia, *169
polyendocrinopathy, *48
and vitamin B₆ deficiency, *380

ENTEROPATHY, DIABETIC, *455

ENZYME
 activity and glucose 6-P, *749
 and carbohydrate metabolism, *683-684
conversion in liver, *233
and diabetes, 370, 373
and fatty acid synthesis, *232
and glucocorticoids, 484
and gluconeogenesis, 307
 and lipogenesis, *236
and glucose metabolism, 355-359
and glycogen synthesis, 306, *533, 734-735
and glycolysis and tricarboxylic acid cycle, *377
hepatic and pancreatic, 146
and hypoglycemia, 333-338
and insulin, 87, 633, 662
and liver carbohydrate synthesis, *378
metabolism
 and low pH levels, *113
pancreatic
 and fibrocystic disease of pancreas, *117
 and plasma arachidonic acid, *681

EPILEPSY
 and diabetes, 259
 and fructose intolerance, 337

EPINEPHRINE
 and adipose tissue electrical potentials, 529-530
 and arachidonic acid in pancreatectomized dogs, *681
and blood glucose, 156, *747
and 3,5-dimethylpyrazole, 508, 514
and fatty acid release and lipolysis, *231
and hyperglycemia, *235, 353
and hypoglycemia, 333-335, 338, 536

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

and insulin secretion, *444
and lipid synthesis, and glucose and fatty acid metabolism, *446-447
and metabolism, 561, 562
 in muscles, *378
 in obese adolescents, *746-747
and nonketocacidotic coma, 162
and obese adolescents, *610
and phosphorylase activity, *534
response in infants, *815

ERYTHROCYTES
and blood sugar concentration, 672
and galactosemia, 335
and glucose movement, *232-233
glucose-6-phosphate dehydrogenase deficiency, *315

ESTROGENS
and diabetes, 368, *452, *458
and partial pancreatectomy, 593

ETHANOL, 15
assay
 Fisher method, 15
 Harger dichromate method, 15
 Somogyi method, 15
effect on lipids, ketones, and blood sugar, *52, *171
and glucose uptake, *172
and hypoglycemia, 350-360, *448
and iron, 144
and lipid metabolism, *533
metabolism, 14-18
precipitates, 26

ETHYL-a-p-CHLOROPHENOXYSOBUTYRATE, *467

EUROPE
Sweden
 diabetes detection in, *531
 mass diabetes survey, *534-535

EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES, 812-813

EXERCISE
and blood sugar, *317, 419
and calorie expenditure
 device for measuring, *814-815
and free fatty acids, *380, *611
and glucose utilization, 369
and juvenile diabetes, 677
and serum cholesterol and liver lipids, *533

EYE
blepharoptosis, and diabetes, *455-456
diabetic changes in, 41, 428
in juvenile diabetes, 241, 257
and microangiopathy, *47
and pituitary irradiation, 310
visual acuity and vascular anatomy, 126

F

FAMILY HISTORY, *116, 371
and carbohydrate tolerance and tolbutamide response of obese children, *438-439
and diabetes detection
 in Sweden, *531
 test, *454
of diabetics and nondiabetics, *609
and glucose tolerance tests, *318, 473, 477, 481, 482, 489
and hyperlipidemia, 258
and hyperthyroidism and diabetes study, 741
and insulin
 antagonism, *438
 -like activity, *170
in juvenile diabetes study, 242
and marriage, 260
and multiple sclerosis, *464
and obesity, *612
in phenformin hydrochloride study, *465
and postgastrectomy hypoglycemia, 526
and prediabetes, 175
and red faces, 201, 204
and RH negative pregnant subjects, *460
and South African diabetics, *470
and study of menarchial age of diabetics, 788
and synalbumin antagonism, 566

FATTY ACIDS
and acetate I-C-14 incorporation, 709-715
and basement membrane thickening, 370
in depot fat
 and diet, 395
and diabetes onset, 411
esterified
 and alloxan diabetic rats, 180, 182, 184
 and pancreaticized dogs, *681
 and triglyceride determination, 636
free
 and adipose tissue, 181, 184
 and amino acid nitrogen, *448
 and blood sugar, 369
 determination, *684
 and diabetic acidosis, 370
 and diazoxide, *610
 and emotional stress, *467-468
 and estrogen, *458
 and ethanol, *52, *171
 and exposure to cold, *379, *683
 and glucose
 ingestion, *748
 and insulin in pregnancy, *113
 tolerance tests, 77-82
 utilization, *455
 and growth hormone, 374
 and hormone activity, 87

and hyperlipidemia, *232
and insulin, 633
and insulin-induced hypoglycemia, *532
and ketones and glucose, 286, 287
and medium-chain triglycerides, *448
metabolism, *233, 559-562
 and 3,5-dimethylpyrazole, 507-514
 and insulin, *117
 and obese adolescents, *610, *746-747
and myocardial infarction, 84-86
and pancreatitis, *462
and phenformin and tolbutamide, *456
and stress, 380
turnover rate, *232
utilization, *531
and glucose carbon incorporation, 26
-glucose cycle, *117
glucose metabolism, *171
of human depot fat, 105
in juvenile diabetes study, 251
and lipogenesis, *457

FETUS
abnormalities
 and sulfonylureas, 435-436
of alloxan-diabetic rats, 724-728
beta cell granulation
 and glucose, *444-445

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58
February, 59-120
March, 121-174
April, 175-238

May, 239-324
June, 325-386
July, 387-472
August, 473-549

September, 549-618
October, 619-688
November, 689-754
December, 755-824

SUBJECT INDEX 1965

B

 blood sugar levels, *235
 and diabetic pregnancy, 372
 and glucose and fructose metabolism, *113
 and hyperglycemia, 137-141
 indications for early delivery, 158
 and insulin, 573-578
 and maternal diabetes, 44, 435
 and maternal prediabetes, 175-176, *485, *681
 mortality, 261
 and urinary estriol treatment, *682
 and placental gradient, *172
 plasma insulin and blood sugar, *381

FIBRIN
 and diabetic glomerulosclerosis, 756, 765

FIBRINOGEN, 756, 767

FIBRINOLYSIS
 and phenformin, *532

FLUORESCEIN ISOTHIOCYANATE
 and insulin, 274-278

FOOD
 intake, and methylprednisolone, 732
 for juvenile diabetic campers, 679-680

FORMOL-DIMEDONE, 180

FRANCE
 and diabetes, 214, 221

FRUCTOSE
 autoclaved, *48
 and electrical potential studies, *47
 and ethanol ingestion, 14, 359
 and glucose tolerance tests, 96
 intolerance, and enzyme defects, 333, 335-336
 metabolism, *113, *446
 tolerance
 in infants, 156
 and uremia, *169, *459
 uptake, and insulin, *115

FRUCTOSE-1,6-DIPHOSPHATE, 147

FRUCTOSE-6-PHOSPHATE, *52

FRUCTOSE-1-PHOSPHATE ALDO-LASE, 336

FRUCTOSURIA
 and hereditary fructose intolerance, 335-336

FURUNCULOSIS, 77

G

GALACTOSE
 and blood glucose levels, 156
 and cataracts, *611
 and electrical potential studies, *47
 and glucose tolerance tests, 96, 335

-induced hypoglycemia, *681-682
 and insulin-like activity, *444

GALACTOSE-1-PHOSPHATE, 335

GALACTOSE-6-PHOSPHATE, *52

GALACTOSEMIA, 44, *681-682
 and enzyme defects, 333, 335

GAMMA GLOBULIN
 insulin-like activity, 71-76
 and serum assay of bound and free insulin, 397

GANGRENE, 516, *531, 761
 of feet, *172
 and mortality, 221
 and neuropathy, 7, 426

GASTRIC SECRETION
 and insulin, *316

GASTRIN, *316

GASTROINTESTINAL TRACT, 295
 bleeding, and nonketacidotic coma, 162
 and diabetes, 371, *465
 disturbances
 and diabetic neuropathy, 428
 and sulfonylurea therapy, 67
 and glucose, 193, 345
 and insulin
 hypoglycemia, *532
 secretion, *167, *168
 and pancreas, *48
 and phenformin overdose, 811-812
 in pregnancy, *683
 proteinases, and insulin activity, 698
 and pyrazole action, 514
 surgery, and hyperinsulinism-hypoglycemia, 526-528
 and tolbutamide, *814

GENES
 and abortions and stillbirths, 340, 367
 and biochemical defect, 41
 and diabetes, 43, 221, *234, 371, 519, 550, 610
 juvenile, 780
 potential, 491
 and fatty acid metabolism, 709
 and hyperthyroidism and diabetes, 743
 and insulin antagonism, *438
 and prediabetes, 481
 and renal lesions, 550
 and retinopathy, *379

GERMANY
 and diabetes, 214

GLOMERULI
 of prednisolone-fed rabbits, 600-602

GLOMERULOSCLEROSIS, 310
 and auto-immune reaction, 402
 cause of, 110
 and cortisone, 595

and diabetic dogs, 706, 709-710
and electron microscopy, 310, 604
experimental diabetic, *377
and glomerulonephritis and systemic lupus erythematosus, *441-442

and insulin, 276, 278, 551
in juvenile diabetes study, 265-266
and prediabetes, 550
and renal lesions, 755-770
and retinal lesions, 517

GLUCAGON, *50
 and amino acid nitrogen, *447
 and alcohol hypoglycemia, 351, 353
 and blood glucose, 156
 and bronchogenic metastases, *53
 and cobaltous chloride, 51
 and fasting, *816
 and free fatty acids, 87
 -free insulin, *169
 and glucose, 368
 and glucose anomers, *747
 and hypertriglyceridemia, *611
 and hypoglycemia, 333, 334
 immunoassay, two antibody system, *450
-induced hyperglycemia, *444
and insulin, 368
and islet cell tumors, *115
and lipid synthesis and glucose metabolism, *446
and liver, *167
and phosphorylase activity, *534
and plasma arachidonic acid in pancreatectomized dogs, *681
radioimmunoassay, *167
test, 100, 101-102

GLUCOCORTICOIDS
 and glucose tolerance test, 481, 484
 and pancreatic islets, 194, 198

GLUCOKINASE
 and insulin, *468

GLUCONEOGENESIS
 and adrenal cortical hormones, *113
 and adrenal steroids, 729-736
 and alcohol ingestion, 350-360
 and diet and hormones, *445
 and enzymes, *236, 306
 and hypoxia, 104
 increase, 333
 and stress, 518

GLUCOSAMINE
 and atherosclerosis, *380

GLUCOSAMINE-6-PHOSPHATE, *52

GLUCOSE
 and amino acids, *235
 and beta cell granulation, *444-445
 breakdown to glycogen, and insulin, *815
 concentration in liver, *167

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

-cortisone tolerance tests, 481-487
 disposal
 in elderly diabetics and nondiabetics, 579-582
 and intestinal mucosal extract, *440-441
 and electrical potential studies, *47
 and ethanol metabolism rate, 14
 and fat metabolism, *235
 -fatty acids
 cycle, *117, 369
 and fatty acids
 free, *534
 metabolism, *684
 release, *231
 synthesis, *683-684
 uptake, *171
 and hyperinsulinism, *49
 and hypoglycemia, 249, 344-346
 and infant acidosis, 160
 inhibitors, *51
 and insulin
 dosage, 280-281
 and free fatty acids in pregnancy, *113
 in pregnancy, *381
 response, *683
 secretion, *444
 intolerance
 azotemic, *459
 and diabetic neuropathy, 428
 intravenous and oral, *168
 and islet cell secretion, 305
 kinetics, and diabetes, 373
 and lipogenesis, *447
 -loading
 and acromegaly, *167
 and insulin-like activity, 10, 11, 12, 71, 72-76
 and serum insulin assays, 27-32, *116
 in maternal and cord plasma, *613
 metabolism, *50, *236
 and adrenal steroids, 729-736
 and fatty acids, *171, 374
 and glucose-6-phosphate, *468-469
 and glycosides, *534
 and growth hormone, *379
 hormonal effects, *446-447
 and insulin, *682, 689-695
 and insulin antibodies, 369
 of islet cell tumors, *49
 in leucocytes of diabetics, 584-590
 and liver, *466
 and L-xylulose, 311
 and nutrition, *746
 in obese adolescents, *610, *746
 in pregnancy, *609
 in sheep fetus, *113
 movement
 in erythrocytes, *232-233
 and newborn infants, 127, 156
 output and hypoglycemia, *114
 and palmitate, *171
 and pancreatic changes, 493-500
 and pancreatic diabetes, 93
 phosphorylation, 26, 306
 and plasma insulin, 778
 and plasma lipids, in pregnancy, *609
 and respiration, *685
 response in normals, *442
 and serum insulin, *470, *532-533
 and sulfonylureas, 209-211
 tasting tests and diabetes, *536
 and thiazides, *115
 tolerance
 and age, sex and test conditions, 413-422
 and antihypertensive drugs, *377
 and atrophy, *454
 and cortisol, 194
 and diet, *611
 in fasting diabetics and nondiabetics, *442
 and growth hormone, *444, 557-559
 and hyperthyroidism, 740-743
 and insulin, *314
 and L-leucine sensitivity, *47
 and mebanazine, *236
 and multiple sclerosis, *464
 and myocardial infarction, 84-86
 and obesity, *378, 553-556, 559
 in old age, 579-583
 and renal disease, 550
 and serum insulin, *457-458
 and triglyceride-induced hyperketonemia, *448
 and uremia, *169
 tolerance tests, *52, 53, *316
 and adrenal steroid therapy, *114
 and asteroid hyalitis, *171-172
 and atherosclerosis, *682
 and blood saccharin, 719-722
 and chronic hypoxia, 100-104
 compared, 481-487, *535
 and coronary heart disease, *116-117
 and diabetes detection, 202, *315, *462, *531, *685
 and diabetes with endocrinopathies, 301
 and diabetic heredity, *318
 and diazoxide hyperglycemia study, 592-594
 and erythrocyte deficiency, 315
 and free fatty acids, 77-82
 Hagedorn-Jensen, 209
 and hematocrit analysis, 672-674
 and hypertension, *749
 in juvenile diabetes study, 242
 new, 296, 297
 new carbohydrate solution for, 96-99
 and normals and potential diabetics, *466
 and normal urine, *609
 and obesity, *438-439, *612
 oral
 and oral sodium tolbutamide tests compared, *451
 reproducibility study, 473-479
 and RH negative pregnancy, *460
 and Oxford, Mass., diabetes survey, *461
 and phenethylbiguanide study, *461
 and postgastrectomy patients, 526-528
 in prediabetes, 175
 prednisone, 489-491
 in pregnancy, *170, 371
 and premature artery disease, *611
 rapid intravenous, *683
 and reactive hypoglycemia with mild diabetes, *612
 and thiazide therapy, 132-133
 in thyrotoxicosis, *50
 and tolbutamide tolerance tests, *536
 triamicinolone-, 481-487
 and xerostomia, *48
 transformation to glycogen, *235
 transport, 368
 and adipose tissue electrical potential, 529
 and insulin, *815
 and polyphosphates, *749
 and protein synthesis, 662
 and true anaphylaxis and granuloma formation, *116
 uptake
 and albumin antagonism, *356-357
 and anaerobiosis and cell poisons, 128-131
 by fractured dog limbs, *383
 and insulin, *117
 and insulin inhibitors, *115
 and ketosis-resistant diabetes, *814
 and lactate production, 310
 of muscle tissue in diabetics, 716-718
 new test for, 186-193
 rat hemidiaphragm, *438
 and secretion, *167
 urine tests, 59, 224-225
 utilization, 8
 and alcohol hypoglycemia, 350-360
 by chick embryo heart homogenates, *746
 and chlorothiazide therapy, *612
 and exercise, 369
 and fatty acids, 370
 and insulin, 341-349, *455
 and intestinal absorption, *314
 and ischemic heart disease, *234
 and morphine, *172
 and plasma sugar determinations, 165-166
 and thyroid enzymes, *377
GLUCOSE-C-14, *48, 310, *467
 and adrenal steroid study, 729-736
 and alloxan diabetes, 180, 182, 184
 and benzoic acid insulin-like activity assay, *681
 conversion to C-14 lipid, *170
 and ethanol, 356-360

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

and fructose, 336
 incorporation
 and insulin, 19-26
 into lipids, *457
 and insulin assays, 309
 and insulin study of pancreatectomized dogs, 689-695
 and liver glycogen synthesis in dogs, *531
 metabolism
 and blood reticulocytes, *747
 and 3,5-dimethylpyrazole, 508
 and hormones, *231

GLUCOSE-U-C-14
 uptake, *443

GLUCOSE OXIDASE METHOD, 127, 224-225

GLUCOSE-6-PHOSPHATASE, *115, *682
 and Embden-Meyerhof pathways, *446
 and hypoglycemia, 337
 pancreatic, 146-156

GLUCOSE-6-PHOSPHATE, *52, *682
 and glucokinase inhibition, 307
 and glucose metabolism, *468-469
 and glycogen synthesis, 735
 and liver enzyme activity, *233, *749

GLUCOSURIA
 in pregnancy, 482

GLUTAMATE
 and Krebs cycle, *748

GLUTAMIC-OXALACETIC TRANS-AMINASES, 637

GLUTAMIC-PYRUVIC TRANSAMINASES, 637

GLUTATHIONE, 133, 135, 136
 -insulin transhydrogenase, 369, *749

GLUCOCORTICOIDS
 and diabetes, 550, 556

GLYCEMIA
 and diabetic lesions, 550
 and myocardial infarction, 84, 85
 in pancreatectomized and normal dogs, 34

GLYCERIDES
 and sugar and starch ingestion, *378

GLYCERIDE-GLYCEROL
 activity of plasma lipoprotein, *467
 formation, 184
 and hormones, *231

GLYCEROL
 and fat metabolism, *235
 and fat pads of diabetic rats, 180, 181, 183, 184
 mobilization in diabetes, 77

GLYCEROPHOSPHATES, 147
 and alloxan diabetic rats, 183, 184, 185

GLYCINE
 incorporation into protein, *171

GLYCOGEN
 activity studies, *52
 and anaerobiosis, *749
 content
 and diabetes, *682
 of rat liver, heart, and muscle, *232
 conversion to lactate, *115
 determinations
 Good, Kramer and Somogyi, 209
 formation and glucose-6-phosphate, *468-469
 and glucagon, 102, 104
 glucose transformation to, *235
 and infants of diabetic mothers, 436
 in livers of Indian diabetics, 408
 metabolism and insulin, *238
 and muscle glycogenesis, *169
 in normal and diabetic nerve tissue, *447
 and obesity in infants of diabetic mothers, 724
 and ouabain, *534
 and palmitate, *171, *455
 in pancreas beta cells, *450
 of rat diaphragm and adipose tissue, 19-26
 storage disease
 and enzyme defects, 104, 333-338
 synthesis, 306, 729, 734-735
 and albumin, *457
 and insulin, *531
 and metabolism, *533
 and puromycin and actinomycin D, *236

GLYCOGENESIS
 and enzyme defects, 333-338
 and hyperthyroidism, 743

GLYCOGENOLYSIS, *534
 and adrenalin, 345
 and ethanol ingestion, 355
 and hyperthyroidism, 743
 inhibition, *171
 and D-ribose, *685

GLYCOGENOLYTIC AGENTS
 and liver phosphorylase, *534

GLYCOGENESIS
 and skeletal muscle, *169

GLYCOLYSIS
 and insulin, 369

GLYCONEOGENESIS
 and chlorpropamide, 209-211

GLYCOPROTEINS
 and diabetes and atherosclerosis, *168
 and prediabetes, *448-449

GLYCUSURIA, 43, *236, 397
 in alloxan diabetic mice, 325
 and alloxanized rats, 181, 502
 and diabetes
 diagnosis, 527, 700
 severity, 60
 study in India, 407
 and diabetic lesions, 550
 and diet-induced diabetic syndrome, *441
 and family history study, *609
 and fasting blood sugar values, 3
 and glucocorticoids, 194, 481
 and glycoproteins in hamsters, *448-449
 and growth hormone, *444
 and hypoglycemia, *459-460
 incidence in British town, *53
 and insulin, *50, *449, *815
 and juvenile diabetes, 242, 246-247, *531
 and mass survey in Blekinge, Sweden, *535
 and myocardial infarction, 84, 85
 and nalidixic acid, *683
 and neonatal diabetes, *233
 and neuropathy, 1, 4, 518
 and oral hypoglycemia, 405
 and pancreatectomized dogs, 690
 in pancreatic and steroid diabetes, 93-95
 postprandial, *464
 and prediabetes, 175
 and prednisolone-fed rabbits, 595-598
 and pregnancy, *170
 and pyruvate levels, *231
 renal, and itching, *168
 and retinopathy, *379

GOLGI COMPLEX
 and cortisone-alloxan-treated rabbits, 793, 794, 796, 802

GONADOTROPINS, *452, 562

GOUT
 and reducing diets, 739

GREAT BRITAIN
 diabetes in, *48, 214, 221
 survey in village, *53

GREECE
 and diabetes incidence, 215

GROWTH HORMONE
 and alloxan diabetes, *50
 antagonism, and dwarfism, 562
 assays, *610
 and beta cell changes, 373
 deficiency, and hypoglycemia and dwarfism, *613
 -dependent sulfation factor, *172
 and diabetes, 43-45, 308, 369, 373, 411
 and glucose metabolism, 193, 311, *379
 and hypoglycemia, 333, *610

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

and hypophysectomy, *171
 -induced diabetes
 and retinopathy, 705
 in infants, *378
 and insulin
 antagonism, 368
 secretion, *167, *444
 and lipogenesis, 369
 and lipolysis, 369
 measurement, *315
 and metabolism, *117, *231
 and obesity, 370
 and plasma free fatty acids, 556
 and prediabetes, 369-370
 radioimmunoassay, *167
 role, 374
 secretion, and diabetes, 550, 552, 556-558
 and serum insulin response, *683
 and sex, 370
 survival in plasma, *50
 and thymic activity, 331

H

HASSAL'S BODIES, 329, 331

HEART
 carbohydrate and fatty acid metabolism, *171
 free fatty acid utilization and acetooacetate, *531
 glucose utilization, *746
 glucose uptake, and adrenal steroids, 735
 glycogen
 and amyloglucosidase, *232
 perfused rat
 and anaerobiosis, 128
 carbon dioxide formation, *685
 and ouabain, *534
 sugar penetration and inhibitors, *48

HEART DISEASE
 coronary
 and race, *236
 and diabetic mortality, 221
 and diabetic neuropathy, 4, 2
 and glucose tolerance tests, *116-117
 ischemic
 and glucose utilization, *234
 and study of diabetic women, *169
 in juvenile diabetes study, 266-267

HEMATOCRIT, 165-166

HEMOCHROMATOSIS, *818
 and kidneys, 277
 and neuropathy, 8
 and pancreatic antibodies, 227
 and retinopathy, *682
 and serum L-xylulose, 312
 and siderosis, 699, 708

HEMORRHAGE
 adrenal glands, *815

and diabetic retinopathy, 264
 in induced pancreatitis in rats, 636
 retinal, 517
 metasomatotropin-diabetic dog, *378
 subarachnoid, in tubular necrosis patient, 33

HENLE'S LOOPS
 in prednisolone-induced nephropathy, 599

HEPARIN, 186-187, 192
 and insulin-like activity, 805-810
 and plasma insulin activity, 387
 and radioimmunoassay of serum insulin, 772-778

HEPATOMEGLY, 253, *465

HEREDITY
 and diabetes, 41, 43, *116, *234, *318, *370, *609
 and diabetic atherosclerosis, 307
 and facial redness in diabetes, 207
 and fibrocystic disease of pancreas, *117
 and insulinase inhibition, 786
 and iron in osteoid seams, 145
 and juvenile diabetes, 107
 and neuropathies, 516, 518-519
 and obesity, *314

HEXOKINASE, *115

HEXOSE
 intestinal transfer and phlorrhizin, *51

HISTAMINE
 and insulin-like activity, *443

HISTIDINE
 and insulin, *818

HODGKIN'S DISEASE
 and serum L-xylulose, 312

HORMONES
 binding to plasma protein, 562-565
 and blood sugar, 333
 and diabetes, 222, *234
 and diet in gluconeogenesis, *445
 and hyperglycemia and hypoglycemia, *469
 and induced hyperglycemia in rabbits, 792
 and insulin inactivity, 87-92
 from islet cells, 305
 and metabolism, 368, *446-447
 and neuropathy, 429
 ovine prolactin
 and metabolism, *231
 pituitary gonadotrophin
 and diabetic impotence, 428
 in pregnancy
 and free fatty acid increase, *113
 secretin
 and glucose uptake, *167
 sexual
 and diabetes, *452, 501-505

testosterone
 and mammary glands of alloxan-diabetic rats, 501-505
 thymic reticular, 331

HYALINE MEMBRANE DISEASE, 158, 159, 160, 435, 436, 577

HYDRAMNIOS, 261

HYDROCHLORTIAZIDE, *115, 182

HYDROCORTISONE, *49
 and glucose metabolism, 729-736
 and infant hypoglycemia, *815

HYDROXYBUTYRATE, 498

17-HYDROXYCORTICOIDS, 132, 133, 135, *169

17-HYDROXYCORTICOSTEROID
 and infants of diabetic mothers, 436

HYDROXYHEXAMIDE, *456

HYPERAZOTEMIA, *236

HYPERBILIRUBINEMIA
 and infants of diabetic mothers, 158-159, 161, 436

HYPERCHLOREMA, 162

HYPERCHOLESTEROLEMIA
 and diabetic neuropathy, 3
 and glucose metabolism in leucocytes, 584-590
 and high cholesterol diets, *611
 and retinal vascular changes, 121, 126

HYPERCORTICALISM, 95

HYPERGLYCEMIA, 43, 397, 425, 429
 and alloxanized rats, 180, 181
 and antihypertensive drugs, *377
 and antisera, *170
 and beta cell

 activity, 306
 damage, 199
 granulation, 137-141
 and caffeine, *169
 and COCl₂-injected rats, *51
 and diabetes diagnosis, 176, 202
 and Dextrostix tests, *817
 and diabetic neuropathy, 517-518
 and dialysis, 37
 and diazoxide, *450, *469, 591-594
 and diet-induced diabetic syndrome, *441

 and ethanol, 353
 glucagon-induced, *444
 and glucocorticoids, 194
 and glucose disposal rate in elderly nondiabetics, 581
 glucose and insulin antibody induced, 493-500
 and glycogenolytic agents, *534
 and glycosuria, *168
 and growth hormone, *50, 193, *378, *444

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58

May, 239-324

September, 549-618

February, 59-120

June, 325-386

October, 619-688

March, 121-174

July, 387-472

November, 689-754

April, 175-238

August, 473-548

December, 755-824

SUBJECT INDEX 1965

and guinea pig anti-bovine insulin serum, *49
hormone-induced in rabbits, 792
hydrocortisone-induced
and 3,5-dimethylpyrazole, 508, 509, 514
and hyperketonemia, *458
and hyperosmolar coma, 164
and hyperthyroidism, 743
and hypophysectomy, 556
and hypothalamic gold uptake, *378
and insulin, *815
antiserum, 370
intestinal, 696-698
-like activity, *685
secretion, 345
and islet-cell formation, 368
and juvenile diabetes study, 240, 242, 246, 247, 249
and ketoacidosis, 290
and liver glucose production, 736
and nalidixic acid, *683
and obesity, *610
and pancreas islet and beta cells, 578
and pancreatic insulin regulation, 309
and peptide, *445
and phenformin, *465-466
and potential diabetes, 491
and red faces, 201
and retinopathy, 550
and sulfonylurea therapy, *463
and thiazide therapy, 133, 134, 135
and thymic changes, 329
and xerostomia, *48

HYPERGLYCERIDEMIA
and carbohydrate tolerance, *458

HYPERINSULINEMIA, *52, *816
and alloxanized rats, 291
and Cushing's syndrome, *684
and diabetic neuropathy, retinopathy, nephropathy, and premature vascular disease, *685
and hypoglycemia, *314, 338, 344-346, 526-528
and insulin sensitivity, 552, 553
and maturity onset diabetes, 343
in multiple sclerosis, *464
and obesity, 553-555
and pancreas alpha cells, 334
and pancreatitis, *462
and pregnancy, *749
and tolbutamide, leucine, and glucose, *49-50

HYPERKETONEMIA, *235, *458, *683
and ethanol and wine, *171
and guinea pig anti-bovine insulin serum, *49
triglyceride-induced
and glucose tolerance, *448
and urate excretion, 739, 787, 804

HYPERLIPIDEMIA
and choline deficiency, 666-668

and clofibrate therapy, *452-453
and diet, 332
and diet-induced diabetic syndrome, *441
and ethyl-a-p-chlorophenoxy-isobutyrate, *467
and fatty acid metabolism, 713
and insulin, 33-35
and phenformin, *465-466
of pregnancy, *609
postprandial
and glucose utilization, *234

HYPERNATREMIA, 162, 164

HYPERPHAGIA
and hyperglycemia, *378

HYPERPHOSPHATEMIA, 162

HYPERPLASIA, *115
adrenal
and diabetes, *169
of blood vessels
and diabetic neuropathy, 426
islet cell, 641
and exocrine pancreatic tissue, 194-200
in fetuses and infants of diabetic mothers, 44, 573, 574, 577

HYPERPROTEINEMIA, 604

HYPERTENSION, *168, 201
and diabetes, 126
and glomerulosclerosis, 759
and glucose tolerance, *377
and ischemic leg ulcers, *318
in juvenile diabetes study, 265, 266-267
and menarchial age of diabetic women, 788, 789
and neuropathy, 425, 428
and potential diabetes, 489
and pregnancy, 577
renal arterial
and diabetes, *748-749

HYPERTHYROIDISM
and blood glucose test, 186-187
and glucose tolerance, 740-743

HYPERTRIGLYCERIDEMIA, 250, 251
and carbohydrate metabolism, *611
and chlorophenoxyisobutyrate and androsterone, *814

HYPERTROPHY, *115
islet cell
in fetuses and infants of diabetic mothers, 573, 574, 577

HYPURURICEMIA
and diagnosing diabetes, *116
and fasting, 787, 804
and reducing diets, 739
and thiazide therapy, 135

HYPOGLYCEMIA, *168, 429
adrenocorticotropic hormone-induced, *748
and alcoholism, *233, 350-360
and alloxan diabetes, *235
and amino acid nitrogen, *448
and birth weight, *535
and calcium and magnesium, *462
and carbohydrate tolerance, *459-460
and diabetes, *314
and diabetic neuropathy, 1, 2, 3, 4, *114, 428
and diazoxide, *450, *469, *610
and dichloroisoproterenol-treated rats, *447
and diguanides, *53
and dwarfism, *613
and enzymes, 333-338
and enzyme strip test, *452
and epinephrine, *235
and face color, 201
and free fatty acid levels, 78
and glucose tolerance testing, *52
and growth hormone, *315, 374, *378, 558
and hyperglycemia and glycosuria, *459-460
and hypothermia, *233-234
and infants, *468, *815
and insulin
activity, 431
insulin-induced
adrenocortical response, *169
and antisera, *170
and epinephrine, *536
and gastric secretions, *532
and growth hormone concentration, *50
and plasma free fatty acids, *532
and postgastrectomy, 526-528
and insulin
resistance, *377, *818
secretion, 341-348
therapy, 162
and islet cell tumors, *115
and juvenile diabetes study, 240, 245, 249-250, 259
and ketone bodies, *531
ketotic, *315
and labile diabetes, 287
lactose- or galactose-induced, *681-682
leucine, *439
and L-leucine, *47
and multiple sclerosis, *464
neonatal, 127, 156, 261
and neuropathy, *234
and newborn calves, *49
and pancreas tumor, *53
and pancreatectomy, *683
and pancreatic extracts, 389
and pancreatitis, *462
and phenformin, 812
postprandial, and Regular Insulin, *316
and premature infants, *613
and Protamine Zinc Insulin, *534

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

and protein synthesis, 633
 and pyridoxine-deficient diet, *380
 and salicylate poisoning, *315
 reactive, and mild diabetes, *612
 and D-ribose, *685
 and shock
 during sulfonylurea therapy, *377
 and sugar determinations, 166
 and sulfated insulin, *440
 and thiazides, 132
 and thymic changes, 325, 328-331
 and tolbutamide, *114, 315, 606-607,
 *816
 and Wilm's tumor, *316
 and xerostomia, *48

HYPOKALEMIA
 and thiazide therapy, 135

HYPONATREMIA, 162

HYPOPARATHYROIDISM
 and infants of diabetic mothers, 436

HYPOPHOSPHATEMIA, *49

HYPOPHYSEAL GLAND
 and hypoglycemia, 334

HYPOPHYSECTOMY, 556, 557
 and adipose tissue metabolism, *171
 and diabetic retinopathy, 43
 and diazoxide, *469, 591, 592
 and growth hormone concentration,
 *50
 and insulin response, 368
 and insulin-like activity in dogs, 658-
 661
 and ketone bodies, 556
 and lipids and hormones, 33-35
 and retinopathy, 558
 and sodium and aldosterone metabo-
 lism control, *316-317
 and sulfation-factor, *172

HYPOPHYSEO-ADRENAL FUNCTION
 in diabetic angiopathy, *53

HYPOPITUITARISM
 and diabetes mellitus, *50
 diagnosis, *315
 and hypoglycemia, 348
 and irradiation in retinopathy, 308

HYPOPROTEINEMIA, 126

HYPOTENSION
 and diazoxide, *469
 and fasting for obesity, *532
 and hypophysecomy, *316-317
 orthostatic, 7
 responses to, 562

HYPOTHALAMUS
 and diabetes, *233, 425
 during hyperglycemia, *378
 and vitamin B₆ deficiency, *380

HYPOTHERMIA
 and hypoglycemia, *233-234

HYPOTHYROIDISM, 300, *455
 and hypothermia, *284

HYPOTONIA, *456

HYPOXIA
 and carbohydrate metabolism, 100-104
 and lactic acidosis, 162
 and phenformin, *464-465

I

IMMUNOCHEMICAL METHOD, 28,
 31

IMMUNOELECTROPHORESIS, 27, 31,
 *170
 antiserum, 755-756
 growth hormone, *610
 and pancreatic isoantibodies, 227
 and serum proteins, *438

IMMUNOGLOBULIN, 755, 756

IMMUNOHISTOPATHOLOGY
 of diabetic glomerulosclerosis, 755-770

IMPOTENCE
 and diabetes, 370
 and diabetic neuropathy, 5, 7, *47,
 267, 427, 429, 520

INDIANS
 and diabetes mellitus, *236

INFANTS
 big, 28, 77
 and diabetic susceptibility, *612
 and hyperthyroidism and diabetes
 study, 741, 743
 and maternal diabetes, 481, 482,
 577-578
 and maternal prediabetes, 550
 and prediabetic parents, 175-177
 congenital malformations, 160, 161
 and hypoglycemia, *815
 and maternal diabetes, 160, 161,
 260, 371, 429, 436, 482
 and urinary estriol, *682
 and diabetic parents, 260
 fatty acid determination method, *684
 and fibrocytic disease of pancreas,
 *117
 and fructose intolerance, 336
 glycogenesis, 333, 337
 growth hormone metabolism and se-
 cretion, *378
 hyperglycemia, 137
 hypoglycemia, *115
 hypoglycemic
 and diabetic plasma injections, *613
 and maternal diabetes, *53, 157-161,
 372, 435-437, 520, 724
 and maternal diabetes
 and allergic pancreatitis, 641
 and islet cell hyperplasia, 44

neurologic abnormalities, 425, 429
 and pancreas insulin content, 573-
 578
 and serum proteins, *438
 tolbutamide tolerance tests, *468

neonatal
 and blood sugar, *815
 and diabetes, *233
 and hypoglycemia, 127, 156
 premature, and hypoglycemia inci-
 dence, *613
 with RH negative and diabetic moth-
 ers, *460
 stillborn, and chromosome abnor-
 malities, 340, 367

INFECTIONS
 and juvenile diabetes, *317-318

INSULIN
 and acromegaly, *167
 activity
 augmentation, 10-13
 and calcium and magnesium, 430-
 431
 and diet and minerals, *114
 extrapancreatic regulation, 309
 and obesity and starvation, *748
 and adipose tissue, *454
 electrical potentials, *451, 529-530
 inactivation, 87-92
 and adipose tissue metabolism, 307
 and alcohol hypoglycemia, 351, 353-
 354
 and alloxan diabetic rat fetuses, 727
 and alloxanized pregnant rats, 137, 139
 and amino acid incorporation, *115
 antagonism, 82, 86, 369, 373, 610, 810
 and albumin, *456-457
 and chlorothiazides, 435
 in elderly nondiabetics, 581
 and glomerulosclerosis, 755, 756
 and glutathione-insulin transhydro-
 genase of liver, *749
 and growth hormone, 368
 and lesions, 518
 and siblings of diabetics, *438
 antibodies, *449, *747-748
 assay, *449
 and glomerulosclerosis, 551
 and insulin binding, 396-402
 in insulin-resistant diabetes, *52
 and pancreas studies, *449-450
 and anti-insulin serum, *49, 637, 638
 and arterial cholesterol uptake, *746
 assay
 Grodsky and Forsham immunochem-
 ical method, 28
 intraperitoneal, *443
 and resistance to insulinase, 783-786
 spectrophotometric, *468
 tumor slices, *49
 autoimmunity, 551-552
 and beta cell phosphatase activity,
 *168
 beta chain, and albumin, 568

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

binding
 and antibodies, *51, *531
 and cationic exchange resins, *316
 and fluorescein isothiocyanate, 51
 and insulin antagonism, 563-568
 and blood glucose
 anomers, *747
 regulation, 308
 and blood, symposium, 308-309
 "bound," activity, *443
 bovine, 14, 15
 absorption in newborn calf, *117
 and antibodies, *170
 and bronchogenic metastasis, *53
 and carbohydrate metabolism, *233,
 307, *380
 cod and ox, 306
 and citrate-cleavage activity, *683-684
 concentration, in thyrotoxicosis, *50
 crystalline, 565
 beef, *449
 and "bound," *443, *683
 in diluted serum, 10, 11
 and postprandial hyperlipidemia, *234
 crystalline zinc
 and blood sugar study of children,
 *460
 and protein incorporation, *167
 deficiency
 and epididymal adipose tissue, *382
 and hormonal activity, 505
 and retinopathy, *379
 and diabetes control study, *469
 and diabetes study in India, 405, 408
 and diabetic angiopathies, 110
 and diabetic lesions, 310, 551
 and diazoxide hyperglycemia, *450
 and diet, 121-122
 dosage, 2
 and aged diabetics, 47
 in alloxan diabetes and ketoacidosis
 study, 290
 and juvenile diabetic campers, 678
 electrolytic reduction of disulfide
 bonds, *235
 and emotional stress study, *467-468
 and enzyme activity, 307, 633, 662
 and ethanol metabolism rate, 14, 16,
 17, 18
 and exercise, *317
 and fat metabolism, *235
 and fatty acids, *232, 709-715
 free, 77-82, *380, *447, *534, 559-
 561
 and fluorescein isothiocyanate uptake
 in kidney tissue, 274-278
 free and bound, 12, *608
 functions, *815
 and gastric secretion, *316
 and glucagon, 368
 glucagon-free, and amino acid nitro-
 gen, *448
 and glucokinase, 307, *468
 and glucose, *168
 disappearance rate, 156
 and free fatty acids, *113
 intolerance, *169
 response in azotemia, *459
 transport, 369
 uptake, 128, 131
 utilization, *455
 and glyceride levels, *458
 and glycogen synthesis, *236
 and glycosuria control, *50
 and growth hormone, 43, *50
 and hepatic tissues, electrical poten-
 tials, *451
 history, 37-40
 and hyperthyroidism and diabetes
 study, 740
 and hypoglycemia, *49, 162, *169,
 333-334, *462, *532
 and epinephrine, *536
 and hypothermia, *234
 lactose or galactose induced, *682
 and oral administration, 696-698
 immunoassay
 and alloxan, 669-671
 Berson and Yalow, *470
 enzyme hydrolysis, *460-461
 pancreatic and serum, 387-390
 of prediabetics, 370
 inactivation, and photo-oxidation
 study, *818
 inhibition, and antagonism, *117
 inhibitors, *115
 albumin, *608
 diazoxide, *439
 insufficiency, and fatty acid synthesis,
 *749
 and insulin-like activity, *684-685
 intraperitoneal action, 19-26
 and juvenile diabetics, 41, 107, *317-
 318, 240, 245-246, 249, 780-
 786
 and ketosis-resistant diabetes, *814
 Lente, compared to NPH, *457
 and lesions, 43
 -like activity
 in animals and man, *52
 and anti-sera, 369-370
 assays, 10, 27, *48, 78, 79, 387-390,
 *443, 580, 643-649, 713-714
 and glucose and mannose, *444
 and glucose response in normals,
 *442-443
 and heparin, 805-810
 and hypophysectomy and pancreatectomy in dogs, 658-661
 and immunoreactive insulin in serum
 and lymph, *463
 and juvenile diabetes, *49, 619, 630
 in serum proteins, 71-76, *116
 in urine, *681
 -like thymic factor, 325-331, *447-448
 and lipid formation, *457
 and liver, *167
 glucose balance, 307
 glycogen synthesis in dog, *531
 potassium uptake, 307
 lyophilized gelatin-, 10
 metabolism, 84-86
 of muscles, *378
 in obese adolescents, *746-747
 and pancreatitis, *462
 studies, *117
 and mitochondria phosphorylation, 516
 and myelosclerosis, *172
 and N-acetyl-DL-homocysteine thio-
 lactone, *236
 and neonatal diabetes, *233
 and nerve conduction, *232
 and neuropathy, *234, *682
 NPH
 and blood sugar studies of children,
 *460
 compared to Lente, *457
 and pancreas tumor, *53
 and pancreatectomy, 14, 16, 93, *683
 and adrenal steroids, 730, 731, 732,
 735
 pancreatic, and spontaneous diabetes
 in mice, *747
 and phenformin, *465
 and phosphorylase activity, *534
 and plasma lipids in pregnancy, *609
 pork
 and hypophysectomized dogs, 659
 pork and beef
 and antibody-binding capacity, *816
 pork I-131, 772, 773
 and pregnancy, 175
 Protamine
 and pancreatectomized dogs, 33-35
 Protamine Zinc, *440
 and alloxan diabetic rats, 179-184
 and chickens, *534
 and choline deficiency study, 666-
 667
 and hypothalamic-obese rat, *233
 and pancreatectomy, *613
 and vitamin B₆ deficiency, 515
 and protein
 metabolism, 306
 synthesis, *168-169, *533-534
 and pyridine nucleotides, *446
 and pyruvate levels, *231
 radioimmunoassay, *167, *816
 double antibody technic, 771-779
 and glucose, tolbutamide, and L-
 leucine, *49-50
 Rapitard and Actrapid, *685
 Regular, 36, *316
 and hypoglycemia, *459
 and pancreatectomy, 33-35, *683
 release
 and basement membrane thickening,
 110
 and leucine, *439
 requirements, 373
 and high fat diet, 369
 and hyperlabile diabetes, 279-288
 resistance, 432-434
 and acromegaly and Cushing's syn-
 drome, 556
 and adrenal steroids, *235, *818
 and glucose uptake of muscle tis-
 sue, 716-718

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

to insulinase in juvenile diabetics, 780-786
and 6-mercaptopurine, *612
and peptide, *445
and pregnancy, *377
response
adipose tissue, *454
and glucose-6-phosphatase pathways, *446
and hypertriglyceridemia, *611
to ingested protein, *442
role of, 8
secreting tumors, *115
secretion
and carbohydrate-restricted diet, *748
endogenous, 12
and glucose metabolism, 305, 689-695
and growth hormone, *444
in hypoglycemia, 341-348
and insulin antibodies, 493-500
in juvenile diabetes, 619
and pancreas beta cells, *459
and pancreas islet changes, 550, 552
and regulation, *232
study, *444
sensitivity, *613
and obesity, *378, *611
and serum L-xylulose, 311
and starvation, 556
and steroids, *381-382
and sugar inhibitors, *48
sulfated, and insulin-resistant diabetes, *440
and sulphydryls, *114
and sulfonlureas, 60, 63, 66-67, 103-104, *114, 392-394
and tolbutamide, and blood glucose, *114
tolerance
and phenethylbiguanide, *461
tests, *315
and true anaphylaxis and granuloma formation, *116
Ultralente, 38
uptake
and thiazides, *115
and vitamin B₆ deficiency, 515
and water uptake, *379
Zinc, and photo-oxidation, *818

INSULIN I-125
and antibodies to insulin, *449
and insulin radioimmunological assay, *816

INSULIN I-131
antibodies, *51
and electrophoresis, *50-51
and autoantibodies study, 397-402
binding, 27-32, 564-566, 568
immunochemical aspects, 309
and insulin assays, 344-345
purification and study, *381

and serum protein fractions, *534

INSULINASE
and insulin breakdown in juvenile diabetics, 780-786

INSULINOMA
diagnosis, *816

INTERNATIONAL DIABETES FEDERATION, FIFTH CONGRESS, 305-310, 368-373

INTESTINES
and fatty acid metabolism, *535
and glucose, *314, *440-441
hexose and fluid transfer, *51
insulin transport, *117, 696-698
and leukemic mice, 325, 328
sugar transfer, *47

IRON
-binding capacity
and menarchial age, 788, 790
in bones of diabetics, 142-145, 375

ISLETS OF LANGERHANS
in induced pancreatitis in rats, 635
and insulin, 552
in juvenile diabetes, 624-626, 629
and leukemic mice, 327, 330
and malnutrition, 411
and severe hypoglycemia, 607, 608
and sulfonylureas, 394

ISOANTIBODIES
to human pancreas, 226-227

ISONIAZIDE, 4

ISOPROTERENOL, *534

ISRAEL
diabetes incidence, 215
and diabetics
among arteriosclerotic Yemenites, 86
and face color study, 201-208

J

JAPAN
and diabetes incidence, 215

JAUNDICE
and sulfonylurea therapy, 67

JERUSALEM
face color and diabetes study, 102-108

JEWS
and diabetes, 215
and essential pentosuria, 311

K

KETOACIDOSIS, 43
and alcohol hypoglycemia, 354
and alloxan diabetes
in rat, 289-294
and atrophy, *454
and diabetic pregnancy, 261
and enzyme-strip test, *452
and fluid loss, *318
and growth hormone, 558
and infection resistance, *114
and insulin
resistance, 432, *818
secretion, 493
and juvenile diabetics, 41, 107, 242, 247-249, 258
and muscle metabolism, 82
and plasma cortisol, 744-745
and plasma insulin, 553
and sodium lactate, *440
and sulfonylurea therapy, 650, 656

KETOGENESIS
and growth hormone, 368, 374

KETONEMIA
and ethanol, *52
and fasting for obesity, *532
and insulin, *815
and ketoacidosis criteria, 290
and lipid infusion, 33-35

KETONES
Acetone, 179
and alloxanization, 180, 181, 184, 291
and anti-insulin serum, *49
Bessman's method for determination, 33
and cold exposure, *683
and ethanol ingestion, *52, *171
and hypophsectomy, 556
and insulin, *235, 280-281, 285-286
and juvenile diabetes study, 247, 251
and myocardial metabolism, *531
in normal and hypophsectomized rats, 35
and triglyceride-induced hyperketonemia, *448
and urate excretion, 739
in urine of juvenile diabetic, 121
urine test for, 59

KETONURIA, 77, 370
and alloxan-injected rats, 180, 183
in diabetics in India, 407
and insulin antibodies, *449
and juvenile diabetes study, 240, 245, 247
and ketone bodies, 286
and menarchial age study, 788
and pyruvate levels, *231
and severity of diabetes, 60
and steroids, *234

KETOSIS, *50, 370, 371, *609
and adrenocorticotrophic hormone, *748

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

and alloxanized rats, 180, 181, 183
and blood sugar values, 3
in diabetes study in India, 405
and diabetic neuropathy, 429
and diet, 338
and fatty acid metabolism, 713
and growth hormone, 43, 556-557
and 17-hydroxycorticoids, 744-745
and hypoglycemia, *315
nondiabetic, and diabetic pregnancy, *464
and plasma insulin, 552
-prone patients, 82
resistance in young diabetics, *814
and sodium lactate, *440

17-KETOSTEROIDS, 132, 133, 135

KIDNEY
and amino acids, 335
arterial hypertension, and diabetes, *748-749
artificial, in acute tubular necrosis case, 36-37
and atherogenic diet, 369
blood vessels, 426
damage and alloxanization, 291
in diabetics, 3, 8, 17, 41, *235-236, 702, 706
disease
and glucose tolerance, 550
and insulin uptake, 274-278
and juvenile diabetes study, 246
and prediabetes, 518
and prediabetic symptoms, 44
electromicroscopy
and glomerulosclerosis, *377
function
and chlorphentermine, *452
and diet, *816
glucose
excretion, 193
uptake, *172
glycosuria and itching, *168
and hormones, *231
in induced pancreatitis in rats, 639-640
infections in juvenile diabetics, 256
insufficiency, and diabetic acidosis, 36-37
and insulin-degrading enzymes, 87
Kolff Disposable Twin-Coil, 36
lesions, 550
diagnosis, 517
and plasma proteins, 755-770
and microangiopathy, *47
and mortality, 221
and neuropathies, 516
papillary necrosis, *167, *383
of prednisolone-treated rabbits, 595-604
and severe hypoglycemia, 607-608
and sulfonylureas, 59, 68, *377
and tolbutamide
excretion, *114
metabolism, *235

urate excretion in hyperketonemia, 739, 787, 804

KIMMELSTIEL-WILSON SYNDROME, 550

KREBS CYCLE, *447, *748

KREBS INTERMEDIATE METABOLITES
and vascular effects, *532

KREBS TRICARBOXYLIC ACID CYCLE, 747

L

LACTATE, 102
acidosis
and phenformin, 812
and cerebral metabolism, *748
formation from glycogen
and insulin, *233
and glucose uptake, *172, 310
-induced hypoglycemia, *681-682
metabolism
and diabetic acidosis, *440
and phenformin, *464-465
-pyruvate ratios, and lactic acidosis, 162

LEPROSY, 8

LESIONS
atheromatous, 369
atropic skin, *817
and auto-immune mechanism, 518
and cartilage powder, *171
and diabetes, 43, *236, 550-551
and diabetic neuropathy, 1-8, 425, 426
enzymatic, and hypoglycemia, 333-338
eosinophile, in prednisolone-fed rabbits, 596
glomerular, 274, *377, 596-604
hypothalamic, *169, *233
ischemic, and diabetics and nondiabetics, 110
Kimmelstiel-Wilson, 550
pancreatic
in anti-insulin serum-induced pancreatitis, 636-641
in juvenile diabetes, 629
placental, *817
renal
and plasma proteins, 755-770
vascular
and diabetes, *817
and diabetic neuropathy, 516
and glucose metabolism, 311
and insulin, 310
and potential diabetes, 491

LEUCINE, *49
and glucose oxidation, *49
and hyperinsulinism, *49-50
and hypoglycemia, 346-347
incorporation into protein, 306

and insulin release, 156, *439
and respiration, *685
sensitivity and glucose tolerance, *47

LEUCINE-I-C-14, *167
protein incorporation, *231, 305

LEUCOCYTES
and diabetes mellitus, *114
and diabetic neuropathy, 5
glucose metabolism, 584-590
in induced pancreatitis in rats, 635

LEUKEMIA
and insulin-like thymic factor, 325-331, *447-448

LIPEMIA
and clofibrate, *453
and glucose utilization, *234
in pancreatectomized and normal dogs, 33-34
and tolbutamide, *232

LIPIDS
and alloxan diabetes, 181, 184
assay, Bragdon's, 33
and choline deficiency, 666
and clofibrate therapy, *452-453
and diabetic retinopathy, 44
and high fat diabetes diet, *464
in induced pancreatitis in rats, 639-640
infusion in pancreatectomized dogs, 33-35
and juvenile diabetes, 241, 250
and mebanazine, *236
metabolism, *50
and carbohydrate metabolism, 514
and ethanol, *536
and glucose uptake, 590
and insulin, *447
and serum and insulin, *457
mobilization, and insulin deficiency, *447
and newborn of alloxan-diabetic rats, 724-728
in pancreatic tumor cells, *50
and phosphorus in pregnancy, *609
radioactivity
and Packard Tri-Carb Scintillation Counter, 180
radioactivity incorporation, 709-715, *747
and respiration, *685
and sugar and starch ingestion, *378
synthesis
and albumin, *356-357
and insulin, glucagon and epinephrine, *446-447
and leucocytes, 584

LIPOGENESIS
and adipose tissue, 82, *454
and enzyme metabolism, *236
and growth hormone, 368
and hormones, 369
and insulin, 8

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

LIPOLYSIS

and diabetes, 633
and epinephrine, *231
and glucose production, 355
and heredity, 370
and hormones, 369
and pituitary, 556-557
and tolbutamide, *232

LIPOPROTEIN, *231

and choline deficiency, 666
and ischemic heart disease, *234
lipase
and ethyl-a-p-chlorophenoxy-oxisobutyrate, *467
pre-B, and diet, *458

LIPOATROPHIC DIABETES, 786

LIVER

acetate metabolism and fat mobilization, *447
acute hepatitis and blood glucose, 186, 191
adenosine phosphates synthesis and alloxan diabetes, *684
alcoholic damage and tolbutamide, *232
and alcohol ingestion, 353, 355-360
and alloxan diabetes, *232, 713
anaerobic rat, and polyglucosides, *749
in anti-insulin serum-induced pancreatitis in rats, 639
and "atypical" insulin, 649
biopsy of Indian diabetics, 408
carbohydrate
and chronic hypoxia, 100
cirrhosis, 221, 228
citrate-cleavage enzyme, and carbohydrate metabolism, *683-684
and cortisol and triamcinolone, *113
synthesis and puromycin aminonucleoside, *378
and diabetic acidosis, 370
of diabetic dogs, 17
dihydroxyacetone metabolism, *382-383
disease
and clofibrate, *453
and coma, 162
and hemochromatosis, 699, 708
and insulin-like activity, *441
and reduced hyperglycemic response, 104
and tolbutamide and glucose tolerance tests, *536
and tolbutamide metabolism, *235
DPN:DPNH ratio, 18
electrical potentials, and insulin, *451
enlargement and diabetes, 121
enzymes
conversion, *233
and hypoglycemia, 333-338
fatty acid synthesis, *749
function
and chlorphentermine, *452

in juvenile diabetes study, 241, 252-253
and glomerulosclerosis, 759

glucokinase
and insulin, *468
regulation, 306
gluconeogenesis, and adrenal steroids, 729
glucose, 333-338
and adrenal steroids, 732-733
balance, and insulin, 307
extraction, 193
-glycogen metabolism, *749
output and hypoglycemia, *114
storage, *314
uptake, *172
and glucose-6-phosphatase, 146
glucose-U-C-14 incorporation, 19, 20
glutamic-pyruvic transaminase and insulin, 515

glutathione

and insulin inactivation, *816
-insulin transhydrogenase, *749

glycogen

and amyloglucosidase, *232
and glucagon, *816-817
and gravity changes, *535
and insulin, *531
response to glucagon, 102, 104
and stress, *382

hemochromatosis

and serum L-xylulose, 312

homogenates

and glucose transformation, *235
and hyperbilirubinemia, 159
insufficiency, and mortality, 68
and insulin
-binding, 31
-degrading enzymes, 87, 91
and glucagon, *167
secretion, *168, 341-348
and leukemic mice, 325, 328

lipids

and alloxan diabetic rats, 180, 184
and diet and exercise, *533
synthesis, 666

metabolism

and glucose and fructose, *466

perfused rat

*235
phosphorylase, and glycogenolytic agents, *534
potassium uptake, 307
protein metabolism and insulin, 306
and sulfonylureas, 59, 60, *114
and thiazide therapy, 132
triglycerides, *458
urea synthesis and glycogenesis, and chlorpropamide, 209-211

LUNGS

and fibrocystic disease of pancreas, *117
and infants of diabetic mothers, 158, 160
and leukemic mice, 325, 328

LUPUS ERYTHEMATOSUS

and glomerulonephritis and glomerulosclerosis, *441-442

L-XYLULOSE

in sera of diabetics, 311-312

LYMPH

insulin-like activity, *463

LYMPH NODE

and leukemic mice, 325, 328

M

MAGNESIUM

and insulin activity, 430-431

MAGNESIUM SULFATE

and hypoglycemia in rabbits, *462

MALATE

and lipogenesis, *447

MALNUTRITION

and diabetic neuropathy, 516
from diarrhea, 429
and metabolism studies, *50

D-MANNITOL, *382, *532

MANNOHEPTULOSE, *236
and glucose oxidation, *49

MANNOSE

and glucose tolerance tests, 96
and insulin
release, *232
secretion, *444
uptake, and insulin, *115

MEBANAZINE, *236

MENTAL RETARDATION
and galactosemia, 835

MENSTRUATION

and glucose-1-C-14 oxidation, *50
and juvenile diabetes, 255-256
onset age
and diabetes, 788-791

6-MERCAPTOPURINE

and insulin resistance, *612

METABOLISM

acetohexamide, *456
of adipose tissue, 19, 77, *115, 179-185
and hypophysectomy, *171
and insulin, 307
amino acid, and hyperketonemia, 804
aortic, and diabetes, 310
carbohydrate
and adrenal steroids, *113
and atrophy, *454
and benzothiadiazine drugs, *612
and chronic hypoxia, 100-104
comparison of mammals, *454
and diabetes, *170, 489-491

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58

May, 239-324

September, 549-618

February, 59-120

June, 325-386

October, 619-688

March, 121-174

July, 387-472

November, 689-754

April, 175-238

August, 473-548

December, 755-824

SUBJECT INDEX 1965

and 3,5-dimethylpyrazole, 507-514
 and dry mouth, *48
 and endocrine glands, *452
 and estrogen, *458
 and ethanol, 14
 and fatty acids, *171
 and fatty acid metabolism, *171
 and fat and insulin, *380
 and glycogenesis, 209-211
 and gravity changes, *535
 and growth hormones, *613
 and hormones, *231, 333
 and hyperglyceridemia, *458
 and hyperlipidemia, *234
 and hypertriglyceridemia, *611
 and insulin, *233, 307
 and liver enzymes, *683-684
 and myocardial infarction, 84-86
 and neuropathy, *454
 and plasma sugar, 165
 and pregnancy, *113
 and radioimmunoassay, 771
 and sugar metabolism, *378
 and suspected diabetes, *170
 and thiazides, 132-136
 and thyroid therapy, *49
 and uremia, *169
 in vitamin B₆ deficiency, 515
 cerebral, *748
 chylomicrons and triglycerides, *535-536
 cortical bone, and diabetes, *455
 and diabetic neuropathy, 1-8, 516
 dihydroxyacetone, *382
 and early diabetes detection, 110
 enzymes
 and diabetic acidosis, *113
 enzymes, and lipogenesis and gluconeogenesis, *236
 and epinephrine, 561, 562
 ethanol, 14-18
 fat, 281, 395
 and growth hormone, 44
 and muscle and adipose tissue, 82
 fatty acid, *232, *747
 and carbohydrate and 3,5-dimethylpyrazole, 507-514
 and glucose, *684
 and insulin independent diabetes, 709-715
 in rat intestine, *535
 free fatty acid
 and exercise, *611
 free fatty acid and glucose
 in obese adolescents, *746-747
 and obesity, *748
 in frog muscle, *378
 fructose, and liver, 336
 glucose
 and ethanol, 350-360
 and free fatty acids, 559-562
 and fructose, *113
 and glucose-6-phosphate, *468-469
 and growth hormone, *379
 and insulin antibodies, 369
 and L-xylulose, 311
 studies, *236
 and thiazides, *115
 and thymus gland, 325-331
 glucose C-14, *747
 growth hormone, 374
 and blood sugar, 43
 and hormones, *167, *231, 368
 after hypophysectomy, *316-317
 and idiopathic hemochromatosis, 699, 708
 in infants, *378
 and insulin and glucose C-14 incorporation, 19-26
 intestinal sugar transfer in rats, *47
 and Krebs intermediate metabolites, *532
 lactate
 and diabetic acidosis, *440
 and phenformin, *464-465
 lipid
 in fetuses of alloxan-diabetic rats, 724-728
 and insulin, *447
 and insulin and serum, *457
 liver, *466
 liver acetate
 and free fatty acids, *447
 and multiple sclerosis, *464
 myocardial, and ketone bodies, *531
 nucleic acid, and juvenile diabetes, 631
 and pancreatitis, *462
 of perfused rat heart, *685
 and prediabetes, 481
 protein and fatty acid and insulin, 633, 662
 pyruvate, *231, 369
 and diabetic neuropathies, 516
 and sex, nutrition, and body weight, *50
 and stress, *382
 studies, *117
 sugar and starch compared, *378
 sulfonylurea, *382
 and tissues symposium, 306-307
 tolbutamide, *235
 uridine diphosphate glucose-glycogen glucosyltransferase from rat liver, *749

METALS
 gold, hypothalamic uptake and hyperglycemia, *378
 iron in bones of diabetics, 142-145, 375
 poisoning, 8

METFORMIN
 in diabetes study in India, 405

METHANOL, 20

METAPYRAPONE, *169

α-METHYLDOPA, *53

3-METHYLGLUCOSE, *47

α-METHYLGLUCOSIDE, *47

METHYLPRUDNISOLONE-SUCCHINIC NATE
 and glucose metabolism, 729-736

MICROANGIOPATHY, *234, 550
 and facial redness, 207
 of human toes, *47
 and mortality, 308
 and necrobiosis lipoidica diabetorum, *314-315

MICROPHTHALMIA, *172

MICROSCOPY
 of brain sections of diabetics, 425
 of cerebrovascular and pancreatic insular amyloid in old age, *612
 of diabetic kidney tissue, 276
 electron
 and beta cells of diabetic rabbits, 792-803
 and capillary basement membrane, *234
 and capillary lesions, 517
 and glomeruli of diabetic dogs, 700
 and glomerulosclerosis, 310, *441-442
 of islet cell secretion, 305
 of kidneys, *377
 and microangiopathy, *47
 of pancreatic beta cells, 147-155, 497-499
 of pancreatic tumors, *50
 of prednisolone-induced nephropathy, 595-604
 kidney, 759-763
 light, of pancreatic beta cells, 147
 of mammary glands of alloxan-diabetic rats, 502, 504, 505
 of pancreatic tissue
 from juvenile diabetics, 620-629
 of rats, 635-641
 skin
 and red faces of diabetics, 204
 and thickened basement membranes, 110

MINERALS
 calcium and magnesium, and hypoglycemia, *462
 and glucose transport, *749
 iron, and hemochromatosis and siderosis, 699, 708
 and serum insulin-like activity, *114

MINNESOTA MULTIPHASIC PERSONALITY INVENTORY, 107

MITOCHONDRIA, DIABETIC, 516
 of cortisone-alloxanized rabbits, 794-795
 and glycolysis, *177

MONAMINE-OXIDASE INHIBITORS, *236

MONONEUROPATHY, 425, 427, 516

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

MOROCOCHA
carbohydrate metabolism study in, 100-104

MORPHINE
and glucose utilization, *172

MORTALITY
and alloxan-diabetic ewes, *235
and alloxanization, 290-291
of alloxanized rats, 180
causes in bone-study group, 142-143
and diabetes, 215-216, 221, 222, 489
and diabetic pregnancy, 371
and diet-induced diabetic syndrome, *441
and fasting in obesity, *532
fetal, *379-380, 435, *682
and fibrocytic disease of pancreas, *117
and glycogenesis, 337
of hypophysectomized dogs, 658, 661
infants of diabetic mothers, 159, 175, 177, 261, 435-437
of juvenile diabetics, 241, 242, 268-269, 619
and Kimmelstiel-Wilson syndrome, 550
and ligation of pancreatic duct, 194-195
and microangiopathy, 308
and nonketacidotic coma, 162
and pancreatectomy, 93-95, 690
renal papillitis, 167
and severe hypoglycemia, 607, 608
and siderosis and hemochromatosis, 708
and sulfonylureas, 59, 68, 654

MUCOPOLYSACCHARIDES, 26
metabolism, and insulin, 84
and muscle glycogenesis, *169

MUCOPROTEINS
and fibrocytic disease of pancreas, *117

MULTIPLE SCLEROSIS
and hyperinsulinism and edema, *464

MUMPS
and diabetes, 243

MUSCLE
and adipose tissue metabolism, 82, 88
aldolase, and fructosuria, 336
atrophy, 520
and neuropathy, 5
cells, and anaerobiosis and cell poisons, 128
disorders, and diabetes, 424, 425-426, 427
glucose uptake, *49
glucose uptake and adrenal steroids, 735
glycogen, and amyloglucosidase, *232
hexokinase regulation, 306
and insulin
-degrading enzymes, 87

and insulin-like activity assay, *48
and intraperitoneal insulin injections, 19, 20, 21
and protein metabolism, 306
metabolism, *378

MYASTHENIA GRAVIS, 331

MYELOPATHY, 424, 427, 428, 520

MYELOSCHISES
and insulin, *172

MYOCARDIUM
disease
and diabetic neuropathy, 1, 3
infarct
and carbohydrate metabolism, 84-86
and diabetic neuropathy, 518
and diabetics and nondiabetics, 110
and glomerulosclerosis, 759
and sulfonylureas, 59, 68, 654
infarction
and glucose tolerance, *117
in juvenile diabetes study, 267
and nonketacidotic coma, 162
and tolbutamide tolerance tests, *536
metabolism, and ketone bodies, *531

MYOPATHY, 424

N

NADP-XYLITOL DEHYDROGENASE, 311

NARCOLEPTIC COMPLEX, *464

NECROBIOYSIS LIPOIDICA
and diabetic microangiopathy, *314-315
and ketonuria, *234

NECROSIS, TUBULAR
and dialysis, 36-37

NEGROES
and diabetes incidence, 215, 218
and erythrocyte deficiency, *315

NEMBUTAL, 663, 690
resistance, and tolbutamide, 392, 394

NEPHROPATHY
and diabetes, 310
etiology, 550-551
and heredity, 518
and hyperinsulinism, *685
prednisolone-induced, 595-604
and retinopathy in diabetic dogs, 700-707

NEPHROPATHY, DIABETIC
and hypertension, *749
in India, 408
and insulin dosage, 246

and mortality, 221
and neuropathy, 1, 3, 4, 7

NEPHROTIC SYNDROME, 126

NERVOUS SYSTEM
abnormalities in infant hypoglycemia, *815
and blood glucose levels, 127
damage, and hypoglycemia, 436
disorders and diabetes, 424-429
and experimental diabetes, *232
and insulin reactions, 249-250, *534
and lipid formation, *447
motor, and diabetes duration, *115
peripheral, insulin response, *682
and retrograde ejaculation, *455

NEUROPATHY
and achilles reflex, *380
and adrenal function, *169
definition, 424
and diabetes, *234
and hemochromatosis, *682
and multiple sclerosis, *464

NEUROPATHY, DIABETIC, 424-429, 516-520, 759
and abnormal taste threshold, *536
and atrophy, *454
and diabetes duration, 370
etiology, 110, 550-551
and hyperinsulinism, *685
and hypoglycemia, *114
and insulin metabolism, *682
in juvenile diabetes study, 267
nature of, 1-8
and pseudotubes syndrome, *47
and retrograde ejaculation, *455
treatment, 519

NINHYDRIN, 90, 91

NITROGEN
and adipose tissue, 183
metabolism
and protein metabolism, 209-211

NITROGEN MUSTARD
and islet cell tumors, *115

NOREPINEPHRINE
and adipose tissue electrical potential, 529-530
and nonketacidotic coma, 162

NORWAY
diabetes in, 221

5-NUCLEOTIDASE
and cortisone, *380

NUTRITION
and diabetes onset, 411
and glucose metabolism in dogs, *746
and insulin sensitivity of rat adipose tissue, *683
and liver disease, 699, 708
and metabolism studies, *50

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

and neuropathies, 518
and Project Head Start, 723

O

OBESITY, *380
and adipose tissue function, 82, 86
and aged diabetics, *47
and atherosclerosis, 307
and children of diabetic families, *438-439
and diabetes, 221-222, *612
 detection, *453, 473
 diet-induced, *610
 in India, 405, 406-407
and energy metabolism studies, *50
and fasting, *532
 glucagon response, *816-817
and fatty acid
 mobilization, *380
 uptake, *171
and glucose
 and free fatty acid metabolism, *610-611, *746-747
 tolerance, 559
 and insulin sensitivity, *378
 test study, 482
 utilization, *467
and growth hormone, 370
and hyperglycemia, *168, *169
and hyperinsulinism, 553-555
and hyperuricemia, 787, 804
and hypothalamic lesions, *233
and infants of diabetic mothers, 724
and insulin activity, *748, 806
and menarchial age of diabetic women, 789-791
and neuropathy, 2, 4
and phenformin, *52
and serum insulin, 27, 28
 -like activity, *442
 response, *532, *683
and sulfation factor, *172
and sulfonylurea therapy, 59
and triglyceride levels, *314
and urine insulin-like activity, *681

OPHTHALMOPLEGIA
in diabetic neuropathy, 5

ORAL HYPOGLYCEMIC AGENTS. *See also* Sulfonylureas
and aged diabetics, *47
and diabetes, 59-70, 77
 and pregnancy, 435-436
 study in India, 405, 408
3,5-dimethylpyrazole, 507-514
and emotional stress study, *467-468
and hyperthyroidism and diabetes study, 740
and insulin-like activity, 809
and islet-cell formation, 369
and lactate metabolism, *464-465
new, *684

overdose, 811-812
and Regular Insulin, *316
and serum insulin-like activity, *318
and serum insulin levels, *444
and severe hypoglycemia, 606-607

OSTEITIS CONDENSENS ILIA, 261

OSTEOID SEAMS, 142-145

OSTEOMALACIA, 142, 145

OSTEOMYELITIS, 257

OSTEOPOROSIS
and diabetes, *316, *683

OUABIN
and metabolism of perfused rat heart, *534

OVARIES
and leukemic mice, 325, 328
neoplasm, *114

OXALACETATE
and lipogenesis, *447

OXIDATION. *See also* Metabolism
of ethanol to acetaldehyde, 18
of tumors, *49

OXIDATIVE-PHOSPHORYLATION
and glucocorticoids, 484

OXYGEN
and carbohydrate metabolism, 100-104
and glucose uptake, *172
and new blood sugar test, *458
and premature infants, 160
uptake and fatty acid synthesis, *115

OXYTOCIN
and glucose metabolism, *379
and protein synthesis, *533-534
and urine volume, *464

P

PACKARD TRI-CARB SCINTILLATION COUNTER, 180

PALMITATE
and glucose, *171
and insulin, *455
and respiration, *685

PALMITATE-I-C-14, *171
metabolism, *232
 and 3,5-dimethylpyrazole, 508, 509, 511

PANCREAS
abdominal graft in dogs, 689-695
and glucose-6-phosphatase, 147
and hyperinsulinism, 334

alcoholic damage, and tolbutamide, *232
in alloxan diabetic pregnant rats, 138-141

alpha and beta cells
 tumors compared, *50

alpha cells
 distribution, *231

and autoantibodies to insulin, 396-402

beta cells
 acid phosphatase and insulin secretion, *168
 and aging, 310
 and alloxan, 180, 289, *532
 degranulation, 493-500
 and diet-induced diabetic syndrome, *441
 in diabetic rabbits, 792-803
 and glucose-6-phosphatase, 146-156
 granulation, 137-141, *169, *444-445
 and growth hormone, 373
 and insulin
 response to sulfonylureas, 392-394
 secretion, *459
 and leucine hypoglycemia, *439
 and vitamin B₆, 515
blood vessels and diabetes, 426
carcinoma, hypoglycemia, and carcinoid syndrome, *53
and cortisol, 194-200
of diabetic dogs, 17, 18
and diazoxide hyperglycemia, 591
exocrine function and diabetes, *53
fibrocystic disease, *117
glucagon levels and COCL_e, *51
and insulin
 -antibody injected mice, *449-450
 -binding, *316
 in fetuses and infants of diabetic mothers, 573-578
 immunoassay, 387-390
 and insulin, 552-553, 555
 release, *232
 -secretion capacity, 100
 transfer, *52
islets
 adenoma, *815
 in alcohol hypoglycemia, 351
 and alloxan, *383, 671
 amyloidosis, *612
 and auto-immune mechanism, 518
 and chronic hypoxia, 103-104
 and formation, 368
 hyalinized, 110
 and hypothalamic lesions, *233
 and infants of diabetic mothers, *468
 and insulin secretion, *167, 550
 insulinoma, 345-346
 and leukemic mice, 325, 327-328
 and neonatal diabetes, *233
 quantitative studies, *380
 and sulfonylureas, *114
symposium, 305-306

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

tumors, *115, *747
and isoantibodies, 226-227
and malnutrition, 411
neoplasms in diabetics, *815
of postgastrectomy patients, 528
proteinases and oral insulin, 696
secretion studies in diabetics, *48
study of juvenile diabetes, 619-632

PANCREATECTOMY
and adrenal steroids, 729-736
and alloxan diabetes, 183, 184
and diazoxide, *469
 hyperglycemia study, 591
and ethanol metabolism, 14, 16, 18
and insulin
 degradation, 343-344
 deprivation and restoration, 689-695
 -like activity in dogs, 658-661
 secreting tumors, *115
and ketoacidosis, 289
and ketonemia, 33-35
management, 14, *683
and plasma
 arachidonic acid, *681
 free fatty acids and lactic acid, *534
and retinopathy and nephropathy, 550-551
study of case, *613
and sulfonylureas, 103
in tumor growth and glycosuria studies, 93-95

PANCREATIN, N.F., 14

PANCREATITIS
allergic interstitial, 634-642
and diabetic dogs, 705-706
and diabetic neuropathy, 8
and insulin
 degradation, 343
 metabolism, *462
and isoantibodies, 226-227
and retinopathy and nephropathy, 551
and thiazide therapy, 135

PARKINSON'S DISEASE, 427, 607

PENTOBARBITAL
and glucose uptake, *172

PENTOSE PHOSPHATE CYCLE, *172

PENTOSURIA
essential, and glucose metabolism, 311-312

PEPTIDES
and hyperglycemia and insulin resistance, *445
insulin-inhibitory activity, 87-92
radioimmunoassay, *167

PERIARTERITIS NODOSA, 8

PERITONEAL CAVITY
and insulin injections, 19-26

PERITONITIS, 36

PHENETHYLBIGUANIDE
and glucose and insulin, *461

PHENFORMIN
in diabetes study in India, 405
and digestive alterations, *465
effects on blood lipids, *456
and glucose uptake, *318
and lactate metabolism in hypoxic rats, *464-465
and lactic acidosis, 162
overdose, 811-812
and rheumatoid arthritis, *532
and weight reduction, *52

PHENFORMIN HYDROCHLORIDE
and serum lipids, *465-466

PHENOBARBITAL
and serum L-xylulose level, 312

PHENYLHYDRAZINE, 745

PHENYLEPHRINE
and blepharoptosis, *455

PHENYLKETONURIA, 44
and epinephrine, 334

PHLEBOTHROMBOSIS
and toxic intravenous fluids, *48

PHLORETIN
and insulin inhibiting, *115
and sugar inhibiting, *48

PHLORHIZIN, *47, *48
and insulin inhibiting, *115
and intestinal hexose and sugar transfer, *51

PHOSPHATE
and cell poisons, 131
and galactosemia, 335
and insulin, 289

PHOSPHOENOLPYRUVATE CARBOXYKINASE, *236

PHOSPHOFRUCTOKINASE
activity in muscle, *378

6-PHOSPHOGLUCONIC ACID, 147, 148

PHOSPHOLIPIDS
and ethanol, *52, *171
and high fat diet, *464
in juvenile diabetes study, 251
and newborn of alloxan-diabetic rats, 724-728
and pancreatectomy, *681

PHOSPHORUS, 102
radioactive, and islet cell tumors, *117
serum inorganic, and glucose loading, *49

PHOSPHORYLASE, 128, *533
and alloxan diabetes, *684
conversion, *378

of 2-deoxyglucose, 184
of glucose, 306, 310
and glycogen storage disease, 337-338
and hypoglycemia, 334
and insulin, 369
and muscle glycogenesis, *169
oxidative, 102
and pancreatic beta cell glucose-6-phosphatase, 146-156
and sugar transport, 368

PIMA INDIANS
and diabetes prevalence, *439-450

PITUITARY GLAND
ablation, 121, 308
bovine, peptide from, *445
and diabetes, 556
and diazoxide hyperglycemia, 591
function and diabetic retinopathy, 308
gonadotrophic functions and diabetes, 370
insufficiency and plasma cortisol level, *169
irradiation and retinopathy, 310
radiosurgery, 44
and vitamin B₆ deficiency, *380

PLACENTA
and atropine test, *747
in diabetes, *817
and fructose production, *113
and growth hormone, 44
hormones and free fatty acid increase, *113
immature, and diabetic pregnancy, 435
and plasma insulin and blood glucose transport, *172

PLASMA
albumin, and insulin, 369
alpha-amino nitrogen, and hormones, *231
amino acid during carbohydrate tolerance tests, *448
arachidonic acid, and pancreatectomy, *681
assays and diabetes detection, *533
cholesterol, arterial uptake and insulin, *746
bicarbonate, and nonketooacidotic coma, 162-164
cholesterol, and steroids, *382
cholesterol esters, 105
corticoids, and diabetic ketosis, 744-745
cortisol, *169
 and diabetic angiopathy, *53
 and insulin, *169
 and obesity, *381
fatty acids, glucose and insulin, *50
fetal sheep
 and fructose and glucose, *113
free fatty acids
 and diazoxide hyperglycemia, *450
 and ethanol, 352
 and exercise, *611
 and glucose tolerance tests, 77-82

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

and growth hormone, 374, 556
and lactic acid, *534
and stress, *382
glucagon, and COCL₂, *52
glucose
and ethanol, 350-360
and metabolism, *50
and pancreatectomized dogs, 690-692, 694-695
and thyrotoxicosis, *50
glyceride, and insulin, *458
growth hormone survival, *50
hormone determinations, *167
hyperglycemic factor, *613
immunoreactive insulin, and infants of diabetic mothers, 436
inorganic phosphorus, and insulin resistance, *377
insulin
activity, *168, 387
and adrenalectomized rats, *748
and alloxanized rats, 669-671
and diet, *453
immunoassay, 552
and insulin secretion, 341-348
-like activity
and insulin binding, 564-565
and ketosis-resistant diabetes, *814
and obese ketotic diabetes, 552-555
and placenta, *172
and pregnancy, *749, *818
and sulfonylurea therapy, *463
and urine insulin-like activity, *681
ketones
and exposure to cold, *379
and urate clearance, 787, 804
lipids
and ethanol ingestion, *52, *171
and fatty acids, 395
and insulin and glucose in pregnancy, *609
proteins
and binding to hormones, 562-564
and cortisone-induced glomerular lesions, 604
and renal lesions, 755-770
steroids, 556
sugar determinations, 165-166
triglycerides, 666
and cholesterol in pregnancy, *609
and ethanol, *52

PNEUMONIA
in juvenile diabetics study, 257

POLYARTERITIS NODOSA, 274

POLYCYTHEMIA, 201
and plasma sugar, 165

POLYDIPSIA, 619
and diabetes diagnosis in dogs, 700

POLYGLUCOSIDES
in anaerobic rat liver, *749

POLYNEUROPATHY, 427

POLYPHOSPHATES
and glucose transport, *749

POLYSACCHARIDES
and glycogenoses, 337

POLYURIA, 619
and diabetes diagnosis in dogs, 700
in juvenile diabetes study, 245

POLYVINYL CHLORIDE, 76

PORTAL VEIN
and insulin secretion, 341
and medium chain triglyceride absorption, *448

POSTGASTRECTOMY SYNDROME
and blood glucose, 190-191

POTASSIUM, 102, 132, 136
chloride, *172, *609
cyanide reagent, 187
deficiency lesions, 604
ferricyanide
reagent, 187, 192
reduction method, 78
hydroxide, 20
metabolism, and insulin, *117
and thiazides, 228-229
and tissue electrical potential, 529
uptake of liver, 307

PRADER-WILLI SYNDROME, 786

PREDIABETES
and capillary basement membrane, *234
detection, 44, *438
and diazoxide treatment, 593
and growth hormone, 370
in hamsters, *448-449
and large birth weights, 518
and menarche, 788-791
and neuropathies, 1, 518
and nodular glomerulosclerosis, 550
and obesity, *380, *612
and pregnancy, 175-177, 436, *460, *681
and serum insulin
activity, *453
levels, 309
response, *532-533
symptoms, 44
tests, *52, 371-372, 481-487
and triglyceride infusion, *455

PREDNISOLONE
and adrenal steroid therapy, *818
and glucose tolerance test, *612
and hypoglycemic coma, 606
-induced nephropathy, 595-604

PREDNISONE
glucose tolerance test, 489-491
and insulin resistance, *612

PREGNANCY
and alloxan-diabetic rats, *235, 727

and carbohydrate metabolism, *113
complications, nondiabetic, 577
edema, 228
and effect of insulin and glucose on plasma lipids, *609
and glucose
infusions, *381
loading, 27
production in dogs, *746
tolerance, *458
tolerance test, 96, *170, 481-487, *683

and hyperglycemia, 137-141
and hyperthyroidism and diabetes study, 741

and insulin
inhibition, *608
resistance, *377
in juvenile diabetes study, 249, 260-261

and placental morphology, *817

and plasma
glucose and fatty acid, *613
insulin, *749, *818
and prediabetes, 175-177
RH negative, and glucose tolerance tests, *460

PREGNANCY, DIABETIC, 435-436, *681
and atropine test, *747
decline, 222
and insulin, 41, 630
management, 372, *379-380, *682
and neonatal problems, 157-161
and nondiabetic ketosis, *464
and sulfonylureas, *51
and tolbutamide, *381

PRISCOLINE, 427

PROCAINE, 186

PROGESTINS, *452

PROJECT HEAD START CHILD DEVELOPMENT CENTERS, 723

PROLACTINS
and glucose metabolism, *379

PROLINE, *115

PROSTATE GLANDS, *167, 256

PROTAMINE SULFATE
and protein synthesis, *534

PROTEINS
and adipose tissue electrical potential, 529
and basement membrane thickening, 110
beef hemoglobin, and insulin-like activity, *443
cerebrospinal fluid, and diabetic neuropathy, 429
of colostrum, *117

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

deficiency and diabetes, 411
and diabetic neuropathy, 5-8
dietary, 60
and insulin response, *442
and juvenile diabetics, 240
and glomerulosclerosis, *442
and glycine incorporation, *171
of granuloma tissue, and amino acid incorporation, *115
and growth hormone, 374, 557
insulin
-binding, 27-32
and insulin
-like activity, 387, 388
leucine-1-C-14 incorporation and hormones, *231
metabolism
and insulin, 84
and nitrogen metabolism, 209
radioimmunoassay, *167
synthesis, 306
and carbohydrate-free diet, *318
and ergastoplasm in rabbits, 802
and insulin, *168-169, 633, 662
and insulin or oxytocin, *533-534
urinary loss, 126

PROTEINURIA, *236
and capillary basement membrane, *234
and diabetic nephropathy, 2
and glomerulosclerosis, 265
in juvenile diabetic, 121, 126, *315
and renal lesions, 517
and urine sulfonylureas, 366

PROTEOLYSIS
and glucose production, 355

PRURITIS, 60, *168

PSEUDOTABES, 267, 425, 426

PSEUDOTABES SYNDROME, *47

PUBLIC HEALTH SERVICE, 478

PULMONARY SARCOIDOSIS, *114

PULMONARY TUBERCULOSIS
and diabetic neuropathies, 4

PULSE WAVE VELOCITY
and diabetes detection, 489-491

PURINES
and blood sugar, *169

PUROMYCIN
and carbohydrate synthesis, *378
and glycogen synthesis, *236

PYELONEPHRITIS, 256
and diabetic pregnancy, 261
and renal vascular disease, *167

PYRIDINE NUCLEOTIDES
glucose and fatty acid metabolism and hormones, *446-447

PYRIDOXINE, 515

PYRIMIDINES
and blood sugar, *169

PYROGEN, *169

PYRUVATE, 102
and cerebral metabolism, *748
conversion to phosphoenolpyruvate, *236
and diabetes, *231
and ethanol, 357-360
and fatty acid synthesis, *749
and glucose metabolism, 587
and lactate conversion, 162
and lipogenesis, *447
metabolism
and diabetic neuropathy, 516
and insulin, 369
and muscle glycogenesis, *169
and protein synthesis, *534

R

RACE
and atherosclerosis, *470
and sulfonylurea study, 655

REGISTRY OF TISSUE REACTIONS TO DRUGS, 480

RENAL DIABETES
and insulin uptake, 274-278

RESERPINE
and free fatty acids, *532

RESPIRATORY DISTRESS SYNDROME, 436
and maternal diabetes, 158-159, 160

RETINA
detached, and diabetes, *466
hemorrhages, *168
lesions, 550
microaneurysms, 517
photography of, 122-125
vascular changes in diabetes, 3, 121-127

RETINOPATHY
and adrenal function, *169
and diabetic control, 267-268
etiology, 110, 550-551
and microaneurysms and exudates, 110

RETINOPATHY, DIABETIC, 759
and anabolic steroids, *168
and diabetic neuropathy, 1, 2, 3, 4, 7
and diet, *816
and experimental diabetic glomerulonephritis, *377
and erythrocytes, 8
and hemochromatosis, *682
and heredity, 518
and hyperinsulinism, *685

SALICYLATES
and diabetic retinopathy, *462-463
and hypoglycemia, *315
and insulin inhibition, 130
and nonketotic acidotic coma, 162

SCHMIDT'S SYNDROME
and diabetes mellitus, *48, 300-303

SCHIZOPHRENIA
and insulin degradation, 342
in juvenile diabetes study, 259

SECRETIN, *53

SEPHADEX, 28, *816

SEPHARDI
and study of diabetes and face color, 201-208

SEROTONIN
and pancreas tumor, *53

SERUM
albumin, and adipose water uptake, *379
amylase, and antihypertensive drugs, *377
anti-insulin, *449

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

and acute insulin deficiency, *49
 and alloxan diabetic rats, 180, 183, 184
 avian, *170
 and beta cell degranulation, 305, 493-500
 and free and bound insulin, *608
 guinea pig, 14, 15, 17, 18
 and hypophysectomized dogs, 659-661
 and induced allergic interstitial pancreatitis, 634-642
 and insulin, 780-786
 beta-glucuronidase, and atherosclerosis, *682
 bilirubin, and infants of diabetic mothers, 161
 carbon dioxide
 in juvenile diabetes, 242, 249
 and ketoacidosis criteria, 290
 cholesterol, 761
 and atherogenic diet, 369
 and chlorophenoxyisobutyrate and androsterone, *814
 and diet and exercise, *533
 and hyperthyroidism study, 741
 and phenformin and tolbutamide, *456
 determinations in thiazide study, 132-136
 diastase, and diabetes, *53
 ethanol concentration, 15
 free fatty acids
 in insulin-induced hypoglycemia, *536
 and myocardial infarction, 84-86
 and growth-hormone-dependent sulfation factor, *172
 -induced papillary necrosis, *383
 inorganic phosphorus response, *49
 insulin
 activity
 and diet, *816
 in normals and diabetics, *453
 and adipose tissue, *48
 antagonism, 12
 and antibodies to insulin, 397-402
 assays, *683
 -binding antibodies, 279
 -binding properties, 27-32
 and carbohydrate-restricted diets, *748
 and cholesterol in pregnancy, *609
 and glucose, *683
 and glucose loading, *49
 and glucose and tolbutamide, *470
 and glucose tolerance, *442, *457-458
 immunoassay, double antibody technique, 771-779
 immunochemical assay, 27
 -like activity, 10-13, *52, 78, 79, *116, 132, 133, *170, 309, *382, *442, 643-649
 compared with immunoreactive insulin, *463
 and diet, *114, *441
 and intestinal glucose absorption, *314
 and hypoglycemic agents, *318
 in hypophysectomized and depancrectomized dogs, 658-661
 and insulin resistance, 432-434
 and intestinal mucosal extract, *440-441
 and tolbutamide, *381
 in newborn calf, *117
 and postgastrectomy patients, 526-528
 and potential diabetes, *466
 response
 and mild diabetes with hypoglycemia, *612
 and prediabetes, *532-533
 isoantibodies, 226
 lactate, and muscle glycogenesis, *169
 lipids
 and chlorophenoxyisobutyrate and androsterone, *814
 and diet, 332
 formation, *457
 and phenformin hydrochloride, *465-466
 and skinfold thickness, and blood sugar, *314
 L-xylulose, 311-312
 and phagocytic activity of leukocytes, *114
 phosphorus
 and chlorothiazide, *609
 potassium, 761
 and antihypertensive drugs, *377
 protein
 -bound iodine, 740
 in diabetic hamsters, *448-449
 electrophoresis, *168
 globulin fraction, 12
 and immunoelectrophoretic method, 27
 and infants of diabetic mothers, 371, *438
 insulin
 -like activity, 71-76, *382
 separation, 780
 and insulin 1-131, *534
 in juvenile diabetics, 251-252
 pyruvate, and muscle glycogenesis, *169
 sickness, 8
 sodium
 and nonketotic coma, 162, 164
 sulfonylureas, 362-367
 triglycerides
 and clofibrate, *452
 and high fat diet, *464
 urate, and hyperketonemia, 739
 uric acid
 and antihypertensive drugs, *377
 and chlorophenoxyisobutyrate and androsterone, *814
 and social class, 804
 SEX
 of animals in insulin-inactivation studies, 88
 and bone study of diabetics, 142
 and blood sugar levels, 247, 416-422
 and cholesterol, *453
 and degenerative complications in diabetes, 261
 and diabetes, 216, 219, 222, *454
 incidence, 406, 409, *454
 juvenile, 241
 and diabetic acidosis, 248
 and fasting serum L-xylulose, 311
 and glycosuria, 246
 and growth hormone levels, 370
 and infections in juvenile diabetics, 256-257
 and insulin dosage, 246
 and ketonuria, 247
 and lipid concentrations, 250
 and liver enlargement, 252-253
 and metabolism, *50
 and neuropathy, 428, 520
 in pancreatic antibodies study, 226
 and serum protein levels, 252
 and skin disorders in juvenile diabetes, 257
 and sulfonylureas, 63, 64
 and triglyceride level, 251
 and urine
 bacteria, *533
 glucose, *746
 SHOCK, 201
 hypoglycemic, 95
 and fasting blood sugar values, 3
 and sulfonylureas, *377
 therapy, and insulin, 342
 SKIN
 allergies in sulfonylurea therapy, 59, 60, 67
 changes
 and diabetic neuropathy, 427
 color, and diabetes, 201-208
 and diabetic neuropathy, 516, 517
 disorders in juvenile diabetes study, 257
 -fold
 technic, and diabetes detection, *461
 thickness, serum lipids and blood sugar, *314
 infections, and diabetes, 256
 lesion, atrophic circumscribed, *817
 and necrobiosis lipoidica, *234-235
 and sulfonylureas, 654
 SODIUM
 acetoacetate, and urate excretion, 787, 804
 arsenite, and insulin inhibition, 130
 beta-hydroxybutyrate
 and hyperuricemia, 739
 and urate excretion, 787, 804
 bicarbonate, 37
 and diabetic acidosis therapy, *113
 carbonate, 187

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

chloride, 72, 187
 and ethanol, 15
 and insulin-protein separation, 388

cyanide
 and insulin inhibition, 130

lactate, 37
 and plasma free fatty acids, *534

metabolism, *316-317

and nonketocacidotic coma, 162, 164

pentobarbital, 32

sulfite, and enzyme conversion, *233

SOMATOTROPIN, *378

SORBITOL
 and ethanol, 359

SOUTH AFRICANS, *469-470

SPINAL CORD
 lesions, and diabetic amyotrophy, 520
 syndromes, and diabetic neuropathy, 425, 427

SPINAL ROOTS
 and diabetic neuropathy, 425, 427

SPLANCHNIC NERVES
 and hypoglycemic convulsions, *49

SPLEEN
 and leukemic mice, 325, 328

STAPHYLOCOCCAL ENTERITIS, 36

STARVATION
 "accelerated"
 in pregnancy, *113
 and diabetes, *815
 and growth hormone, 559
 onset, 411
 symptoms, 555-556
 and glucagon response, *816-817
 and growth hormone, 559
 and hyperketonemia, 739
 and insulin, 21, 25
 activity, *748
 dosage, *117
 and reduced hyperglycemic response, 104
 and urine insulin-like activity, *681

STATISTICS
 abnormal insulin in juvenile diabetes, 781-785
 abortions and chromosome defects, 340
 Addison's disease, diabetes, and other endocrinopathies, 301, 303
 adipose tissue carbohydrate metabolism and insulin response, *454
 adrenal steroids and glucose kinetics, 731-734
 age at menarche of juvenile diabetics, 255
 albumin antagonism to insulin, *456-457
 alloxan diabetic and normal rats, 182, 183

anaerobiosis and cell poisons, effect of on glucose uptake, 129-130

antibodies to insulin, 398-401

associated conditions at diabetes diagnosis, 243

attitudes of juvenile diabetics, 106-108

augmentation of insulin-like activity, 11, 12, 13

birth weights of infants with prediabetic parents, 176-177

blepharoptosis in diabetics, *455-456

blood glucose, 188-192
 in elderly, 580
 and hypnotically-induced emotional stress, *467-468
 and insulin dosage, 284
 and intestinal insulin administration in rabbits, 697-698

and ketoacidosis, 291
 and plasma insulin, 554, 555
 in premature infants, 127, 156

blood plasma, red cell sugars, and hematocrits, 165-166

blood saccharoid content in neuropsychiatric patients, 720-722

blood sugar
 in juvenile diabetes study, 247
 tests in leukemic mice, 326

body and gland weights of alloxan-diabetic rats given testosterone, 503

C-14 incorporation into fatty acids by blood, 710-714

cataracts and diabetes, *231

census of patients in juvenile diabetes study, 241-242

chlorpropamide and glucose and nitrogen metabolism, 210

clinic visits of juvenile diabetics, 243

cortisol, effects of on pancreas, 198-199

Dextrostix method, *381

diabetes
 in Blekinge, Sweden, *534-535
 carbohydrate tolerance, age, sex, and test conditions, 413-422
 in Chinese hamster, 371
 detection campaign in Sweden, *531
 detection method, *461
 and early or late menarchial onset, 788-791
 and facial redness, 202, 203, 207, 208
 incidence in British village, *53
 in India, 405-410
 diabetic program for aged, *47

diazoxide
 -hyperglycemia study, 592, 593
 and insulin inhibition, *439

diet and human depot fat, 105

digestive alterations in diabetes, *465

3,5-dimethylpyrazole and metabolism, 509-514

double antibody radioimmunoassay of insulin, 772-777

educational attainments of juvenile diabetics, 259

epinephrine in insulin-induced hypoglycemia, 334

ethanol metabolism, 15-17

exocrine pancreas in diabetes, *53

experimental alcohol hypoglycemia, 350-360

external pancreatic secretion and diabetes, *48

free fatty acid and glucose tolerance, 78-81

glucose
 metabolism in leucocytes, 586-589
 tolerance in hyperthyroidism, 742
 tolerance tests, 97-99, 100-104, *116-117, *466-467, 481-487, 691-694, *438-439

glucose C-14 incorporation, 22-25

glucose-6-phosphatase activity in glycogen storage disease, 337

glycosuria, effect of tumors on, 93-95

gouty arthritis and diabetes, *116

glycosuria incidence in juvenile diabetics, 246

growth hormone metabolism and secretion in infants, *378

hemoglobin levels in juvenile diabetes study, 255

heparin and insulin-like activity, 806-809

hyperglycemia and beta granulation, 137-141

hyperosmolar coma and plasma bicarbonate levels, 163-164

immunoassay of glucagon, *450

inactivation of insulin by adipose tissue, 88-91

incubation media and methods in glucose uptake studies, 128-129

infants of diabetic mothers, 157-161

infections in juvenile diabetics, 256

insulin
 activity and calcium and magnesium 430-431
 and blood glucose and alloxan, 670, 671
 concentration in hypoglycemia, 348
 dosage, 245-246, 282, 283
 and (rat) hepatic glucokinase, *468
 immunoassays, 330, 388-390
 -like activity, 72-75, *463, 646-648
 resistance, *818
 response to protein, *442

iron in osteoid seams of bones from diabetics, 144

ischemic heart disease in diabetic women, *169

isoantibodies to human pancreas, 226-227

juvenile diabetes diet, 244, 255

ketoacidosis in juvenile diabetes study, 247-249

ketonuria in juvenile diabetes study, 247

labile diabetes study, 280

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

juvenile diabetes
duced hypoglycemia, *53
n and dia-
e tolerance,
, 586-589
ism, 742
100-104
7, 481-487,
22-25
ity in gly-
ease, 337
on, 93-95
*116
venile dia-
and secre-
78
e diabetes
ivity, 806-
granulation,
asma bicar-
164
450
lipose tis-
ds in glu-
, 128-129
157-161
es, 256
agnesium,
oxan, 670,
emia, 348
ase, *468
90
646-648
nes from
diabetic
eas, 226-
55
es study,
es study,

lactate metabolism and phenformin, *464-465
lipids in newborn of alloxan-diabetic rats, 725-727
liver function in juvenile diabetics, 253
mass screening method for diabetes, 298, 299
microangiopathy in toes, *47
mortality, 68-69, 180, 268, 291
motor-nerve function and duration of diabetes, *115
myocardial infarction and carbohydrate metabolism study, 84-85
neuropathy, 2, 3, 427, 518
occupational achievements of juvenile diabetics, 260
oral sodium tolbutamide test for diabetes, *451
pancreas
insulin content in fetuses and infants, 574-575
tissue of juvenile diabetics, 620-628
pancreatic lesions in rats, 637, 638
phenethylbiguanide and glucose tolerance, *461
phenformin and weight reduction, *52
plasma lipids in juvenile diabetics, 250, 251
pregnancy, diabetic, 371, *379-380
pulse wave velocity in potential diabetics, 490-491
retinopathy and diabetic control, 264, 268
Schmidt's syndrome with diabetes, 302
serum insulin
-binding, 28-31
and glucose tolerance, *457-458
serum proteins
in juvenile diabetics, 252
and urine sulfonylureas, 362-367
stillbirth rate in prediabetic women, 177
"stress" postprandial blood sugar and diabetes detection, *462
sulfated insulin study, *440
sulfonylureas, 59, *114, *382, 652-656
symptoms prior to diagnosis of juvenile diabetes, 241
thiazide therapy, 133-136
triamcinolone-glucose tolerance test, 482-487
uptake of labeled insulin by kidney tissue, 275
urine and blood pyruvate, *231
urinary ketone bodies, serum ketone bodies, and serum free fatty acids and insulin dosage, 285
vapor phase chromatography and acetone concentration, 664-665
vascular complications in juvenile diabetes study, 262
weight and height of juvenile diabetics, 254-255

world survey of diabetes mellitus, 212, 223

STERILITY
and retrograde ejaculation, *455

STEROIDS
adrenal
and carbohydrate metabolism, *113
and glucose metabolism, 729-736
and insulin resistance, *235, *818
anabolic
and diabetes instability, *381-382
and diabetic retinopathy, *168
binding, 563
and diabetic acidosis, *114
and glucose-6-phosphatase, 337-338
and growth hormone secretion, *315
and ketonuria, *234
and ketosis, 744-745
and nephropathy in rabbits, 595-604
and pancreas, 194-200
and pancreatic diabetes, 95
and tolbutamide, 132, *233

STILLBIRTHS
and sulfonylurea drugs, *51

STRESS
blood glucose level, and diabetes detection, *462
and diabetes, 106, 107
emotional, and blood glucose levels, *467-468
and free fatty acid mobilization, *380
and hypercorticalism, 95
and juvenile diabetes, 243, 258-259, *317
and metabolism, *382

STUDENT'S *t* TEST, 209

ST-WAVES
in diabetic neuropathy, 2

SUCCINATE
and lipogenesis, *447

SUCROSE
metabolism, and carbohydrate metabolism, *378

SULFATION FACTOR, *172

SULFHYDRYL
and insulin, *114

SULFONYLUREAS, 103, *612

SULFONYLUREAS. See also Oral hypoglycemic agents
and alcohol, *114
and blood glucose and plasma insulin, *463
and blood sugar, 650-656
and digestive alterations, *465
evaluation, 39-40
and glucose output, 209-211

retention, *114
and hypoglycemia, *114, 346-347
and hypoglycemic shock, *377
and insulin response, 392-394
and juvenile diabetes, *531, 553
and ketosis-resistant diabetes, *814
and leucine hypoglycemia, *439
and metabolism, *382
and pancreas beta cells in rabbits, 800
and pregnancy, *51
in serum and urine, 362-367
and therapy of Bertram, Bendfeldt and Otto, 59

SULFUR, RADIOACTIVE, *172

SURGERY
adrenalectomy, 308
amputation, 7, *172, 427, 429
cataracts, *231-232
and diabetic neuropathy onset, 518
gastrectomy, *116, 526-528
and ischemic leg ulcers, *318
islet tissue transplantation, 41-42
and lesions, *684
mastectomy, 257
pancreas
autograft in dogs, 689-695
resection, *115
pancreatic tumors, *117
pituitary gland, 44
spinal transection and evisceration of rats, 508
venous system, *116

SWEDEN
diabetes in, 214-215
and juvenile diabetics treated with unmeasured diet, 244

SYNALBUMIN
insulin antagonism, *438, 566, *749, *815

SYPHILIS
and neuropathy, 2, 4, *47

T

TABES DORSALIS, 520

TEMPERATURE
and blood glucose levels, 419
and infants of diabetic mothers, 438
and insulin inactivating, 88-89
low
and ketones and fatty acids, *379, *683

TES-TAPE, 281

TESTOSTERONE
and alloxan diabetic rats, 501-505
and protein incorporation, *167

THALAMUS
and diabetes, 425

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

THIAZIDES
and carbohydrate intolerance, 132-136
and glucose uptake, *115
and small-bowel ulcers, 228-229

THROMBOPHLEBITIS, 227

THROMBOSIS
mesenteric, and nonketacidotic coma, 162

THYMUS
of alloxan diabetic rats, 502
in diabetic pregnancy, 371
glucose uptake, and adrenal steroids, 735
insulin-like factor, *447-448
and leukemia, 325-331

THYROID, 43
and adrenal insufficiency, *48, 300-303
desiccated, and carbohydrate metabolism, *49
disorders and diabetes, 261

THYROXIN
antagonists, 562, 564
and insulin requirement, *50

TISSUE
adipose
activity and insulin, *683
assay of insulin and insulin-like activity, *48
carbohydrate metabolism and insulin responsiveness, *454
and chylomicrons and triglyceride metabolism, *535-536
and fatty acids
free, 559
release and lipolysis, *231
stability, 395
synthesis, *447, *749
and glucose
metabolism, 369, *379
uptake, *49, 77-82, *443
uptake and adrenal steroids, 735
uptake and thiazides, *115
glucose C-14 incorporation, 19-26
and glucuronic acid pathway, 311
glycogen synthesis, *533
and hypophysectomy, *171
and insulin, *379
bioassay, *441
effect on electrical potentials, *451
deficient, *382
inactivation, 87-92
-like activity
and 3,5-dimethylpyrazole, 508-509, 510
-like activity assay, 71-76, 643-649
uptake and myocardial infarction, 84-86
and malnutrition, 411
metabolism, *115, *117, 179-185,

*233, 307
and obesity, *314
and plasma insulin activity, 387
protein synthesis, *533-534
pyridine nucleotides, glucose and fatty acid metabolism, and hormones, *446-447
in AKR mouse, 325-331
and alloxan action, *532
capillary basement membranes, *234, *235-236
circulation, and diabetes, 373
electrical potential and insulin, 529-530
epididymal fat
and alloxan diabetic rat studies, 180
and glucose-I-C-14 metabolism, *681
and glucose uptake and cell poisons, 128-131
and insulin, 669
-like activity, *49, 72, *116, *170, 387, 658, 659, 805-810
and lipid formation, *457
and serum insulin-like activity, 132
fibrin and fibrinogen detection, 756
glomerular, and renal lesions, 517
glucose
uptake and phenformin, *318
utilization, *314
granuloma, and amino acid incorporation, *115
hyaline membrane, 158, 159
hypoxia, 162
iron, 142
kidney
and immunohistopathological study of glomerulosclerosis, 755-770
and insulin uptake, 274-278
metabolism
and hormone immunoassays, *167
symposium, 306-307
mouse diaphragm
and insulin and palmitate, *455
serum insulin assay, *453
muscle
and glucose uptake, 716-718
and glycogenesis, *169
metabolism studies, *117
pancreatic
and alloxan, *383
and cortisol, 194-200
transplanted to eye, 306
rat diaphragm
and albumin and insulin antagonism, *456-457
and glucose C-14 incorporation, 19-26
and glucose-6-phosphatase, *446
and glucose uptake and ketosis-resistant diabetes, *814
and insulin
inhibition, *608
-like activity, 74, 78, 805-810
and serum insulin-like activity, 387
rat epididymal fat
and glucose tolerance, 580
and insulin and palmitate, *455
rat hemidiaphragm
assays, 566, 567-568
glucose uptake, *438, 778
and cell poisons, 128-131
retinal and renal, of diabetic dogs, 702-704
vascular wall, and insulin, 84

TOLBUTAMIDE, 18, *49, *51, *234, 397
and alcohol, *114
and alcoholism, *233
and blood lipids, *456
and blood sugar, 650-656
comparison with new hypoglycemic agent, *684
in diabetes study in India, 405, 408
and exercise, *317
and gastric secretion, *814
and glucose and leucine-H-3 incorporation into protein, 305
and hyperinsulinism, *49-50
and hypertriglyceridemia, *611
and hypoglycemia, *114, 347, 606-607, 697-698
and insulin
and blood glucose, *114
conversion, 387
release, 156, *232, 392-394
response, 309
and islet cell secretion, 305
and lipemia, *232
metabolism, and kidney and liver disease, *235
and monamine-oxidase inhibitors, *236
and neuropathy, *234
in oral hypoglycemic study, 59-70
oral sodium, and diabetes diagnostic test, *451
and phenformin, *465
response
and erythrocyte deficiency, *315
in mild and severe diabetic hamsters, *449
and obese children of diabetics, *438-439
and serum insulin levels, *470
-like activity, *381
in serum and urine, 362-367
test, 100, 101, *816
dangers, 607
and triamcinolone-glucose tolerance tests compared, 481-487
and thiazide therapy, 132, 134
tolerance
and hypoglycemic children, *315
tolerance test
and glucose tolerance test, *536
in infants of diabetic mothers, *468

TRIAMCINOLONE
and carbohydrate metabolism, *113
-glucose tolerance test, 481-487

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

T

TRIAMCINOLONE ACETONIDE, *234

TRIGLYCERIDES, 184
and diabetes, 44, 666
and ethanol and dry wine, *171
and ethyl-a-p-chlorophenoxy-isobutyrate study, *467
and free fatty acids, 77, 87
and hyperlipemia, *232
and ischemic heart disease, *234
in juvenile diabetes study, 251
metabolism, *233
in adipose tissue, *535-536
and insulin, *233
and weight gain, *314

TRIGLYCERIDE GLYCEROL and palmitate, *455

TRYPSIN, *53
and diagnosing fibrocystic disease, *117

TUBERCULOSIS
adrenal, 301
and diabetes mellitus, 301
and juvenile diabetes, 257

TUMORS. *See also* specific types
in diabetics and nondiabetics, *608-609
and hypoglycemia, 330, 347-348
islet cell, *53
blood insulin level studies, *49-50
clinical and biochemical studies, *49
and glucose tolerance, 346, 347
and insulin secretion, *115
and peptic ulcer, *116
and spontaneous diabetes in mice, *747
ulcerogenic, *117
and neuropathy, *47
ovarian, *114
pancreatic
electron microscopy, *50
in pancreatic and steroid diabetes, 93-95
Wilms' and hypoglycemia, *316

T-WAVES
in diabetic neuropathy, 2

TWINS
and diabetes and hyperthyroidism, 743
and hypoglycemia, 338, *535
and organ transplantation, 41
and skeletal muscle glycogenesis, *169

TYRODE SOLUTION, 209, 210, 211

TYROSINE
and insulin degradation, 91

U

ULCER
duodenal
and tolbutamide, *814

ketone bodies, 285-286, 287
in lactose- or galactose-induced hypoglycemia, *682
metabolites of acetohexamide, *456
3-methoxy-4-hydroxy-mandelic acid, 78
nitrogen, *459
17-OHCS excretion and diabetic angiopathy, *53
and phenformin overdose, 811
pituitary gonadotrophin, and diabetic neuropathy, 427-428
plasma acetone, 162
polypeptide, *445
protein, and pancreatectomy, *613
pyruvate, *231
steroids, 556
and tolbutamide, *233
sugar
and diabetes control study, *469
and diabetes detection, *461
of guinea pigs in cortisol study, 195-196
in juvenile diabetes study, 246
and nonacidotic coma, *609
sulfonylureas, 362-367
tests
Benedict's method, 224
Combistix, 224
copper reduction, 224
enzyme impregnated paper, *53
for glucose, ketone bodies, and albumin, 59
glucose oxidase, false negative reactions in, 224-225
and insulin study, *457
and juvenile diabetics, 107, 108, 241, *315, 678
in prednisolone-fed rabbits, 595
for sugar, 41
in tubular necrosis case, 36
urate
and hyperketonemia, 739, 787, 804
uric acid, 93, 132, 224
L-xylulose and hereditary pentosuria, 311

V

VASCULAR DISEASE
and chlorpropamide, *814
and diabetes, 47, 110-111, 157, 162
juvenile, 241, 262
among diabetic Pima Indians, *440
and hyperinsulinism, *685
mortality, 268-269
and neurologic classification, 425
and neuropathy, 1-8
occlusive
and diabetic neuropathy, 426
and preclinical diabetes, *611
and prediabetes, 44
renal, *167
symposium, 307-308

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

VASCULAR SYSTEM

- and diabetes, 516, *531, 489-491, 549-552
- diabetic changes, and red face, 207
- and diabetic deaths, 221
- and headaches, and multiple sclerosis, *464
- and Krebs' intermediate metabolites, *532
- lesions
 - and diabetes, *817
 - and diabetic neuropathy, 518
- surgery, *116

VEINS

- portal-peripheral
 - and serum insulin concentration, *444

VITAMINS

- B-complex
 - and diabetic neuropathy, 516, 519
- Be deficiency
 - and carbohydrate and fat metabolism, *380
 - and insulin, 515
- deficiency
 - and diabetic neuropathy, 2, 4, 8, 516
- and fibrocytic disease of pancreas, *117
- K, and premature infants, 160
- and pancreatectomy, *683
- and rickets, 142

VOMITING, *168

- and diazoxide, *610
- and glucose tolerance tests, 96, 296
- and hypoglycemia, 249
- and juvenile diabetes, 121, *317-318
- and phenformin overdose, 811

W

WALKER CARCINOMA, 256, 93

WEIGHT. See also Obesity

- of adrenal glands during cortisol treatment, 197

and alloxan diabetes, 179, *235

of animals in insulin-inactivation studies, 88

and bicarbonate deficit calculations, *113

at birth

- and hypoglycemia, 333, *535
- of infants of diabetic mothers, 175-177, 371, 436, *468

and blood saccharoid content, 721, 722

and diabetes control study, *469

of diabetics in India, 406-407, 410

of diabetic infants, *233

of dogs in tolbutamide study, 392

gain, and triglycerides, *314

and glucose tolerance test study, 474, 475, 477

of guinea pigs during cortisol study, 194, 195, 196

and insulin

- distribution, 342
- dosage, 291

and insulin-like activity study, 71

in juvenile diabetes study, 245, 255

and ketoacidosis, 293

loss

- and alloxanization, 180, 291
- and chlorphentermine, *451
- and diabetes control, 2
- and diabetic neuropathy, 427, 516
- and hyperketonemia, 739
- and hyperthyroidism, 740
- and juvenile diabetes onset, 619
- and ketosis, 787, 804
- and phenformin, *52
- and serum insulin levels, *748
- and sulfonylureas, *114

and metabolism, *50

of newborn of alloxan-diabetic rats, 724, 725-728

of pancreas in juvenile diabetes, 632

of partially pancreatectomized rats, 93

and phenformin hydrochloride study, *465

and phenformin and tolbutamide treatment compared, *456

and prediabetes, 518

of premature infants, 127, 159, 160

of rats

- in chlorpropamide study, 209
- in hypoglycemia study, 137
- and sulfonylureas, 59, 61, 64, 68, 69, 655

and thiazide therapy, 132

and triamcinolone-glucose tolerance test study, 482

WEST BERLIN

- study of oral hypoglycemic agents, 570

WORLD HEALTH ORGANIZATION

- 216

WORLD SURVEY OF DIABETES, 212, 223

X

XANTHOSIS

- and juvenile diabetes, 258

XEROSTOMIA

- and carbohydrate metabolism, *48

XYLOCAINE, 186

XYLOSE

- and cataracts, *611

Y

YALOW AND BERSON IMMUNOASSAY, 771

YEMENITES

- diabetes and arteriosclerosis, 86

YTTRIUM, RADIOACTIVE, 44, 308

Z

ZINC GLUCAGON

- and hypoglycemia, 334

W

WALKER CARCINOMA, 256, 93

WEIGHT. *See also* Obesity
of adrenal glands during cortisol treatment, 197

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

ly, 209
137
64, 68, 36

e tolerance
agents, 5

NIZATION

BETES, 21

sm, *48

MUNOAS

, 86

44, 308

Abbott, M. M., *47
Abdine, F. H., *316
Abdul-Haj, S. K., *314-315
Abdulhayoglu, Sefik, *167
Abelson, Denis M., *317
Abraham, S., *377
Adams, Levi C., *447, *682
Adamson, Lucille, *448
Addis, G. J., *113
Ahrén, Kurt, 501-506
Ahuja, M. M. S., *814
Albrink, Margaret J., *314
Alden, James S., *609
Alexander, D. Pauline, *113
Allen, William E., 392-395, *439
Al Weiss, David M., *453
Alm, G., *231
Almonte, Alicia A., *451
Alp, Haluk, *316, *608
Alpert, Norman R., *749
Altszuler, N., *531
Anderson, Elmer A., *317
Anderson, G. V., *460
Anderson, J., *231
Anderson, John, 362-367
Anderson, John B., 350-361
Angervall, Lennart, 501-506, 724-728
Antoniades, Harry N., *443, *608, *683
Appelman, David H., *47
Arai, Y., *167-168
Aranda, Barbeito A., *452
Arenas, Jorge Cinco, *817
Arky, Ronald A., 350-361, *448
Arnold, Craig R., *47
Arnott, James H., *440
Arnould, Yvette, *314
Aronson, Betty E., *608-609
Aronson, Stanley M., *608-609
Arquilla, Edward R., *449
Avill, Anders, 501-506
Ashmore, James, 179-185, *447, *749
Awai, Kozi, 709-715, *747
Aylett, Pamela, *814
Azerad, E., *235-236
Azuela, Jose Chaves, *817
Azuma, Tohru, *113

B

Back, Kurt W., *380
Bailey, C. Cabell, *531

AUTHOR INDEX 1965

In this index are the names of authors of articles that have appeared in DIABETES and those whose articles have been abstracted in the Journal during 1965. Entries marked with an asterisk (*) indicate authors of material that appeared in the Abstracts only. The Subject Index appears on page 1.

A

Bailey, Richard E., *816
Ball, Eric C., *115, *233
Balodimos, Marios C., *451
Balter, Abraham M., 719-723
Bamforth, J., *316
Banson, B. B., *47
Barden, Herbert, 146-156
Barnard, Donald M., *314
Barron, Edward J., *440
Barry, R. J. C., *47
Barsky, R. F., *234
Bassenge, E., *531
Bauer, Hans G., *377
Bauer, Marjorie Frantz, *314-315
Bayley, T. J., *613
Beardwood, Donald M., *466-467, *609
Beardwood, Joseph T., Jr., *609
Beck, J. C., *231, *440-441
Becker, Frank O., *47
Beigelman, Paul M., *451, 529-530
Bell, Louisea, *453
Belleau, Roger, *451
Bellens, Roger, *314
Benjamin, W., *232
Benner, Ernest J., *814
Bennett, Ivan L., Jr., *48, 300-304
Bennett, Peter H., *439-440
Berger, Sheldon, *442, *453
Berkow, Joseph W., 700-708
Berkowitz, Donald, *814
Bernard, A. G., *609
Bernhard, Hella, 59-70
Berry, Roger J., *47-48
Berson, Solomon A., *167, 341-349, 549-572
Best, Charles H., 493-500, 666-668
Bethune, Robert W. M., *663-665
Bewsher, P. D., *447
Beyer, Jurgen, 658-662
Bianchi, Albert, *684
Bihler, I., *48
Bing, R. J., *531
Bird, R., *232
Bishop, J. S., 531
Bissel, Grosvenor, 650-657
Bjerknes, C., *531
Björntorp, Per, *231, 724-728
Bledsoe, Turner, *48
Bleicher, Sheldon J., *113, 350-361
Blereau, Robert P., *114
Block, Melvin A., *172
Bloodworth, J. M. B., Jr., *377, *379, *441-442
Bloom, Walter Lyon, *814-815
Blum, Stuart F., *816-817

Blümchen, G., *531
Bogdonoff, Morton D., *380
Bolinger, Robert E., *232, *681
Bolton, R., *684
Bondy, Philip K., *317
Bonessi, J. V., *49
Bongiovanni, Alfred M., *613
Booij, H. L., *749
Borman, Aleck, *684
Borondy, Paul E., *382, *612
Boronow, Richard C., *681
Boshell, Buris R., 132-136, *608
Bouthilet, R., *534
Boyle, Constance, *446-447
Brandt, Lars, *531
Brecher, George, *378
Brechner, Verne L., 663-665
Bregant, Robert, 186-193
Brennan, Mildred T., 392-395
Brien, T. G., *815-816
Britton, H. G., *113
Broadhead, Charles L., *233
Bronstein, Seymour B., *451-452
Brooks, Frank P., *532
Brown, Harold, *233
Brown, J., 224-225, *442, *748
Brown, Joseph D., *231
Brown, Joseph P., *114
Brown, F. E., *53
Brown, Robert W., *681
Brummer, Benta, *378
Bullock, Weldon K., *314
Burch, Thomas A., *439-440
Burkholder, Peter M., 755-770
Burnham, Clinton, 473-480
Burns, Thomas W., 186
Burt, Richard L., *377, *388, *609
Bybee, J. D., *114
Byrne, John J., *462
Byron, J., *460-461

C

Cahill, George F., Jr., *48, *443, *445-446, *463, *747, *815
Caird, F. I., *231-232
Calame, Simone S., *167
Calderon, Rolando, 100-105
Camerini-Dávalos, Rafael A., *318, *466-467, *815
Cameron, J. Stewart, *167
Campagnoli, Mario, *452
Campbell, James, *444
Canfield, Craig J., *747

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

AUTHOR INDEX 1965

Caren, Raymond, *681
 Carliner, Nathan H., *377
 Carpenter, Charles C. J., *48, 300-304
 Cary, Eliza, *170
 Cashaw, Jesse, *233
 Cavert, H. M., *48
 Cederquist, Dena, *533
 Cesari, E., *167
 Chai, P. Y., 27-32
 Chaikoff, I. L., 377
 Chazan, Joseph A., 132-136
 Cheldelin, Vernon H., *746
 Cheraskin, E., *48
 Chester, Edward M., *459-460
 Chetty, M. P., *531
 Chey, Woo Yoon, *48
 Chlouverakis, C., *234
 Choufoer, J. C., *53
 Christensen, S., *746
 Christopher, Terrence C., 96-99
 Chryssochos, Themistocles J., *452
 Cintra, Ulhoa A. B., *461
 Clark, James, *47
 Clark, William C., 14-18
 Cochran, Burt, Jr., *452-453
 Coffey, R. G., *746
 Cohen, Aharon M., 84-86
 Cohen, Alex K., 350-361
 Cohen, Geoffrey F., *815
 Cohen, Simon L., *232
 Cohn, Clarence, *453
 Cohn, Keith, *454
 Colby, Anthony Owen, 424-429, 516-525
 Colle, Eleanor, *315
 Colwell, Arthur R., Jr., 110-111, *114
 Colwell, Arthur R., Sr., *442
 Colwell, John A., *170
 Compton, C. M., *231
 Conard, Victor, *314
 Cone, Lawrence, 325-332, *447-448
 Conn, Jerome W., 10-13, *49-50, 71-76,
 *170, *382, *439, *442-443, *445
 Conrad, Marcel E., *747
 Cooke, A. M., *51
 Cooperstein, S. J., *383, *531-532
 Coore, H. G., *232
 Copp, E. F. F., *468-469
 Corbo, Lucille, *681
 Cornblath, Marvin, *377-378, *535,
 *613, *815
 Cortazar, Jaime, *465
 Cotton, Ernest K., *315
 Coulson, Walter, *383
 Cowan, J. S., 689-695, *746
 Cox, James, 700-708
 Crampton, Joseph H., *463-464
 Crane, C. W., *613
 Crevasse, Lamar E., *685
 Crofford, Oscar B., *378
 Crombie, D. L., *609
 Cronkite, Eugene F., *378
 Crooks, Hulda, *379
 Csapó, G., *53
 Cubberly, Peter T., *532
 Culp, Hilman W., *456
 Cunningham, George C., Jr., *315
 Cunningham, N. F., *49

Cunningham, Richard W., *818
 Cuthbertson, W. F. J., *232

D

Danforth, William H., *378
 Dangela, Mary Z., *610-611
 Dannenburg, Warren N., *609
 Danowski, T. S., *49, 162
 Daugela, Mary Z., *746-747
 Daughaday, William H., *377
 Davidson, John K., *453, 493-500
 Davidson, Mayer B., *456-457
 Davis, Charles B., *451
 Davis, Charles K., Jr., *378
 Davis, David M., 106-109
 Davis, Miles, *377, *536
 Davis, Richard A., *532
 Daweke, H., *49
 Dawson, A., *381
 de Bodo, R. C., *531
 del Castillo, E. J., 33-35
 De Moor, Pieter, 788-791
 Dennis, Brown W., *453-454
 DePew, L. L., 71-76
 De Prati, Victor J., 311-313
 Devlin, James G., *815-816
 Di Girolamo, Mario, 87-92, *454
 Dikstein, S., *47
 Dilley, Ralph B., *115
 Dillon, Richard S., 672-674
 Dinwoodie, A. J., *169
 Ditschuneit, Hans, 658-662
 Dobson, Harold L., 489-492, 811-812
 Doisy, Richard J., *114, 579-583, *816
 Dollery, C. T., 121-127
 Drapkin, Arnold, *454
 Dray, Jan., *463
 Driscoll, Shirley G., 573-578
 Drorbaugh, James E., 157-161
 Drummey, Gladys D., *536
 Drummond, Keith R., 676-681
 Duhring, John L., *682
 Dulin, William E., *448-449, 507-515
 Dunn, A., *531
 Dupre, J., *167, *440-441
 Dürr, F., *609

E

Edelman, P. Michael, *378
 Edwards, A. V., *49
 Efron, Herman Y., 719-723
 Ehrlich, Robert M., *438
 Eichhorn, John H., *115
 Eisenstein, Albert B., *113, *378
 Eisentraut, Anna M., *51, *53
 Elevitch, Franklin R., *51
 Eliasson, Sven G., *232
 Ellenberg, Max, *454-455
 Elliot, Daniel W., *50
 Elliot, Robert R., 780-787
 Ells, Joyce, *172, *749, *818
 Elrick, H., *167-168
 Engerman, R. L., *379

Enquist, Irving F., 170-171
 Entmacher, Paul S., 212-228
 Epstein, Frederick H., 413-423
 Ernest, Ingrid, *816
 Ernesti, Manfred, *610
 Etzwiler, Donnell, *315, 676-681
 Evans, Philip R., *681-682

F

Fabrykant, Maximilian, *168
 Fahlberg, Vera I., *315
 Fajans, Stefan S., *49-50, *439
 Falk, Sigmund, *451-452
 Faloon, William W., *816-817
 Farkas, Carol Spindell, *682
 Farrant, P. C., 274-278
 Fearnly, G. R., *532
 Felber, J. P., *455
 Fellner, Fredda G., *438-439
 Field, James B., *49, *115, *233-234,
 *446-447

Field, Richard A., *447, *462-463, *682
 Fillisti, L. P., *747
 Fine, J., *746, *816
 Finn, Jack, *449
 Fischer, R. B., *48
 Fisher, Gail F., 473-480
 Fitzgerald, M. G., *51, 175-178, *609
 Fleming, I. D., *232
 Floyd, John C., Jr., *49-50, *439
 Fonkalsrud, Eric W., *115
 Forbath, Nicholas F., 729-739
 Forbes, Audrey E., *377, *535
 Forbes, Clare E., *682
 Ford, Charles R., *232
 Ford, Henry C., *816
 Forrist, Arlington A., *382
 Forsham, Peter H., *444, *532-533, *681
 Foster, Angela E., 350-361
 Francis, Thomas, Jr., 413-423
 Franckson, J. R. Marcel, *314
 Frankl, William S., *168
 Frantz, Andrew G., *315
 Frazer, Russell, *52, *442, *748
 Freinkel, Norbert, *113, 350-361, *462
 French, J. M., *613
 French, Samuel W., *383
 Frerichs, Heiko, *115
 Frey, Harald M., *50
 Fridland, A., *235
 Friedmann, Bernice, *445
 Froberg, Sven, *532
 Frohlich, Edward D., *532
 Frohman, Lawrence A., *816
 Frost, H. M., *316, *455
 Fujita, Kay, 224-225
 Futterweit, Walter, *455-456

G

Galli, M. E., 33-35
 Galloway, John A., *456
 Galton, D. J., *682
 Goadby, H. K., *316-317
 Garcia, Luis A., 87-92

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

AUTHOR INDEX 1965

Garland, P. B., *533
 Gastineau, Clifford F., 279-288, *381-382
 Gebbie, T., *232
 Geddes, L. A., 489-492
 Geerling, Herbert, 658-662
 Gelfand, Maxwell L., *168
 Gelhorn, A., *232
 Genuth, Saul, *816
 Gepts, Willy, 619-633
 Gerritsen, George C., *448-449, 507-515
 Gershberg, H., *456, *458
 Gershoff, Stanley N., *380, *443, *608, *683
 Gerstein, Mordecai M., 579-583
 Gilboa, Ygal, *460-461, *610
 Ginsberg, Jean, *609
 Giordano, J. C., *452
 Gitelson, Simon, 201-208
 Glick, Seymour M., *50, *167
 Gliemann, Jorgen, 643-649
 Goetz, Frederick C., *172, 226-228, *749, *818
 Goldberg, Marshall, *50
 Gonda, A., *231
 Goodman, Edward H., Jr., *445
 Goodman, H. Maurice, *379
 Goodner, Charles J., *456-457
 Goodrick, William I. M., *116
 Gordon, A., *817
 Gordon, Edgar S., *50
 Gorlin, Richard, *611
 Gruber, Alan L., *450
 Graham, Charles A., *609
 Grasso, Sebastiano G., *444
 Gray, James, 489-492
 Greenberg, Beryl Z., *172, *749, *818
 Greenberg, Ernest, 43-45
 Greene, John W., Jr., *682
 Gregersen, C., *115
 Gregor, Wesley H., *170
 Greider, Marie H., *50
 Grodsky, Gerold M., 27-32, *51, 396-403, *444, *532-533, *611, *683
 Gudbjarnason, S., *531
 Guest, George M., 239-273
 Gundersen, Karel, *470, 805-810
 Gunn, G. C., 489-492
 Gunning, Barbara, *52, *171
 Gutman, Alisa, 77-83, *533

H

Hackel, D. B., *610
 Hadden, David R., *610
 Hagenfeldt, Lars, *682
 Haines, D. S. Milton, 666-668
 Haines, Howard, *610
 Haines, Robert J., 14-18
 Hainline, Adrian, Jr., *315-316
 Haist, R. E., 305-310, 368-373, *453, 493-500
 Halasy, M., *169
 Hales, C. N., *50, *381, *533
 Hall, W. E., *535
 Hamid, M. A., *231

Hamwi, George J., *381, 744-745
 Han, Yvonne, *458
 Hansen, Ruth Osterby, *533
 Hanson, Peter G., *379, *682-683
 Hardinge, Mervyn G., *379
 Harlan, William R., *536-537
 Harley, J. M. G., *379-380
 Harmos, G., *169
 Haro, Expedito N., *816-817
 Harris, E. J., *232-233
 Harvey, A. McGehee, *48, 300-304
 Hashim, Sami A., *380, *448
 Haunz, E. A., *457
 Hausberger, B. C., *233
 Hausberger, Franz X., *233
 Hayner, Norman S., 413-423
 Hazelwood, Robert L., *50
 Hazlett, Barbara, *453
 Heald, Felix P., *610-611, *746-747
 Hecht, A., *456
 Hegsted, D. Mark, *380
 Heideman, M. Lawrence, Jr., *50-51
 Heikinheimo, Rauno, 606-608
 Hellerström, Claes, *168, *380
 Hellier, F. F., *168
 Hellman, Bo., *168, *231, *380
 Hellman, L. M., *747
 Helmreich, Ernest, *378
 Henke, Wilbert J., *53
 Hennes, Allen R., *457, 709-715, *747
 Hennigar, Gordon R., *380
 Herman, Michael V., *611
 Herman, Robert H., *747
 Herman, Yaya F., *747
 Herrera, M. Guillermo, *171
 Herskovits, Theodore T., *818
 Hetenyi, Geza, Jr., 729-739
 Hill, John B., *747
 Hills, Peter R., *47-48
 Himel, H. A., *47
 Hindle, W., *316-317
 Hinks, N. T., *235
 Hirsch, Paul, *314-315
 Hitman, Donald, *317
 Hizukuri, Susumu, *233
 Hlad, C. J., Jr., *167-168
 Hocking, Elizabeth D., *532
 Hogg, James F., *382-383
 Hoisington, Sylvia, *450
 Holcomb, Blair, *814
 Holland, William M., *457-458
 Hollander, C. F., *53
 Holmgren, Luther E., *115-116
 Honick, Mary D., *116
 Hood, Thomas C., *380
 Hood, Tony E., 186-193
 Horwitz, Francis, *316
 House, E. L., 325-332
 House, Lawrence, *447-448
 Houssay, B. A., 33-35
 Hubbell, John P., Jr., 157-161
 Huber, Agnes M., *380, *443, *608, *683
 Huizenga, Kenneth A., *116
 Hulpius, Harold R., 14-18
 Hulse, M., *456, *458

Hutchinson, Mary, *231-232
 Hyams, D. E., *50

I

Ikeda, Masakazu, *685
 Illingworth, Barbara, 333-340
 Inge-Bert, Täljedal, *168
 Ingle, Dwight J., 93-95
 Irwin, Glenn W., *457-458
 Ishmael, William K., *116
 Islam, Mohammed A., *683
 Issekutz, B., Jr., *534, *611
 Isselbacher, Kurt J., *536
 Izzo, Joseph L., *450

J

Jackson, Robert L., 437
 James, V. H. T., *169
 Jampolis, Robert W., *117
 Javier, Z. C., *456, *458
 Jensen, J., *746
 Jersild, M., *612, *685
 Jett, Marian, 740-744
 Johnson, May, *318
 Johnson, Perry B., *533
 Johnson, Robert E., *379, *682-683
 Jones, C. S., *168
 Jones, E. E., *747
 Jones, Evelyn M., *533
 Jordan, Paul H., Jr., *316
 Joshi, Prakash C., *451
 Jungas, Robert L., *233

K

Kadish, Arnold Henry, *458
 Kahil, M. E., *233
 Káldor, Antal, 209
 Kane, John P., *611
 Kaplinski, Naomi Wertheimer, 201
 Kar, Bimal C., 404-412
 Karam, John H., 27-32, *444, *532-533, *683
 Karchmer, Samuel, *817
 Kasi, A. M., *233
 Katsoyannis, P. G., *168-169
 Katz, Harvey F., *380
 Katz, Hyman M., 650-657
 Kaufman, Mildred, *51, *316, *817
 Kaye, Robert, *613
 Kedes, Laurence H., *233-234
 Keen, Harry, *170, *234
 Kelin, M., 142-145, *316
 Keller, Dan F., *315-316
 Kennedy, A. C., *169
 Kent, Gerald T., 295-299
 Kerko, P. R., *377
 Kessler, Margaret, 239-273
 Kim, Jae Nam, 137-141
 King, Edward J., *684
 King, Judith, *749
 Kinsell, Laurance W., *52, *171, *458
 Kirk, Robert F., *683
 Kirsh, Marvin M., *439

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

AUTHOR INDEX 1965

Kjelsberg, Marcus O., 413-423
 Klein, Robert F., *380
 Kleist, Thomas J., 387-391
 Klinenberg, James R., *48
 Klink, D. D., *459
 Knight, William A., *53
 Knizley, Homer, *685
 Knopf, Ralph F., *49-50, *439
 Knowles, Harvey C., Jr., 165-166, 239-273, 740-744
 Koch, E., *683
 Koike, T., *534
 Kolff, Willem J., 36-37
 Kopelovich, L., *377
 Kornacker, Melodee S., *683-684
 Krahl, M. E., *533-534
 Kraus, Shirley D., *116
 Kreines, Kenneth, 740-744
 Kreisberg, Robert A., *534
 Krosnick, Arthur, *380-381
 Kruger, Fred A., *381, 744-745
 Krut, L. H., *234
 Kuftinec, Dubravko M., *169
 Kunitake, G. M., 224-225
 Kurucz, A., *612
 Kurucz, J., *612
 Kuzuya, Takeshi, *612
 Kyle, G. Clayton, *682

L

Lacy, Paul E., *47, 634-642
 Lampe, Joan, 239-273
 Landon, J., *169
 Landau, Bernard R., *442, *446
 Lardy, Henry A., *236
 Larner, Joseph, *52, *233
 Lasagna, Louis, *536
 Lauener, Roland W., *47
 Lauris, Vilma, 19-26, *48, *445-446
 Lazarow, Arnold, *383, *444-445, *531-532, 669-671
 Lazarus, Sydney S., 146, *459, 792-804
 Leake, Norman H., *380
 Lebovitz, Harcid E., *816
 LeCompte, Philip M., *460-461
 Lee, James H., *683
 Lee, R. Hewlett, *117
 Legg, Susan, *232
 Lehoczky, T., *169, 716-718
 Leibel, B. S., *47
 Lentle, B. C., *169
 Leonards, Jack R., 96, 295-299
 Lepkovsky, S., *534
 Lerman, Sidney, *611
 Lerner, Leonard J., *684
 Levine, Rachmiel, *234, *447-448
 Levine, Robert A., *534
 Lewis, G. W., *234
 Liebow, Irving M., *169
 Like, A. A., *441, *747
 Liljedahl, Sten-Otto, *532
 Lin, Boniface J., 805-810
 Linner, Erik, *816
 Linton, A. L., *169

Lippiello, Lee, *438-439
 Little, J. Alick, *440, *535
 Livingston, Linda, *378
 Llerena, Alberto L., 100
 Lochner, J. de V., *51, *53
 Lockwood, Dean H., *534, *747-748
 Logothetopoulos, John, *449-450, 493-500
 Longcope, Christopher, *611
 Lonergan, E. T., *50
 Longmire, William P., Jr., *115
 Lostroh, Ardis J., *167
 Louis, L. H., *445
 Loutfi, A. H., *316
 Love, Thomas A., *748
 Lowell, A., *613
 Lowenstein, J. M., *683-684
 Lubetzki, J., *235-236
 Lucas, Charles, 10-13, *382, *442-443
 Luft, R., *167
 Luke, R. G., *169
 Lukens, F. D. W., *316
 Lukert, Barbara P., *681
 Lyngsoe, Jens, *116

M

MacGregor, Malcolm, *611
 Mackay, N., *817
 Mackenzie, Malcolm S., *459-460
 Madison, James F., *234-235
 Magyar, I., 716-718
 Mainguet, Paul, *814
 Malins, J. M., *51, 175
 Malkin, Martin F., *87-92
 Mandell, Stanley, *115
 Maqueo, Manuel, *817
 Marble, Alexander, *167, *318, *466-467, *809, *818
 Marcus, Gabor, *235
 Mari, S., *456
 Marks, Herbert H., 212-223
 Marks, Vincent, *381, *684
 Markson, C. A., *47
 Marler, Eric, *460
 Marmor, Bruce M., 579-583
 Marshall, Frederick J., *456
 Martin, Dan A., *469
 Martin, Julio M., *438
 Martin, Sister M. John, *533
 Martinson, Alf, 724-728
 Márton, I., 716-718
 Maruhama, Yoshiuke, *611
 Matos, Otsemre E., *685
 Matthews, J., *47
 Matz, Robert, *454
 Maumenee, A. E., 700-708
 Mayer, Jean, *169
 Mayer, L. A., *468-469
 Maynard, Donald E., *381, 744-745
 Mazza, R., *231
 McCullagh, Perry E., 36-37, 96
 McDonald, Glen W., 473-480
 McElin, Thomas W., *681
 McGarry, E. E., *231
 McMahon, Robert E., *456

Meade, Robert C., 387-391, *459, 526, 528
 Medina, Ambrosio M., 676-681
 Medley, D. R. K., *612
 Meigs, J. Wister, *314
 Melin, Hans, *817
 Mendelson, Jack H., *536
 Merimee, Thomas J., *381, *534, *612
 Mestman, J. H., *460
 Miki, E., *441
 Miller, H. I., *534, *611
 Miller, Max, *439-440, *464-465, *466
 Mills, I. H., *316-317
 Mills, S. C., *235
 Milner, R. D. C., *381
 Minick, M. C., *445
 Mirsky, Stanley, *455-456, *465-466
 Mistry, S. D., *236
 Mitchell, M. L., *460-461, *610
 Molnar, George D., *235, 279-288, *381, 382
 Monroe, Mary Lou, *681
 Montgomery, D. A. D., *379-380
 Montoye, Henry J., *533
 Moody, A. J., *455
 Morard, J.-C., *235-236
 Morgan, Carl R., *457-458, 669-671
 Morgen, R. O., *231
 Morley, Nina H., 666-668
 Morris, B., *684
 Morris, J. H., *232
 Moses, C., *49
 Mosonyi, L., *116
 Moutsos, Spero E., *748-749
 Moxness, Karen E., 279-288, *381-382
 Mueller, Peter S., *610-611, *746-747
 Munck, O., *612, *685
 Munke, Arne, *534-535
 Munroe, John F., 584-590

N

Nabarro, J. D. N., 162-165
 Nabwangu, M. J., *469
 Nadon, Grant W., *535
 Nakamoto, Satoru, 36-37
 Nakamura, R. M., 224-225
 Navarrete, Victoria N., 481-488
 Nelhaus, Gerhard, *613
 Neilson, J. McE., *817
 Nelson, Eino, *235
 Nelson, George H., *613
 Nelson, Jerald C., *461
 Newburgh, R. W., *746
 Newey, H., *51
 Newill, Vaun A., *169
 Nielsen, Robert L., *463-464
 Niigam, V. N., *235
 Nihomiya, Rikuo, 729-739
 Nixon, D. A., *113
 Nordern, Ake, *531
 Northcutt, Robert C., *48
 Northrop, Gretajo, *235
 Norton, Margaret, *453
 Novak, Milan, *684
 Nydick, Martin, *612

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

AUTHOR INDEX 1965

459, 526 Nye, E. R., *116-117

O

Oakley, N. W., 121-127
Oberdisse, K., *49
Oberlander, Lawrence, *170-171
O'Brien, Donough, 780-787
Odell, William D., *613
Ogilvie, Robertson F., 595-605
Oji, Nobuyoshi, *467
Okun, Ronald, *377
Ooms, Henri, *449
Oro, Lars, *532
Oseasohn, Robert, *169
O'Sullivan, John B., *113, *461
O'Sullivan, Michael O., *535
Owen, John A., Jr., *453
Owens, James N., Jr., *116
Oyama, Jiro, *382, *535

P

Palumbo, Pasquale J., *235
Pansky, B., 325-332, *447-448
Parker, John W., *51
Parker, Mary L., *377-378
Parks, R. E., Jr., *235
Parish, J. A., *818
Partamian, Jean O., *443
Partidge, John W., *814
Patel, D. P., *52
Patel, Roda K., *613
Patterson, D. S. P., *49
Patterson, Roy, *170
Pattishall, Evan G., 106-109
Patz, Arnall, 700-708
Paul, P., *534, *611
Pauslen, Elsa P., *438-439, *468
Pavlatos, Fotios Ch., *532-533, *611, *683
Payne, Richard W., *116
Pengelly, C. R., *612
Pereira, Virgilio Gonçalves, *461
Perez-Stable, Eliseo, 748-749
Pettersson, Kerstin, *236
Petzoldt, Rudiger, 658-662
Pfeiffer, Ernst F., 658-662
Phair, John P., *317
Picchioni, Janice A., *613
Pierce, A. E., *117
Pines, Kermi L., *454
Pirant, Jean, 1-9
Pirie, Antoinette, *231-232
Pi-sunyer, F. Xavier, *462
Pisziewicz, D., *468-469
Planchart, Alfredo, 430-431, *462
Platt, William T., *382, *535
Pogatsa, Gábor, 209-211
Polakoff, Harry, *462
Polsky, Louis S., *170
Polster, Sheldon A., *532
Pomeranz, Julius, *684
Pometta, Daniel, *318
Porte, Daniel, Jr., *450

Pote, William W. H., Jr., *317
Poucher, Russell L., *452-453
Powell, Elinor D. U., *462-463
Power, Lawrence, 10-13, 71-76, *170, *382
Prahl, James W., 289-294, *440
Pray, Laurance C., *117
Press, Leon, *452
Prout, Thaddeus E., *381, *534, *610, *747-748
Pyke, D. A., *51

Q

Querido, A., *53
Quintana, Rodrigo, *316

R

Raben, M. S., 374, *610
Rabinowitz, David, *117
Rabkin, Mitchell T., *315
Rachmeler, Betty, *453
Rafaelsen, Ole J., 19-26
Randle, P. J., *232, *533
Rapp, Waldean G., *684
Rappaport, A. M., 689-695
Rasio, Eugenio, *463
Rastogi, Krishna Sudha, *444
Read, Charles H., *317-318
Reaven, Gerald M., *318, *463, *684-685
Recant, Lillian, *316, *608
Rees, J. Russell, *167
Reeves, Robert L., *463-464
Reid, J. D., *232
Reid, R. L., *235
Reilly, E. B., 224-225
Reisner, Solomon H., *377-378, *535, *613, *815
Renner, Ruth, *318
Rennie, I. D. B., *170
Renold, Albert E., 19-26, *171
Reyes-Leal, Bernardo, 71-76, *170
Richardson, B. D., *236
Rietti, C. T., 33-35
Ringsdorf, W. M., Jr., *48
Risbrook, Arthur, *462
Risdall, P. C., *117
Robert, Cavett McN., Jr., *532
Roberts, H. J., *52, *464
Robinson, Ronald, *611
Rodahl, K., *534, *611
Rodbell, Martin, *535-536
Rogers, D. E., *114
Roginsky, Martin, *462
Roldán, A., 33-35
Rona, Mira, *378
Roncone, Angela, *450
Rony, Hugo R., *464
Rosell-Perez, M., *52
Rosenberg, Abner S., *168
Rosevear, John W., 279-288, *381-382
Roth, Donald A., *459, 526-528
Roth, Jesse, *50, *167

Roy, Claude C., 780-787
Rubenstein, A., *469-470
Rubinstein, D., *231
Rudman, Daniel, 87-92, *454
Rudnick, P. A., *748
Ruggles, Thomas, *464-465
Rull, Juan, *439, *442-443
Russell, R. Patterson, *377
Russell, Richard O., *818

S

Sabo, Jack, *170-171
Sabour, Mohammed S., 595-605
Sacks, Jacob, *684
Sacks, William, *748
Sailer, F.-X., *683
Sakata, Kazuki, *685
Salans, Lester B., *318, *684-685
Samaan, Naguib, *52, *442, *748
Samarcq, P., *235-236
Samols, Ellis, *612, *684
Sanchez-Medina, Mario, *465
Sandler, Richard, *171
Sanford, P. A., *51
Saravis, Calvin A., *608
Server, M. E., *49
Schachner, Stephen H., *381, 744-745
Schaefer, Louis E., *465
Schapiro, Robert H., *536
Scheig, Robert L., *536
Schelling, Jean-Louis, *377, *536
Schertsen, Bengt, *531
Schichiri, Motoaki, *466
Schless, Guy Lacy, *171
Schlichtkrull, J., *612, *685
Schlierf, Guenter, *52, *171, *458
Schlosser, G. H., *451
Schmidt-Nelson, Kurt, *610
Schnatz, J. David, *382
Schoeffling, Karl, 658-662
Schollmeyer, P., *531
Schulman, Charles L., *532
Schwartz, Irving L., *378
Schwartz, Melvin J., *455-456, *465-466
Schwartz, Philip, *612
Schwartz, Theodore B., *47
Scow, Robert O., *535-536
Seftel, H. C., *469-470
Segal, Barry M., *117
Seibles, Thomas S., *818
Seltzer, Holbrooke S., 392-395, *439
Sether, Lowell A., *613
Seto, Dudley, 36-37
Severson, Arlen R., *613
Shafrir, Eleazar, 77-84, *533
Shahbender, S., *316
Shapiro, Alvin P., *748-749
Shaw, B., *117
Shay, Harry, *48
Shedden, W. I. H., 274-278
Sheldon, Joanna, 362-367
Shepard, Claudine, *382
Shipp, Joseph C., 106-109, *171, 584-590, *685, *818
Short, A. L., 128-131

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58

May, 239-324

September, 549-618

February, 59-120

June, 325-386

October, 619-688

March, 121-174

July, 387-472

November, 689-754

April, 175-238

August, 473-548

December, 755-824

AUTHOR INDEX 1965

Shrago, Earl, *236
 Shreeve, Walton W., *467
 Shuman, Charles R., *48
 Shuman, John, 10-13
 Siemers, Dorothy E., 676-681
 Silbert, Cynthia K., 350-361
 Silverberg, Steven G., *48
 Simon, G., *169
 Simone, Rosemary, *448
 Simons, E. L., *233
 Simpson-Morgan, M. W., *684
 Sims, Ethan A. H., *446
 Singer, David L., 350-361
 Sirek, Anna, *438, 658-662
 Sirek, Otakar V., *438, 658-662
 Sirota, David K., *454
 Skillman, Thomas G., 239-273
 Skom, Joseph H., *466
 Sloane, Dennis, *48, *771-779
 Slonevsky, Lillian, *438
 Sloviter, Henry A., *685
 Smith, David L., *382
 Smith, J. Lawton, *171-172
 Smith, Kaighn, *682
 Smolens, Joseph, *613
 Smyth, D. H., *47, *51
 Sniffen, Ronald C., *115
 Soeldner, J. Stuart, *48, 432-435, *441, *463, *466-467, 771-779
 Solomon, Neil, *48, 300-304
 Southon, Ann, *170
 Sovik, O., *236
 Spellacy, William N., *172, *749, *818
 Sprague, Randall G., 37-43
 Spritz, Norton, *467
 Sreedharan, Thekkayil, *683
 Staquet, M. J., *469, 591-594
 Starkman, S. P., *47
 Steele, R., *531
 Steenrod, William J., Jr., 289-294, *440
 Stein, H. A., *47
 Steinberg, Arthur G., *439-440
 Steiner, Donald F., *749
 Steinke, Jurgen, *48, 432-435, *441, 573-578, *747
 Sterne, J., *53
 Stevens, Ronald, *232
 Stiglitz, Robert A., 387-391
 Stimmmer, L., *167-168
 Stone, Daniel B., *114, *231, *318
 Stoner, Linda, 362-367
 Stowers, J. M., *52
 Streeten, David H. P., 579-583
 Styron, Charles W., *460
 Sukowski, Ernest J., *749
 Summerskill, William H. J., *116
 Sussman, Karl E., *467-468, *748
 Swarner, Julia B., *379
 Sweeney, Martin J., *749
 Svanborg, Alvar, *816
 Szucs, S., *53

T

Takahashi, H., *455
 Takemori, A. E., *172

Täljedal, Inge-Bert, *380
 Tarrant, M. E., 179-185, *447
 Tarver, H., *236
 Tashjian, Andrew J., *467
 Taton, Jan, *318
 Tauxe, W. Newton, *235
 Taylor, K. W., *748
 Teagan, Susan J., *382-383
 Tetreault, Leon, *536
 Thomas, J. P., *169
 Thomas, William C., Jr., 375
 Thompson, Howard K., Jr., 460
 Thompson, William P., *461
 Thomson, W. S. T., *113
 Thurnau, Gary, 226-228
 Timmer, Richard F., *748
 Titus, Charles, *467-468
 Tocus, E. C., 696-699
 Tomizawa, Henry H., *749
 Tonelli, G., 696-699
 Torres, Isabel H., 481-488
 Touchstone, Joseph C., *682
 Tovey, J. E., *685
 Tranquada, Robert E., *460
 Travis, Randall H., *459-460
 Trayner, I., *748
 Trayner, R., *442
 Treister, Michael, *464-465
 Trillwood, Wilfred, *47-48
 Tripathy, Bibhuti B., 404-412
 Troyer, William G., *380
 Tryding, Nils, *531
 Tsao, Makepeace U., *382-383
 Tyangkul, Phienvit, *448

U

Ulstrom, Robert A., *315
 Unger, Roger H., *51, *53
 Uzawa, Haruo, *52, *170

V

Vacca, Joseph B., *53
 Vallbona, C., 489-492
 van der Heul, R. O., *53
 van der Sluys Veer, J., *53
 van Dongen, Robert, *172
 Van Huss, Wayne D., *533
 Van Itallie, Theodore B., *380
 Van Peenan, Hubert J., 186-193
 van Rijsel, T. G., *53
 Van Steveninck, J., *749
 Varandani, P. T., *749
 Vecchio, Thomas J., *382
 Verhaegen, Herman, 788-791
 Verhaegen-Declercq, Marie Louise, 788-791
 Viktora, J., 591-594
 Villanueva, A. R., 142-145
 Villavicencio, E., 226-228
 Virupaksha, T. K., *236
 Volk, Bruno W., 792-804
 Voll, Artur, *536
 Vranic, Mladen, 194-200, 689-695, *746

W

Waburton, Richard, *383
 Wahlberg, Fredrik, *682
 Waichenberg, Bernardo Léo, *461
 Walker, Alexander R. P., *236
 Walker, Joan B., *53, *533
 Wall, Mary, *609
 Wallace, John M., *536-537
 Watkins, Dudley, *383
 Watson, K. C., *531
 Weber, Herbert, *454-455
 Wegienka, Laurence C., *444
 Weil, Leopold, *818
 Weingarten, Clifford M., *114
 Weinhouse, Sidney, *445
 Weisenfeld, Shirley, *452
 Weismann, Rodger E., *318
 Welch, J. D., *113
 Weller, John M., *612
 Wellman, Klaus W., *459, 792-804
 Wells, Lemen J., *444-445
 Wendt, V. E., *531
 Whaley, William H., *613
 White, W. L., Jr., *48
 Whitehouse, Fred W., *172, *455
 Whitfield, A. G. W., *613
 Whitney, J. E., 128-131
 Wick, A. N., *468-469
 Wickstrom, Lennart, *236
 Wieland, Ralph G., *381, 744-745
 Wilber, John F., *613
 Wilbur, Blake C., *117
 Williams, A. H., *51
 Williams, Franklin T., *469
 Williams, Robert H., *382, *450, *612
 Williamson, John R., *534
 Winegrad, Albert I., 311-313
 Wizgird, Joseph P., *383
 Wolf, Herman, *452-453
 Wolff, F. W., *469, 591-594
 Wray, James B., *383
 Wrenshall, G. A., 689-695, *746
 Wright, E. M., *47
 Wright, F. E., 128-131
 Wright, Peter H., *49, *449, 634-642
 Wybregt, Susan H., *613
 Wynn, V., *169

Y

Yabo, R., 591-594
 Yallow, Rosalyn S., *167, 341-349, 545
 Yde, Hans, *172
 Yeager, Vernon L., *613
 Young, Jerry W., *236
 Young, R. B., *613
 Younger, Lee, *749
 Youngquist, Ronald, 676-681

Z

Zalme, Elizabeth, 165-166
 Zierler, Kenneth L., *117
 Zuspan, Frederick P., *613

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

*461
6

1

2-804

*455

-745

450, *40

6

4-642

349, 50